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Despite Alzheimer’s disease (AD) being the most common form of dementia, our 
understanding of the molecular mechanisms that underlie the severe cognitive 
impairments of AD patients remains very incomplete. A well-supported hypothesis 
is that AD pathology disrupts neuronal communication at the synapse, a process 
thought to be crucial for memory function. Amyloid beta (Aβ) and phosphorylated 
tau (P-Tau) are key molecules in driving the impairment of synaptic function, but 
the molecular mechanisms involved in their neurotoxic effects are not fully 
characterised. Compelling evidence has positioned two types of synaptic G-protein 
coupled receptor (GPCRs), muscarinic acetylcholine receptors (mAChRs) and 
metabotropic glutamate receptors (mGluRs), as emerging mediators of such 
effects. They are both coupled to the same intracellular pathways but still appear 
to play differential roles in pathological mechanisms. Research has shown that 
blockade of mGluRs and upregulation of mAChRs are beneficial for synaptic 
function in in vitro and in vivo models of AD. The aim of this study is first to 
investigate the consequences of mGluRs activation in physiological conditions, to 
assess whether it is sufficient to cause synaptic impairments and whether it can 
regulate mAChRs function. Second, to characterise the expression of these 
synaptic GPCRs in the pathology of AD, to evaluate whether their potential 
interplay may be relevant to disease mechanisms. Third, to investigate the effects 
of P-tau, a key mediator of AD pathology, on the function of these synaptic GPCRs. 
Results from this study showed a functional interplay between mGluRs and 
mAChRs and a differential regulation of both their protein levels in AD brains and 
their function in the presence of P-tau. Altogether, this work provides new insights 
into possible mechanisms that contribute to synaptic dysfunction in AD, which will 
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1.1 Alzheimer’s disease is a memory disorder 
1.1.1 Dementia 
Alzheimer’s disease (AD) is classified as a neurodegenerative disorder and 
constitutes the most common cause of dementia (Alzheimer’s Association 2018). 
The word dementia does not refer to a specific disease but rather is an overall term 
that refers to a set of symptoms that affect cognitive function, including memory, 
thinking, behaviour and emotions, which characterize progressive 
neurodegenerative brain disorders (Scott & Barrett 2007). Apart from AD, other 
causes of dementia have been described such as vascular dementia, which may 
occur after stroke, dementia with Lewy Bodies (DLB), frontotemporal lobar 
degeneration (FTLD), Parkinson’s disease (PD) dementia and Creutzfeldt-Jakob 
disease, among others (Pohjasvaara et al. 2000; Mrak et al. 2007; Hodges et al. 
2004; Emre 2004; Dupiereux et al. 2009). Regardless of the cause, all patients with 
dementia are eventually unable to perform day-to-day activities and to take care of 
themselves, needing help with all aspects of daily life (Scott & Barrett 2007). This 
fact makes AD patients extremely dependent on their family and friends, having a 
dramatic impact on the life of both. Likewise, given the long duration of the disease, 
patients live in a state of disability for very long periods of time. The number of 
people living with dementia in the UK is forecast to be over 1 million by 2025 (Prince 
et al. 2014). Economically speaking, the average annual cost per patient is £32,250 
in the UK, with a total cost to society of £26.3 billion (Prince et al. 2014). These 
data clearly indicate the huge socio-economic impact of dementia and therefore 
the necessity of searching for more efficient therapeutic interventions for AD, for 
which a cure has not been found yet.  
1.1.2 Symptoms and diagnosis of AD 
The first symptom in AD patients is the inability to remember new information due 
to the malfunction of neurons located in memory-related areas of the brain, such 
as the hippocampus. As the disease progresses and other brain areas degenerate, 
multiple cognitive difficulties arise, although the pace at which they develop varies 
from person to person (Huang & Mucke 2012). These include difficulties 
completing day-to-day activities, trouble solving problems, speaking and writing, 
changes in mood and confusion with time and place (Alzheimer’s Association 
2018).  Although these are classic symptoms of AD patients, they may be caused 
by other dementias such as the previously mentioned ones (Scott & Barrett 2007; 
 




Dupiereux et al. 2009). Therefore, one important challenge in AD is finding efficient 
diagnostic tools that allow for clear identification of the disease and consequently 
appropriate treatment.  
One of the main problems in the diagnosis and treatment of AD is that when the 
above symptoms develop, the pathophysiological changes in the brain are already 
in a very advanced state. Usually patients with AD are diagnosed at late stages 
when the diagnosis is fundamentally of clinical nature, through cognitive tests and 
neuropsychological evaluation (McKhann et al. 2011). Importantly, AD-related 
brain alterations may start 20 years before the emergence of memory loss and 
other noticeable symptoms (Sperling et al. 2011; Price & Morris 1999). For this 
reason, it is widely believed that future treatments to stop or slow down the 
progression of the disease (disease-modifying treatments) should be administered 
during the preclinical stage to have the most beneficial effects (Korolev 2014). The 
difficulty remains, however, in detecting AD at early stages. One promising 
approach is the identification of biomarkers that define the preclinical 
(asymptomatic) stage of AD and that can be used at the clinic. For example, a 
biomarker model has been proposed based on the detection of the two of the 
pathological hallmark proteins in AD, namely amyloid β42 (Aβ42) and tau protein, 
in cerebrospinal fluid (CSF) (Jack et al. 2010; Sperling et al. 2011; Tarawneh et al. 
2015). In addition, imaging techniques, such as positron emission tomography 
(PET), to track levels of amyloid protein and magnetic resonance imaging (MRI), 
to detect brain atrophy that correlates with cognitive decline, have been tested to 
detect early AD in clinical trials (Hampel et al. 2010; Frisoni et al. 2010; Putcha et 
al. 2011; Albert et al. 2011; McKhann et al. 2011). These studies have shown that 
although the definitive biomarker profile that defines preclinical AD is still difficult 
to identify, moving towards early intervention is a promising avenue to prevent AD. 
1.1.3 Aetiology and risk factors of AD 
As with many other chronic diseases, there is no single cause for AD but rather it 
is the result of complex interactions between multiple factors. These include 
genetic, epigenetic and environmental factors that act in combination to cause 
aberrant brain function and increase the likelihood of developing the disease 
(Huang & Mucke 2012). The only exception of this is the familial Alzheimer’s 
Disease (FAD) variant, which is caused by specific genetic mutations. So far, three 
genes for which mutated forms originate autosomal dominant forms of FAD have 
 




been identified: APP, which codes for the amyloid precursor protein (APP), and 
presenilin 1 and 2 (PSEN1 and PSEN2), which code for the APP processing 
proteins (Bertram et al. 2010). The carriers of any of these mutations will develop 
FAD, which is characterized by an early-onset (<60 years old) and accounts for 
approximately less than 1% of AD cases (Bekris et al. 2010). The rest of the AD 
cases correspond to the sporadic AD variant (late-onset, >65 years old) where the 
aetiology is not that well established. However, various risk factors have been 
described in the literature, of which the greatest is age. Most of the AD cases are 
diagnosed at the age of 65 or older where differentiating between aging-related 
cognitive decline and AD is problematic (Craik 1994; Swerdlow 2007). From a 
clinical perspective, cognitive decline in the elderly must impede the subject’s 
independence to perform daily activities to be considered pathological (Swerdlow 
2011). From a neuropathological perspective, atrophy and gross changes in brain 
anatomy are features of both aging and AD, but they seem to follow distinct 
patterns. For instance, reductions in hippocampal volume and in specific 
populations within hippocampal neurons are more predominant in AD brains than 
in non-demented subjects (West et al. 1994; Frisoni et al. 2010). These studies 
have supported that although a significant degree of overlap in the manifestation 
of aging and AD-associated changes exits, AD is not part of the normal aging 
process (Swerdlow 2011). Importantly, age alone is not sufficient to cause AD, 
further supporting the multifactorial basis of AD aetiology (Sperling et al. 2011; 
Swerdlow 2007).  
Genetics also plays an important role in the risk of having late-onset AD. There are 
various genes associated with the risk of developing the disease but the most 
robust one is the gene APOE. Of the three isoforms of this gene, namely, E2, E3 
and E4, the E4 allele is considered the major genetic risk factor for AD (Corder et 
al. 1993). People with two E4 alleles are at a higher risk of developing AD than 
those with only one copy of the allele (Holtzman et al. 2012). There is also potential 
risk of AD associated with having mild cognitive impairment (MCI), traumatic brain 
injury (TBI), a family history of AD and cardiovascular risk factors, such as smoking 
and diabetes (Wei et al. 2016; Lye & Shores 2000; Loy et al. 2014; Green et al. 
2002; Anstey et al. 2007; Gudala et al. 2013). Importantly, it seems that not only 
biological factors but also social factors could influence the likelihood of developing 
AD. Research is now pointing towards education and remaining socially and 
mentally active as means to reduce the risk of AD (Sando et al. 2008; Stern 2012). 
 




In summary, AD probably develops as a consequence of an accumulation of risk 
factors that contribute to triggering neurodegenerative processes in the brain. 
Clinical examination significantly helps to identify these risk factors and in the case 
of aging, to differentiate it from AD. In addition, the assessment of 
neuropathological changes in demented brains is essential for the diagnosis of AD 
and has been largely associated to its aetiology, as they represent a clear sign of 
the disease. 
1.1.4 Neuropathology of AD 
At the macroscopic level, brains from patients with AD show a modest cortical 
atrophy, especially in the frontotemporal association cortex (Frisoni et al. 2010; 
Tarawneh et al. 2015; Gearing et al. 1995). However, it is only upon microscopic 
analysis of the post-mortem brain when a definitive diagnosis can be made. At this 
level, AD is characterized by three pathological hallmarks: amyloid plaques, 
neurofibrillary tangles and neuronal death. These cause serious brain damage, 
giving rise to structural and functional disruption of brain circuits (Perl 2010). 
Neurofibrillary tangles 
Neurofibrillary tangles (NFTs) are intracellular fibrous aggregations of 
hyperphosphorylated tau, a microtubule-associated protein and the primary 
constituent of the NFTs (Iqbal et al. 1989; Lee et al. 1989). Microtubules are 
dynamic protein structures that are part of the cytoskeleton of the cell. Through 
constant assembly and disassembly, microtubules function to maintain cell 
morphology by providing structural support and they are also involved in the 
transport of organelles in the cytosol and the separation of chromosomes during 
mitosis (Song & Brady 2015). The role of tau is to bind and stabilize microtubules 
and this function is determined by the phosphorylation state of tau (Lindwall & Cole 
1984; Ando et al. 2016). Thus, non-phosphorylated forms of tau bind to 
microtubules whereas phosphorylation causes the dissociation of tau and 
microtubules tend to disassemble (Biernat et al. 1993; Lindwall & Cole 1984). 
Under pathological conditions, like AD, tau is hyperphosphorylated so the 
equilibrium of tau binding to the microtubules is altered (Iqbal et al. 1986; Grundke-
Iqbal, Iqbal, Tung, et al. 1986; Goedert et al. 1992), having two important 
consequences. First, microtubules get unstable, which disrupts the characteristic 
neuronal morphology (typically very asymmetrical, with processes extending over 
 




long distances) and the trafficking of cellular components along the axons. This 
greatly affects the functionality of the neurons and their highly elongated processes 
(Ballatore et al. 2007). Second, the levels of free (unbound) hyperphosphorylated 
tau increase in the cytosol, leading to its abnormal aggregation in fibrillary 
structures termed paired helical filaments (PHFs) (Iqbal et al. 1989). The 
ultrastructural analysis of these aggregates has shown that they are formed by 
pairs of fibrils that are bound in a helical fashion, hence the name. PHFs then self-
assembly to form the filamentous inclusions called NFTs (A. del C. Alonso et al. 
2001) (Figure 1-1A).  
In a post-mortem brain, NFTs are observed with silver impregnation staining 
techniques or immunohistochemical approaches (Perl 2010). It is important to 
mention that, although NFTs are a cardinal neuropathological characteristic of AD, 
many other diseases display this lesion. The collectively named “tauopathies” are 
disorders defined by the aggregation of insoluble tau in the brain that most 
commonly cause dementia or degeneration of the motor system (Williams 2006). 
These include AD, which is the most common one, type C Niemann-Pick disease, 
post-encephalitic parkinsonism, corticobasal degeneration and Parkinson’s 
disease complex of Guam (Williams 2006). All these have in common the 
pathological intracellular accumulation of tau, which in turn leads, at least in part, 
to neurodegeneration and cell death (Regan et al. 2017). Therefore, therapies 
focused on decreasing the aggregation of tau or increasing microtubule stability 
are being investigated as potential tools to battle the so-called tauopathies 
(Ballatore et al. 2007; Anand et al. 2014).  
 





Figure 1-1. Key neuropathological processes in Alzheimer's disease. (A) 
Neurofibrillary tangles (NFTs) formation. In the intracellular space, hyperphosphorylated 
tau dissociates from microtubules causing them to depolimeryse while tau undergoes 
various aggregation states, culminating in the formation of insoluble fibrils. (B) Amyloid 
precursor protein (APP) processing. In the amyloidogenic pathway, sequential cleavage 
of APP by β- and γ-secretases results in the generation of Aβ peptides which first aggregate 
into soluble Aβ oligomers (Aβo) in the extracellular space and eventually into fibrils and 
plaques. Adapted from (LaFerla et al. 2007; Götz & Ittner 2008). 
Amyloid plaques 
The main constituent of amyloid plaques, also called “senile” or “neuritic” plaques, 
is the Aβ peptide that results of the proteolytic cleavage of a transmembrane 
glycoprotein termed APP protein (Kang et al. 1987). The precise role of the APP 
protein in the physiology of the neuron remains unknown, although there is 
evidence supporting its involvement in cell growth, motility and neurite outgrowth 
(Oh et al. 2009; Young-Pearse et al. 2007). The processing pathways that this 
 




protein can undergo are well established, however (Figure 1-1B). The non-
amyloidogenic pathway consists in two enzymatic cleavages performed by α-
secretase and then γ-secretase that do not generate pathological Aβ peptides; 
whereas in the amyloidogenic pathway the cleavage sequence changes to β-
secretase and then γ-secretase, which produces the fragment of 4 kilo Daltons 
(kDa) known as Aβ peptide (O’Brien & Wong 2011). The Aβ peptide is released 
into the extracellular space where it aggregates, adopting a β-sheet configuration 
and, together with other proteins, forms the amyloid plaques (Palop & Mucke 2010; 
Castillo et al. 1997; Snow et al. 1996; Dickson et al. 1997).  
Together with the genetic factor APO-E4, the accumulation of pathogenic Aβ 
aggregates in the brain greatly contributes to the risk of having AD and a decline 
in cognitive function (Farrer et al. 1997; Hardy & Selkoe 2002). One prominent 
hypothesis of how Aβ can impair cognition is based on the detrimental effects of 
Aβ on synaptic plasticity and signalling. A lot of evidence from animal models of 
AD supports the notion that Aβ reduces glutamatergic synaptic transmission (Hsia 
et al. 1999; Chapman et al. 1999; Walsh et al. 2002) and that a decrease in the 
number of surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPARs) and N-methyl-D-aspartate receptors (NMDARs) is a mechanism by 
which Aβ reduces excitatory synaptic transmission (Hsieh et al. 2006; Shankar et 
al. 2007). The current model of Aβ-mediated synaptic dysfunction relies on 
evidence showing that Aβ impairs long-term potentiation (LTP) (Cleary et al. 2005; 
Walsh et al. 2002) and enhances long-term depression (LTD) (J. H. Kim et al. 2001; 
Li et al. 2009; Hsieh et al. 2006) of synaptic transmission. Both LTP and LTD are 
considered two of the main molecular processes underlying memory function and 
its impairment is correlated to synaptic loss and memory problems in animal 
models (Martin et al. 2000). Importantly, growing evidence has shown that soluble 
Aβ oligomers play a more important role than Aβ fibrils and amyloid plaques in 
causing these effects (Shankar et al. 2008; W. L. Klein et al. 2001; Tomiyama et 
al. 2010; Cleary et al. 2005; Cheng et al. 2007; Selkoe 2008) and correlate better 
with cognitive decline (Mucke et al. 2000; Näslund et al. 2000; McLean et al. 1999). 
Therefore, efforts are focused in understanding the pathological mechanisms 
triggered by oligomeric species of Aβ. 
 




1.1.5 Pharmacological strategies against AD 
Despite these advances made in AD research, we are far from finding a drug 
treatment that stops the fatal consequences of the disease. To date, only six drugs 
are approved by US Food and Drug Administration (FDA) that can be divided in 
two categories: acetylcholine esterase inhibitors (AChEIs) and one NMDA receptor 
antagonist. The former includes the drugs rivastigmine (Exelon), galantamine 
(Razadyne), tacrine (Cognex), and donepezil (Aricept) (brand name is indicated 
between brackets). The latter is the drug memantine (Namenda), the only one that 
appears to be effective at later stages of the disease (Alzheimer’s Disease 
International 2015). The sixth drug treatment has been approved relatively recently 
and combines donepezil and memantine (Alzheimer’s Association 2018). AChEIs 
act to increase the levels of ACh in the brain and although they slow the 
progression of cognitive symptoms, they do not change the course of the disease 
and half of the people taking these drugs do not respond to them (Kumar & Singh 
2015). For this reason, researchers are shifting their efforts to the search of 
therapies that can stop disease progression.  
Due to the complex nature of AD pathology, our understanding of the molecular 
mechanisms that govern the disease is constantly changing. This represents a 
hurdle for a fast development of disease-modifying treatments, for which a better 
insight of the molecular pathways of the disease is needed (Anand et al. 2014). 
Even though, the therapeutic field in AD has grown in parallel to discoveries 
regarding the pathological mechanisms underlying different aspects of the disease. 
Thus, there is a wide range of strategies in therapeutic research in AD, as diverse 
as the mechanisms involved in the pathogenesis. Very broadly, these include 
modulating levels of various neurotransmitters and intracellular signalling 
cascades, amyloid (Citron 2010; Golde et al. 2011; De Strooper et al. 2010) and 
tau (Gura 2008; Schirmer et al. 2011; Morris et al. 2011) based therapies, oxidative 
stress reduction (Lee et al. 2010), mitochondrial targeted therapy (Bezprozvanny 
2010) and anti-inflammatory therapy (Cole & Frautschy 2010), among others 
(Kumar & Singh 2015; Folch et al. 2016). These studies show that it is without 
question that a better insight of the molecular pathways of the disease is needed 
in order to develop efficacious treatments (Anand et al. 2014). 
 




1.2 Synaptic function in the hippocampus: relation to memory and 
AD 
The discovery that electrical activity underpins nerve function dates back to 1766 
when Luigi Galvani found that an electric current applied to a muscle could provoke 
its contraction. Almost two centuries later, Santiago Ramón y Cajal proposed that 
the nervous system was composed of billions of discrete nerve cells (Cajal 1894), 
for which he is still considered the father of modern neuroscience. Based on this 
concept, Wilhelm Waldeyer enunciated the “neuron doctrine” in 1891, where he 
named the separate entities that composed the nervous system “neurons” (von 
Waldeyer-Hartz 1891). This doctrine established the fundamental basis for 
understanding how information is transported and stored in the nervous system. In 
1897, the term synapse was coined by Charles Sherrington to define the 
specializations found in neurons at which electrical and chemical signals are 
transmitted (Sherrington 1906). Therefore, at the end of the 19th century these 
discoveries lay the groundwork for our exponentially growing understanding of the 
electrical processes taking place in the nervous system. The next landmark 
discovery in this field was the “plastic” nature of synapses, both from anatomical 
and functional perspectives. This gave rise to the term “synaptic plasticity”, 
introduced by Jerzy Konorski in 1948 to define activity-driven changes in synaptic 
efficacy that persisted in time, providing a mechanism of information storage in the 
brain (Konorski 1948). Shortly after, Donald Hebb formulated his famous postulate 
to explain the adaptation that neurons undergo during learning processes: “When 
an axon of cell A is near enough to excite a cell B and repeatedly or persistently 
takes part in firing it, some growth process or metabolic change takes place in one 
or both cells such that A’s efficiency, as one of the cells firing B, is increased” (Hebb 
1949). This theory, known as Hebb's rule, is often summarised as “neurons that 
fire together wire together” and provides the first basic description of synaptic 
plasticity. Importantly, this set the stage to subsequent theories and models linking 
activity-dependent changes occurring at synapses to memory and learning 
processes. Currently, the study of synaptic function is considered the key to 
understand information processing in the brain and a great part of it is still based 
on Hebbian concepts (Brown & Milner 2003). In addition, it is now clear that 
synaptic dysfunction is one prominent pathological hallmark in AD and very likely 
plays an important role in the severe memory impairments at early stages of the 
disease (Selkoe 2002). Therefore, understanding how synapses function has 
become an essential requirement not only in the context of memory and learning 
 




but also to elucidate the molecular basis of pathological mechanisms operating in 
AD.  
1.2.1 Classification of memory 
Memory can be defined as the process of encoding, storing, and retrieving 
information (Jahn 2013). According to how long the information is stored in the 
brain for, memory has been divided in three categories: immediate or working 
memory (lasts for seconds and allows for tasks in the immediate future), short-term 
memory (lasts for seconds to minutes) and long-term memory (lasts for days, 
weeks or a lifetime) (McGaugh 1966) (Figure 1-2). Long-term memory is further 
subdivided according to the type of information that is stored. Thus, declarative (or 
explicit) memory refers to the memory of facts (semantic memory) and events 
(episodic memory), that requires conscious recall of factual information. In 
contrast, non-declarative (or implicit) memory refers to unconscious recalling of 
memories to perform a task, such as skill learning (Kandel et al. 2013). In AD 
patients, memory loss is one of the major and primary symptoms, particularly 
deficits in episodic memory.  
The medial temporal lobe (MTL), where the hippocampus is located, is widely 
accepted to be a central region for memory function (Tulving & Markowitsch 1998). 
For this reason, the study of the physiological processes underlying memory has 
been focused on this brain region. Indeed, a vast amount of evidence arising from 
studies in the hippocampus has led to the discovery of synaptic plasticity, which is 
now believed to be the underpinning physiological mechanism for learning and 
memory (Martin et al. 2000). 
 





Figure 1-2. Taxonomy of memory systems. Memory is classified into different “systems” 
according to the time information is stored for and the type of information stored. The 
interdependence of these systems is not fully delineated but it is clear that each system is 
mediated by distinct brain regions. Adapted from (Kandel et al. 2013; Squire 2004). 
1.2.2 Synaptic transmission 
Synapses are the basic functional units of the nervous system where information 
is conveyed from one neuron to another. Depending on the modality in which 
synaptic transmission occurs, synapses can be classified in two categories: 
electrical and chemical (Pereda 2014). In electrical synapses, pre- and 
postsynaptic intracellular spaces are connected by ion channels termed gap 
junctions, that allow a bidirectional flow of ions between two adjacent neurons. 
Synaptic transmission in chemical synapses occurs from the presynaptic terminal 
to the postsynaptic terminal, by means of a chemical molecule termed 
neurotransmitter. The presynaptic terminal is characterised by the presence of 
synaptic vesicles in a region termed the active zone, each vesicle containing 
thousands of molecules of neurotransmitter (Südhof 2012b; Harris & Sultan 1995) 
 




(Figure 1-3). Upon arrival of an action potential and depolarization of the 
presynaptic terminal, voltage-gated calcium channels (VGCCs) are activated and 
calcium concertation rises in the intracellular space. This causes vesicles to fuse 
with the presynaptic membrane in a calcium-dependent manner, resulting in the 
neurotransmitter being released into the space that separates both terminals, the 
synaptic cleft (Katz & Miledi 1965). Neurotransmitter molecules then bind to 
receptors located in the postsynaptic terminal. Specifically, they bind to a region 
with a high density of postsynaptic receptors that is termed postsynaptic density 
(PSD) and it is a highly specialised structure (Kennedy 1997). Importantly, the 
composition and architecture of this structure has functional implications. 
Synapses with a thick PSD are known as asymmetrical or type I synapses and 
have been shown to be excitatory (Gray 1959; Andersen et al. 2006). Symmetrical 
or type II synapses usually lack a PSD and are thought to be inhibitory (Gray 1959). 
The binding of neurotransmitter to its specific receptor triggers the activation of the 
receptor. In the case of G protein-coupled receptors (GPCR), binding of the 
neurotransmitter results in the activation of the coupled G protein, triggering 
second messenger signalling pathways that can result in depolarization or 
hyperpolarization of the membrane (Betke et al. 2012). In the case of ligand-gated 
ion channel receptors, the channel opens in response to neurotransmitter binding 
and ions flow in or out of the intracellular space. For instance, glutamate, the major 
excitatory neurotransmitter, causes the opening of glutamate receptors which are 
ion channels permeable to sodium and calcium. This ion flow constitutes the 
excitatory postsynaptic current (EPSC) and causes a small depolarization of the 
membrane, giving rise to an excitatory postsynaptic potential (EPSP). In the case 
of inhibitory postsynaptic currents (IPSC), such as chloride currents mediated by 
γ-aminobutyric acid A (GABAA) receptors, hyperpolarization of the membrane 
occurs instead, and the associated response is hence termed inhibitory 
postsynaptic potential (IPSP). The sum of multiple EPSPs can cause the activation 
of regenerative currents that in turn trigger the generation of an action potential. 
Conversely, IPSPs drive the membrane away from the threshold of action potential 
firing, therefore causing synaptic inhibition of the postsynaptic terminal. 
 





Figure 1-3. Synaptic transmission in healthy brain. In a healthy brain, synaptic 
transmission occurs normally: upon receiving a stimulus, neurotransmitter is released from 
the presynaptic terminal into the synaptic cleft where it binds to postsynaptic receptors 
located on the postsynaptic membrane. Their activation by neurotransmitter molecules 
results in the propagation of the stimulus in the postsynaptic terminal and normal synaptic 
function.  
Synaptic transmission is the basis for information flow and storage in the brain and 
ultimately memory processes. Therefore, impairments in synaptic transmission 
may lead to deficiencies in synaptic function which are thought to underlie cognitive 
problems such as memory loss. Indeed, in pathological conditions such as AD, the 
presence of pathological molecules, mainly Aβ and hyperphosphorylated tau, 
triggers a series of events that culminate in disrupted synaptic transmission and 
neurodegeneration (Figure 1-4).  
 





Figure 1-4. Synaptic transmission in neurodegenerative brain. In neurodegenerative 
conditions like in Alzheimer’s disease, synapses weaken due to the presence of 
pathological molecules resulting in impaired synaptic transmission. This may underlie the 
memory loss associated with the disease. 
In summary, neurotransmitter release from the presynaptic terminal generally 
results in a change in the excitability of the postsynaptic membrane. The direction 
and magnitude of this change depends on various factors such as the amount of 
neurotransmitter released, the initial voltage of the membrane, the spatial 
distribution of the synapse and the density and distribution of receptors present in 
the postsynaptic membrane. Out of these factors, synaptic receptors are key 
modulators of synaptic transmission and, therefore, understanding their 
malfunction in disease is vital for successful therapeutic interventions. 
1.2.3 Synaptic receptors  
Glutamatergic receptors  
As mentioned previously, glutamate is the main excitatory neurotransmitter in the 
brain, acting through two major types of receptors, ionotropic and metabotropic. 
Ionotropic glutamate receptors are heteromultimeric ligand-gated ion channels, 
further subdivided in three major classes according to their pharmacological 
 




properties: AMPA, NMDA and kainate receptors. Metabotropic glutamate 
receptors are GPCRs further subdivided according to their sequence similarity, 
signal transduction mechanisms and pharmacological interactions into groups I, II 
and II (Table 1). 
Table 1. Synaptic receptors classification and mechanisms of action. 
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Chloride ion channel 
Metabotropic GABAB 
GPCR coupled to Gi/o and 
AC inhibition 
PLC: Phospholipase C, AC: Adenylyl cyclase. 
AMPA receptors. They are ligand-gated ion channels activated by the agonist 
AMPA and composed of different combinations of four subunits (GluA1-4) 
(Keinänen et al. 1990; Hollmann & Heinemann 1994). Subunit composition is very 
important since it determines the electrophysiological properties of the channel. 
For instance, GluA2-containing AMPARs display very low permeability for calcium 
(Sommer et al. 1991). However, all AMPARs are permeable to sodium and 
potassium and display very fast binding kinetics and high opening probability 
(Jonas et al. 1993). They also deactivate rapidly when glutamate is cleared from 
the synaptic cleft (Colquhoun et al. 1992), or if glutamate is not cleared, they 
desensitise quickly and recover slowly (Mosbacher et al. 1994). These biophysical 
 




properties make AMPARs the main mediators of fast excitatory transmission, a 
role that has been deeply explored in the hippocampus where they are expressed 
at almost all excitatory synapses (Wenthold et al. 1996).  
Kainate receptors. These receptors are composed of five subunits (GluK1-5) 
(Hollmann & Heinemann 1994). They share similar biophysical properties with 
AMPAR, such as rapid opening and desensitisation kinetics and calcium 
permeability depending on subunit composition (Bowie & Mayer 1995; Kamboj et 
al. 1995). They are also expressed in the hippocampus although their contribution 
to synaptic function is less well understood than that of the other glutamate 
receptors (Cossart et al. 2002). However, evidence has emerged for a role of 
kainate receptors in controlling neurotransmitter release in the presynaptic terminal 
(Rodríguez-Moreno et al. 1997; Vignes et al. 1998), axon excitability (Semyanov & 
Kullmann 2001) and synaptic plasticity (Contractor et al. 2000). 
NMDA receptors. They are heteromultimers composed of four subunits derived 
from three families: GluN1, GluN2A-2D and GluN3 (McBain & Mayer 1994; 
Nakanishi 1992). On the one hand, the GluN1 subunit binds the co-agonist glycine, 
which is essential for NMDAR to function (Kuryatov et al. 1994). On the other hand, 
GluN2A-2D subunits contain the glutamate-binding site and they are differentially 
expressed across the brain (Laube et al. 1997). The GluN3 subunit is not well 
characterised and seems to not play a role in the hippocampus (Chatterton et al. 
2002). Having a second agonist-binding site is one well-characterised feature of 
the NMDAR, since both glycine and glutamate binding are necessary for activation 
of the receptor (Johnson & Ascher 1987). Another particular feature of these 
receptors is that in addition to their permeability to sodium and potassium, they 
have high permeability to calcium and monovalent cations, which is intimately 
related to their pivotal role in long-term synaptic plasticity (Ascher & Nowak 1988). 
The third important characteristic of NMDARs is that they only activate, and 
therefore mediate ion flux and EPSCs, when the membrane is depolarised. This is 
because at resting membrane potential, magnesium ions are blocking the 
ionophore of the receptors and impeding ion flux through it, even if glutamate and 
glycine are bound to the receptor (Mayer et al. 1984; Nowak et al. 1984). At 
depolarised potentials, this blockade is removed and the receptor can activate.  
Both AMPARs and NMDARs are expressed at much higher density at synapses 
than at extrasynaptic membranes (Bekkers & Stevens 1989). As a consequence 
 




of their kinetic properties, AMPARs mediate the fast component of the EPSC at 
negative potentials (Kleppe & Robinson 1999; Koike-Tani et al. 2005) whereas 
NMDARs account for the slow component of the EPCS that emerges at 
depolarised potentials (Forsythe & Westbrook 1988; Umemiya et al. 1999). These 
receptors have become central to the study of brain function since activation of 
both receptors provides the molecular substrate for synaptic plasticity mechanisms 
occurring in the brain (Lissin et al. 1998; Rong et al. 2001; Shi et al. 1999; Malenka 
2003). 
Metabotropic glutamate receptors (mGluRs). These are GPCRs and as such, they 
indirectly alter membrane excitability by the transduction of extracellular signals 
(i.e. glutamate) to intracellular signalling cascades. Molecular cloning has revealed 
eight members of mGluRs which have been subdivided into three groups 
according to their signal transduction mechanisms, sequence similarity and 
pharmacological properties (Conn & Pin 1997). Group I (mGluR1 and mGluR5) are 
coupled to phosphoinositide hydrolysis and are selectively activated by 3,5-
dihydroxyphenylglycine (3,5- DHPG); group II (mGluR2 and mGluR3) and group 
III (mGluR4, mGluR6, mGluR7 and mGluR8), both negatively coupled to adenylate 
cyclase, have different selective agonists, LY379268 for group II and 2-amino-4-
phosphonobutyrate for group III (Ferraguti & Shigemoto 2006; Wisniewski & Car 
2002; Schoepp et al. 1999). Being type C GPCRs, mGluRs display the structural 
characteristics of this superfamily: a seven transmembrane domain (7TM), an 
extracellular amino-terminal domain, where the glutamate binding pocket is 
located, and a cytoplasmic carboxy-tail that mediates the activation of the coupled 
G-protein and the transduction of intracellular signalling cascades (Niswender & 
Conn 2010; Pin & Duvoisin 1995; Rosenbaum et al. 2009). The 7TM domain plays 
an important role in the regulation of receptor activity because it contains the 
binding sites for allosteric modulators (Brauner-Osborne et al. 2007). The 
previously described structure applies to an mGluR monomer but it has been 
demonstrated that dimerization is required for agonist activation of mGluRs (El 
Moustaine et al. 2012; Rondard & Pin 2015) although a single 7TM domain is 
responsible for G-protein activation per se (Hlavackova et al. 2005; Goudet et al. 
2005). For instance, an mGluR5 homodimer is formed by two monomers covalently 
linked by disulphide bridges between conserved cysteines in the amino terminal 
domain (Romano, Yang, et al. 1996).  
 




The synaptic location of these receptors also varies with different groups. Thus, 
group I mGluRs are predominantly found in postsynaptic elements, group II are 
expressed at both pre- and postsynaptic sites and group III are primarily expressed 
at presynaptic terminals (Baude et al. 1993; Shigemoto et al. 1993; Lujan et al. 
1996). Within the postsynaptic element, group I mGluRs are distributed 
perysynaptically, where they are thought to be involved in detecting glutamate 
present for long periods of time (Baude et al. 1993) and in mGluR-dependent forms 
of synaptic plasticity (Grover 1998; Balschun et al. 1999; Wu et al. 2004; 
Collingridge et al. 2010; Jo et al. 2010). Similarly, group II mGluRs locate to the 
extrasynaptic site of the presynaptic terminal where they act as auto-receptors that 
regulate neurotransmitter release in response to the levels of glutamate built-up 
(Scanziani et al. 1997). Group III mGluRs have been shown to be present at 
GABAergic synapses and may have a similar role than group II (Shigemoto et al. 
1997; Semyanov & Kullmann 2000).  
Cholinergic receptors (AChRs). Cholinergic receptors are divided into ionotropic 
(nicotinic) and metabotropic (muscarinic) receptors. Nicotinic receptors are 
pentameric units and have been shown to enhance glutamate evoked GABA 
release (McGehee et al. 1995). Muscarinic receptors are GPCRs divided into five 
types: mAChR1, mAChR3 and mAChR5 couple to Gq/11 and the activation of PLC 
whereas mAChR2 and mAChR4 couple to Gi/o and adenylyl cyclase activation 
(Caulfield & Birdsall 1998). Muscarinic receptors play a role in the regulation of 
synaptic transmission. For example, their activation can influence action potential 
properties (Figenschou et al. 1996). Furthermore, activation of mAChR1 results in 
the potentiation of NMDAR-mediated depolarisations in the hippocampus 
(Markram & Segal 1992). In regions such as the perirhinal cortex, mAChRs have 
a central role in synaptic plasticity where they mediate a form of LTD that is thought 
to be the molecular substrate for visual recognition memory (Massey et al. 2001). 
GABAergic receptors. γ-aminobutyric acid (GABA) is the major inhibitory 
neurotransmitter and therefore GABA receptors mediate inhibitory synaptic 
transmission. They are classified into ionotropic GABAA receptors and 
metabotropic GABAB receptors. Some include another type of ionotropic GABAC 
receptors but this is considered by many as a variant of GABAA (Barnard et al. 
1998). GABAA and GABAC receptors are widely expressed in the hippocampus 
 




where they contribute to different types of inhibition on excitatory synapses 
(Overstreet & Westbrook 2001; Andrade et al. 1986; Misgeld et al. 1995).  
1.2.4 Synaptic plasticity 
The concept of synaptic plasticity is defined as the ability of a synapse to 
strengthen or weaken over time in response to increases or decreases in its activity 
(Martin et al. 2000). The idea of a change in the “strength” of synapses was first 
proposed by Donald Hebb in 1949 (Morris 1999). Currently, this plasticity of 
synapses is widely believed to be crucial for the long-lasting experience-dependent 
changes in neuronal function occurring during learning and memory processes 
(Martin et al. 2000). As mentioned previously, the best characterized forms of 
synaptic plasticity are LTP and LTD (Bliss & Collingridge 1993; Collingridge et al. 
2010). In LTD and LTP, the efficiency of transmission at a synapse is respectively 
decreased or increased as a consequence of repeated activity at that same 
synapse (Bliss & Collingridge 1993; Martin et al. 2000; Collingridge et al. 2010; 
Voglis & Tavernarakis 2006). The existence of LTP was first demonstrated by Terje 
Lømo and Tim Bliss in 1973 (Lømo 1966; Bliss et al. 1973) followed a few years 
later by the discovery of LTD (Lynch et al. 1977), both in the hippocampal 
formation. Since then, these two processes have become an essential part of our 
understanding of learning and memory mechanisms. 
Synaptic plasticity is governed by numerous factors but of particular importance is 
the regulation of synaptic receptors located at the postsynaptic membrane. 
Specifically, excitatory synaptic transmission greatly depends on the number of 
NMDARs and AMPARs present at the postsynaptic terminal (Malenka 2003; 
Bekkers & Stevens 1989). The best example of this is the NMDAR-dependent LTP 
(NMDAR-LTP) that occurs at excitatory synapses at the CA1 region of the 
hippocampus, among other regions. This form of LTP has been extensively studied 
and a great amount of our current knowledge in the field of synaptic plasticity 
comes from the molecular mechanisms described in the hippocampus (Citri & 
Malenka 2008). 
The activation of NMDARs can result in LTP or LTD, depending to a great extent 
on the intracellular calcium levels reached during the process (Lynch et al. 1983; 
Malenka et al. 1988; Mulkey & Malenka 1992; Cummings et al. 1996). Generally 
speaking, high levels of intracellular calcium and activation of NMDARs result in 
 




the insertion of AMPARs in the synaptic membrane and LTP (Malenka 2003; 
Malenka 1991; Lu et al. 2001; Hayashi et al. 2000; Shi et al. 1999). This process 
is divided in two broad stages, early-phase LTP (E-LTP), where LTP is induced, 
and late-phase LTP (L-LTP), where maintenance mechanisms are activated. 
During E-LTP, glutamate released from the presynaptic terminal activates 
glutamate receptors located in the postsynaptic membrane, which generates a flux 
of sodium going inside the neuron. This causes the depolarization of the 
postsynaptic terminal and, when a threshold level is reached, the magnesium block 
in the NMDARs inophore is released, allowing an influx of calcium (Bliss & 
Collingridge 1993; Mayer et al. 1984). The increase in the intracellular calcium 
concentration then results in the activation of various signalling cascades, including 
activation of kinases, that lead to the insertion of AMPARs in the postsynaptic 
membrane and LTP (Lu et al. 2001; Pickard et al. 2001; Shi et al. 1999; Hayashi 
et al. 2000). Unlike E-LTP, L-LTP requires de novo protein synthesis (Stanton & 
Sarvey 1984) that is necessary for the morphological changes that allow growth of 
new neuronal connections and a long-lasting expression of LTP (Yuste & 
Bonhoeffer 2001; Desmond & Levy 1986; Stewart et al. 2000; Toni et al. 1999; 
Weeks et al. 2001). It should be noted that apart from NMDAR-dependent LTP, 
other forms of LTP have been described in various regions throughout the brain, 
for example LTP dependent on mGluRs activation (Grover 1998; Balschun et al. 
1999; Wu et al. 2004). 
In contrast to LTP, a modest increase in intracellular calcium levels and removal of 
AMPARs from the synaptic membrane results in LTD (Bliss & Collingridge 1993; 
Cummings et al. 1996; Carroll et al. 1999). Evidence has also supported that 
contrary to LTP, LTD is accompanied by a shrinkage in the size of dendritic spines  
(Nägerl et al. 2004; Zhou et al. 2004). Similarly to LTP, different forms of LTD that 
depend upon activation of non-NMDARs have been described in various brain 
regions (Collingridge et al. 2010; Jo et al. 2010).  
Since the origins of synaptic plasticity, compelling evidence has shown that the co-
existence of LTP and LTD at the synapses is the substrate for mechanisms that 
regulate the encoding and storing of memories (Takeuchi et al. 2014). Due to this, 
both forms of synaptic plasticity have been widely studied in the hippocampus, a 
brain region with a central role in memory processes (Bird & Burgess 2008) (Bird 
& Burgess 2008). Consequently, a very useful experimental approach to study LTP 
 




and LTD has been the in vitro hippocampal slice preparation from rodent brain, 
that combined with electrophysiology techniques, has allowed for the investigation 
of the molecular mechanisms underlying learning and memory (Lein et al. 2011). 
1.2.5 The hippocampal formation 
The hippocampal formation, located in the medial temporal lobe of the brain, is one 
of the most studied structures in the mammalian brain in the memory field of 
modern neuroscience. There are two main reasons for this. First, there is 
compelling evidence that strongly points to the hippocampal formation as a brain 
region with a highly specific role in memory (Van Strien et al. 2009; Neves et al. 
2008). Second, the performance of advanced techniques for the study of synaptic 
plasticity, such as electrophysiological recordings, is particularly convenient in this 
formation (Bortolotto et al. 2001). The reason being that the hippocampal formation 
is highly organised, with cells structured in a laminar distribution (Andersen et al. 
1971; Witter et al. 2000). This allows for clear distinction and control over which 
are the projections being stimulated and which cell’s electrical responses are being 
recorded (Andersen et al. 2006). Moreover, as outlined above, the hippocampus 
is one of the first regions affected by AD pathology (Braak et al. 2006), and 
therefore it is not only a suitable model to study the molecular correlates of memory 
but also their impairment in disease. 
Anatomy of the hippocampal formation 
The hippocampal formation refers to a group of adjoining regions in the medial 
temporal lobe (MTL) of the brain, characterised by a distinct cytoarchitecture 
(Squire & Zola-morgan 1991). These regions include the dentate gyrus, 
hippocampus, subiculum, pre-subiculum, para-subiculum and entorhinal cortex 
(Witter et al. 2000). As first described by Ramón y Cajal, an intrinsic unidirectional 
circuit of excitatory projections connects these regions (Ramón y Cajal 1893). 
Unlike many other brain regions, the hippocampal formation receives highly 
processed multimodal sensory information from the neocortex and thanks to its 
intrinsic network of neuronal connections it is capable of integrating and comparing 
this information (Burgess et al. 2002). Therefore, it is critical to understand the 
anatomy and connections of the hippocampal formation to understand its unique 
role in memory processing (Van Strien et al. 2009). 
 




The entorhinal cortex, that receives information coming from sensory areas of the 
cortex, can be considered the first step in the hippocampal network.  The entorhinal 
cortex sends projections, termed the perforant path, to the dentate gyrus, forming 
the major input pathway into the hippocampus (Witter & Amaral 1991; Steward & 
Scoville 1976). The hippocampus proper is the area containing the Cornu 
Ammonis (CA) which is subdivided in three regions in the rodent brain: CA1, CA2 
and CA3 (Lorente de Nó 1934). Pyramidal cells are the main type of cells in the 
dentate gyrus and display a very characteristic structure, with basal and apical 
dendritic trees and one axon (Pyapali et al. 1998). These cells project their axons, 
termed mossy fibers, to the pyramidal cells in the CA3 of the hippocampus 
(Blackstad et al. 1970; Gaarskjaer 1978) (Figure 1-5). CA3 cells project their 
axons, termed Schaffer collateral, into the CA1 hippocampal region, that also 
contains pyramidal cells (Ishizuka et al. 1990). These CA1 cells then project to the 
subiculum (Amaral et al. 1991) and both CA1 cells and subiculum send projections 
to deep layers of the entorhinal cortex from where the processed information 
returns to the neocortex (Swanson & Cowan 1975). In the present study, 
electrophysiological recordings were obtained from the dendritic region of CA1 
pyramidal cells (stratum radiatum) in field recording experiments or the soma of 
these cells (pyramidal cell layer) in whole-cell patch clamp experiments in rat 
hippocampal slices. 
 





Figure 1-5. Rat hippocampal slice. Diagram showing a transversal hippocampal slice 
from rat brain and the main excitatory pathways. Adapted from (Purves et al. 2004). 
The role of the hippocampus in learning and memory 
The precise function of this particular structure of the human brain has been the 
object of study during the past few decades. Intensive research has finally led to 
two dominant theories on hippocampal function. The first one postulates a critical 
role of the hippocampus in the encoding and retrieval of memories related to facts 
and events, this is in long-term explicit or declarative memory (Squire 1992; Squire 
2004). The second major theory is that the hippocampus plays a critical role in 
spatial memory, specifically hippocampal place cells that create cognitive maps 
used to navigate through space (O’Keefe & Nadel 1978; Burgess et al. 2002). 
Declarative Memory Theory of hippocampal function. Evidence for the involvement 
of the hippocampus in declarative memory first came from the well-known case of 
the epileptic patient Henry Molaison (H.M) (Scoville 1954; Corkin 2002). H.M 
 




underwent an unprecedented neurosurgical practice in which portions of the MTL, 
including the hippocampal formation, were removed in an attempt to relieve his 
otherwise intractable epileptic convulsions. Although the procedure considerably 
reduced the appearance of the seizures, it resulted in a severe and specific 
memory impairment. Whereas memory of early life events as well as working 
memory (short-term memory) and general cognitive abilities remained intact, H.M. 
was unable to acquire long-term memories for new facts or events after the surgery 
(anterograde amnesia). In other words, H.M. could not consolidate newly learned 
information (Scoviille & Milner 1957). This represented the first solid link between 
long-term memory and MTL structures, particularly the hippocampal formation. 
Data from cases of amnesic patients like H.M and lesion studies in animal models 
of amnesia (Zola-Morgan et al. 1994; Aggleton & Brown 1999; Murray & Mishkin 
1998; Beason-Held et al. 1999; Zola et al. 2000) further supported a primary role 
of the hippocampal formation in memory. This is currently considered one of the 
main roles of this brain structure and it is the first proposition of the Declarative 
Memory Theory (Zola-Morgan et al. 1986; Squire & Zola-morgan 1991; Squire 
1992; Squire 2004). The second proposition is that this involvement in memory is 
selective to declarative memory, including semantic and episodic, which in humans 
can be consciously recalled (Cohen & Eichenbaum 1993). Indeed, functional 
magnetic resonance imaging (fMRI) studies, which allow linking anatomical 
regions to specific functions, have shown that MTL components are required for 
the encoding (Small et al. 2001; Davachi & Wagner 2002; Reber et al. 2002) and 
retrieval (Gabrieli et al. 1997; Eldridge et al. 2000; C. E. Stark & Squire 2000; C. 
E. L. Stark & Squire 2000; Stark & Okado 2003) of memories of new facts 
(semantic memory) and events (episodic memory) (Cohen et al. 1999). The third 
proposition defines the hippocampal formation as a part of the MTL memory 
system (Squire & Zola-morgan 1991). Within this system, each component has 
different functions, but it is collectively involved in the formation and temporal 
storage of declarative memories (Squire & Zola-morgan 1991; Squire 1992). 
Finally, the four proposition states the time-limited role of the hippocampus in 
memory (Zola-Morgan & Squire 1990). Thus, memories are initially stored in the 
hippocampus but, as time passes after learning, memory traces are stored in the 
neocortex, where memory is consolidated, and the hippocampus is no longer 
involved in the recall of these memories (Zola-Morgan & Squire 1990; Squire & 
Alvarez 1995; O’Reilly & Norman 2002; Dudai & Morris 2000). 
 




Cognitive Map Theory of hippocampal function. The key finding that triggered the 
postulation of this theory was the discovery of place cells in the hippocampus of 
freely-moving rats by J. O’Keefe and J. Dostrovsky in the 70’s (O’Keefe & 
Dostrovsky 1971). Before this theory emerged, it had been demonstrated that 
hippocampal cells fire at different frequencies, a distinctive electrical activity known 
as theta frequency firing, during the characteristic exploratory behaviour displayed 
by a rat in a new environment (Vanderwolf 1969; Ranck 1973). O’Keefe and J. 
Dostrovsky performed electroencephalographic (EEG) recordings in hippocampal 
pyramidal cells and discovered that some of these neurons only exhibit this firing 
when the animal is in a specific location of the space (O’Keefe & Dostrovsky 1971). 
These location-reactive neurons received the name of place-cells and were 
described as typically silent until the animal entered a specific place of the 
environment where the cell began to fire, hence termed place fields (O’Keefe & 
Dostrovsky 1971). Now it is known that place cells are part of a “locale” neural 
system in which spatial information about external landmarks is stored in the form 
of a cognitive map (O’Keefe & Nadel 1978). These are then stored in the 
hippocampus and are used for spatial navigation (O’Keefe & Nadel 1978). Despite 
the formulation of this theory was made upon EEG recordings in animals, it has 
extended to humans. Apart from pure navigation purposes, cognitive maps in 
humans are also related to the storage and recall of linguistic and episodic 
memories, a function that has been attributed to the left hippocampus (Neyman & 
Manahan-Vaughan 2008; O’Keefe 2003; Burgess et al. 2002).  
It is important to mention that the classical view of the hippocampus as a “memory 
structure” does not exclude its involvement in other brain functions and processes 
other than learning and navigation. The hippocampus has been implicated in other 
aspects of behaviour (Strange et al. 2014), including anxiety (Jimenez et al. 2018) 
and behavioural inhibition (Kimble 1968), as well as in sensorimotor function (Bast 
& Feldon 2003; Grion et al. 2016), novelty discrimination (Kaplan et al. 2014), and 
stress and the hypothalamic-pituitary axis responses (Sapolsky 1985; Kim & 
Diamond 2002).  
The hippocampus during AD 
AD is a neurodegenerative disorder in which the predominant symptom is memory 
loss, that aggravates throughout the course of the disease. Considering the critical 
role of the hippocampal formation in declarative memory, the fact that 
 




neuropathological changes in AD firstly affect the entorhinal cortex and the 
hippocampus is not surprising (Braak & Braak 1991). Indeed, one of the 
consequences of impairment of hippocampal function is deficiency in episodic 
memory (Barker et al. 2017; Piolino et al. 2009; Viard et al. 2012). Accordingly, AD 
patients are unable to remember autobiographical events and recent affairs and to 
learn new information, both impairments related to deficits in encoding and storing 
of information.  
The anatomical progression of AD pathophysiology was described according to 
the distribution of NFTs throughout the brain over the course of the disease by 
Braak and Braak in 1991 (Braak & Braak 1991). This gave rise to a hierarchical 
staging system named Braak staging that is today a reference in neuropathological 
studies of AD. The six stages defined by this system are as follows (Braak & Braak 
1991): 
• Stages I and II (transentorhinal stages). NFTs appear in the entorhinal 
cortex and the field CA1 of the hippocampus. 
• Stages III and IV (limbic stages). NFTs accumulation increases in 
entorhinal cortex and CA1 and extends to other areas of the hippocampus, 
the subiculum and parasubiculum, and amygadala.  
• Stages V and VI (isocortical stages). NFTs severely affect the entire 
hippocampal formation with neuronal loss in the CA region and reach the 
isocortical association areas. 
Not only the hippocampus is greatly affected by NFTs deposition, but it also 
experiences severe changes in its size over the course of AD. Indeed, volumetric 
MRI measurements have shown that hippocampal atrophy correlates well with 
neuronal numbers in the hippocampus (Bobinski et al. 2000) and that AD is 
associated with a loss in hippocampal volume (Jack et al. 1998), a morphological 
change that can be observed at pre-symptomatic stages (Convit et al. 1997). 
In summary, over the past years it has become clear that the hippocampal 
formation is one of the first structures targeted by AD pathology. However, why this 
region is so vulnerable to the pathology and how does this start are questions that 
remain to be answered. 
 




1.2.6 Synaptic dysfunction in AD 
Considering the essential role of synaptic plasticity for memory processes, it is 
without question that its disruption can lead to significant memory impairments, as 
those characterising the first signs of AD. Indeed, abnormalities of synaptic 
transmission have been characterised as part of the neuropathology. 
Morphometric analysis of temporal and frontal cortices of AD patients showed a 
major loss of synapses that was greater than that of neurons (Davies et al. 1987).  
Supporting this initial finding, a reduction in synaptic density in the dentate gyrus 
of AD patients (Scheff et al. 1996) as well as alterations in synaptic transmission 
and plasticity in the hippocampus of transgenic mice models of AD were found both 
in vitro (Larson et al. 1999) and in vivo (Giacchino et al. 2000). The relevance of 
these findings becomes obvious considering that these quantitative post-mortem 
measurements correlate more robustly with cognitive impairments before death 
than numbers of NFTs, amyloid plaques and other indicative parameters of 
neuronal dysfunction (Terry et al. 1991).  
The discoveries described above led to the formulation of the “synaptic hypothesis 
of AD”. This postulates that synapses are an early target of AD, prior to neuronal 
loss and the onset of gross neurodegeneration, which accounts for the subsequent 
memory impairment, the most common initial symptom in AD patients (Selkoe 
2002). Much of the support for this concept comes from studies examining the 
impact of neurotoxic species of Aβ on synaptic function, specifically in brain regions 
that are key for memory, such as the hippocampus. For instance, 
electrophysiological recordings in hippocampal slices from transgenic mice models 
of AD have shown smaller EPSPs as well as failure in maintaining LTP, which was 
correlated with deficits in memory and learning in behavioural tasks (Larson et al. 
1999; Moechars et al. 1999; Chapman et al. 1999). In addition, it has also been 
found a decreased basal synaptic transmission in slices from these mice lines 
(Hsia et al. 1999). One prominent constraint of these studies is the variability in 
results due to differences in age and genetic background of mice lines and as well 
as in electrophysiological protocols used. Nonetheless, they do provide consistent 
evidence that AD transgenic mice display significant deficits in synaptic function 
that occur before plaque deposition. An additional difficulty is the identification of 
the Aβ species responsible for these synaptotoxic effects as transgenic mice are 
likely to accumulate different forms of Aβ in the brain, including monomers, soluble 
and insoluble oligomers, and fibrils (Selkoe 2002). However, it has been possible 
 




to isolate different species of Aβ either from natural or synthetic sources, that can 
then be used to specifically differentiate their effects on synaptic function (Cleary 
et al. 2005; Cheng et al. 2007). For instance, it has been found that 
intracerebroventricular injection of Aβ oligomers, but not fibrils, in adult rats blocks 
hippocampal LTP (Walsh et al. 2002). In support of this, numerous studies have 
proven the concept that soluble Aβ oligomers contribute to a greater extent than 
fibrils and/or plaques to synaptic plasticity and memory impairments (Selkoe 2008; 
Shankar et al. 2008; Tomiyama et al. 2010) and correlate better with cognitive 
decline (Mucke et al. 2000; Näslund et al. 2000; McLean et al. 1999). These 
findings in animal models have led to the obvious therapeutic approach of reducing 
synaptotoxic Aβ forms in the brain as a successful attempt to rescue the 
impairments in synaptic function and cognition in animal models of AD (Dewachter 
et al. 2002; Dodart et al. 2002).  
In summary, the synaptic hypothesis of AD has brought to light the important 
concept that prior to the development of gross AD neuropathology, changes to 
hippocampal synaptic function take place, more likely due to the presence of 
soluble Aβ forms than to amyloid plaques accumulation. Therefore, research 
efforts are increasingly focusing on understanding subtle synaptic alterations 
occurring at early stages of AD, which may hold the key for preventing early 
cognitive dysfunction.  
Alterations in neurotransmitter systems can greatly impact on neuronal function 
and synaptic transmission. Indeed, disturbance of these systems has been 
associated with AD and may contribute to deficiencies in synaptic transmission 
observed in neurodegenerative processes, even before neuronal loss occurs 
(Kandimalla & Reddy 2017). Specifically, cholinergic and glutamatergic systems, 
which play a central role in cognition, appear to be selectively affected by AD 
pathology (Butterfield & Pocernich 2003; Francis 2003). Supporting this idea, 
current treatments for AD aim to restore the function of these neurotransmitters 
(Yiannopoulou & Papageorgiou 2013). Although these drugs do not stop the 
progression of the disease, they can ameliorate the symptoms of AD patients, 
clearly showing a significant involvement of glutamate and acetylcholine-mediated 
transmission in AD. 
 
 




Cholinergic system in AD 
Cholinergic transmission is mediated by the neurotransmitter acetylcholine (ACh) 
and it is involved in various aspects of cognitive function, including attention (Turchi 
& Sarter 1997; Chiba et al. 1995) and memory (Everitt & Robbins 1997). The latter 
is mediated by cholinergic neurons in the basal forebrain that project to the 
hippocampus, particularly neurons in the medial septum and the vertical diagonal 
band of Broca that form the septo-hippocampal pathway (Mesulam et al. 1983). 
These areas have been implicated in spatial and working memory, as ablation of 
these neurons resulted in impairments in spatial navigation tasks in rats (Beninger 
et al. 1986; Dunnet et al. 1987; Hagan et al. 1988; Berger-Sweeney et al. 1994). 
In AD, NFTs have been observed in the basal forebrain together with marked 
neuronal loss (Perry et al. 1977; Spillane et al. 1977; White et al. 1977; Whitehouse 
et al. 1982). The depletion of cholinergic axons is accompanied by a decrease in 
the activity of choline acetyltransferase (ChAT) (Davies & Maloney 1976; Wilcock 
et al. 1982), the enzyme that synthesises ACh, therefore resulting in reduced ACh 
uptake in AD. Since these cholinergic abnormalities are correlated with dementia 
severity (Perry et al. 1978; Bierer et al. 1995; Wilcock et al. 1982), these early 
observations led to the formulation of the “cholinergic hypothesis of AD”. This 
hypothesis postulates that accumulation of NFTs in the basal forebrain and the 
subsequent loss of cholinergic projections into the hippocampus are responsible, 
at least in part, for the cognitive dysfunction observed in AD (Contestabile 2011). 
Although this has been supported by the positive effects of AChEIs inhibitors on 
cognitive deficits associated with AD (Doody et al. 2001; Courtney et al. 2004), the 
fact that they only function as a symptomatic treatment, and not even for all AD 
patients (Connelly et al. 2005; Lemstra et al. 2007), has brought significant 
controversy around the cholinergic hypothesis of AD. 
Glutamatergic system in AD 
AD pathology affects several areas where glutamatergic neurons are located, such 
as the layers III and V of the neocortex and the hippocampus (Kowall & Beal 1991; 
Francis 2003). As opposed to a reduced cholinergic transmission, the effects of 
AD pathology on the glutamatergic system generally lead to an increased 
concentration of glutamate around the synapses. The mechanisms proposed to 
explain this increase are numerous. For instance, a reduced presynaptic release 
of glutamate has been supported by the observation of decreased levels of 
 




presynaptic vesicular glutamate transporters 1 and 2 (VGLUT1 and 2), responsible 
for maintaining the levels of glutamate in synaptic vesicles (Fremeau et al. 2001), 
in the brains of AD patients (Kashani et al. 2008; Kirvell et al. 2006). This may be 
due to preferential accumulation of Aβ peptides in neurons expressing these 
transporters (Sokolow et al. 2012). In addition, a mechanism consisting in reduced 
glutamate clearance could also take place, as levels of excitatory amino acid 
transporters 1 and 2 (EAAT1 and 2), responsible for glutamate clearance from the 
synaptic cleft (Andersen et al. 2006; Shashidharan et al. 1994), are also reduced 
in the cortex and hippocampus of AD patients (Jacob et al. 2007; Scott et al. 2011; 
Masliah et al. 1996; Li et al. 1997). Importantly, these changes may be an early 
sign in disease pathology (Masliah et al. 1996).  
Taken together, these AD-related changes to the glutamatergic system lead to an 
accumulation of glutamate at the synapses (Revett et al. 2013). This has a well-
established excitotoxic effect since built-up glutamate activates NMDARs, 
triggering a receptor-mediated increase in intracellular calcium concentration 
(Dong et al. 2009). Elevation in calcium levels can alter cell homeostasis and has 
various consequences that lead to cell death, such as the activation of calpain 
(Vosler et al. 2008) and the mitochondrial apoptotic pathway (Alberdi et al. 2010), 
which eventually result in neuronal loss associated with AD (Dong et al. 2009).  
The coexistence of glutamate and acetylcholine receptors in pyramidal neurons in 
the neocortex led to the idea that effects mediated by these neurotransmitters may 
act in combination to cause disturbances in synaptic transmission (Francis 2005). 
This is further supported by the approval of a combination therapy consisting in an 
acetyl cholinesterase inhibitor and NMDAR blocker for the treatment of AD 
(Alzheimer’s Association 2018). Although it is not clear how neurotransmitter 
systems interact, it has become evident that AD neuropathology very likely 
involves complex interactions at different levels of these systems that collectively 
contribute to synaptic dysfunction. 
1.3 mGluRs and mAChRs in AD: a metabotropic problem 
As outlined above, glutamatergic and cholinergic transmission are severely 
affected by the pathological effects of AD, which may partially explain the cognitive 
deficits of the disease. Specifically, growing evidence supports that dysregulation 
of metabotropic receptors from the glutamatergic and cholinergic families play an 
 




important role in neurodegenerative mechanisms (Thathiah & De Strooper 2011). 
As a consequence, targeting these receptors may be of therapeutic interest.  
Both mGluRs and mAChRs are synaptic GCPRs coupled to Gq/11 and the activation 
of PLC and phosphoinositide hydrolysis (Huang & Thathiah 2015). This shared 
signalling cascade is also a common pathway affected in disease. Indeed, previous 
studies have shown that Gq/11-associated signalling is compromised in AD brains 
(Shiozaki & Iseki 2004; Albasanz et al. 2005). This is likely to affect APP processing 
through the activation of PKC (Caporaso et al. 1992; Buxbaum et al. 1990) and 
mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase 
(ERK) (Mills et al. 1997), both events regulated by Gq/11 activation by mAChRs or 
mGluRs (Fisher 2012; Sokol et al. 2011; Thathiah & De Strooper 2011). However, 
compelling evidence is now suggesting that there may be other pathways by which 
synaptic GPCRs can mediate pathological pathways. 
Out of all muscarinic receptor subtypes, mAChR1 is the most abundantly 
expressed in the hippocampus (Levey et al. 1991; Wei et al. 1994; Flynn et al. 
1995). In this region, mAChR1 is involved in short term memory and memory 
consolidation (Anagnostaras et al. 2003), a process known to be impaired in AD 
(Levey 1996). Supporting a role of mAChR1 in AD, a study shown that agonism of 
the receptor rescued impairments in hippocampal-dependent memory in an AD 
mouse model (Caccamo et al. 2006). Also, that these effects were due to reduction 
in amyloid-β and tau pathologies (Caccamo et al. 2006). Supporting this, another 
study showed an increase in amyloid-β production and plaque formation as a result 
of the inactivation of mAChR1 (Davis et al. 2010), in line with the concept of GPCR 
regulation of APP processing.  
The involvement of mGluRs in AD has also been linked to the regulation of APP 
processing. Specifically, activation of the mGluR5 subtype has been shown to 
stimulate APP secretion (Sokol et al. 2011). In addition to this, other roles for 
mGluR5 in the pathophysiology of AD have emerged. A large body of evidence 
supports that aberrant activation of mGluR5 can mediate several Aβ-induced 
deficits in synaptic function (Wang 2004; Shankar et al. 2008; Hu et al. 2014; 
Rammes et al. 2011). Further showing the importance of mGluR5 in Aβ pathology, 
mGluR5 appears to be required for the Aβ-mediated impairments in memory and 
learning displayed in animal models of AD (Um et al. 2013; Hamilton et al. 2016; 
Hamilton et al. 2014). Some of these effects may be related to the regulation of 
 




NMDAR-mediated excitotoxicity and degeneration by mGluR5 (Kingston et al. 
1999; O’Leary et al. 2000; Movsesyan et al. 2001), as this is a known mechanism 
activated by Aβ (Molnár et al. 2004; Miguel-Hidalgo et al. 2002; Shankar et al. 
2007; Malinow 2012; Snyder et al. 2005; Doble 1999). These studies have 
positioned mGluR5 as a central mediator of synapse weakening pathways (Figure 
1-6).   
Altogether, the above evidence highlights the importance of synaptic GPCRs, 
mAChRs and mGluRs, in the pathology of AD. Since members of both families are 
coupled to the same G-protein mediated signalling pathway, the possibility of a 
functional interaction between these receptors has emerged. Given that both 
receptors are separately implicated in AD pathology, their potential interplay could 
also play a role in how receptor function is altered in synaptotoxic environments.  
The concept of cross-talk interaction between GPCR-mediated pathways is not 
new, however (Hur & Kim 2002). This concept is based on the idea that G-protein 
subunits can exert competitive stearic hindrance when binding to their receptors 
(Hippe et al. 2013). For this to occur, simultaneous activation of both GPCRs 
coupled to the same specific G-proteins is presumed, as they are present in a 
limited amount in the intracellular space (Thompson et al. 2007). Since mGluR5 is 
aberrantly activated under AD-like conditions and deficiency in cholinergic 
transmission is a hallmark of AD pathology, the potential contribution of mGluR5-
mediated inhibition of mAChRs remains possible. Supporting this functional 
inhibition hypothesis, aberrant expression of mGluR5 leads to the inhibition of 
mAChR-mediated LTD in the perirhinal cortex (Jo et al. 2006). Furthermore, 
preliminary data from our lab have shown that in the same brain region, the Aβ-
mediated inhibition of mAChR-dependent LTD occurs in a mGluR5-dependent 
manner (unpublished results). In line with this, our data also shows that 
dexamethasone-mediated inhibition of mAChRs-dependent LTD is also dependent 
on group I-mGluRs activation (unpublished results). 
 





Figure 1-6. Model of synaptic dysfunction in AD. Under pathological conditions, 
overactivation of mGluR5 leads to increased intracellular calcium levels and the generation 
of calcium excitotoxicity. This triggers multiple pathological mechanisms that result in 
synapse loss and subsequent neurodegeneration. This effect is enlarged by Aβ-induced 
activation of mGluR5-PrPC signalling complex which results in Fyn-dependent 
phosphorylation of NMDARs as well as phosphorylation of tau. Both events trigger 
pathological signalling cascades including removal of AMPAR from the synaptic membrane 
and disassembly of hyperphosphorylated tau from microtubules, that together contribute to 
synapse weakening pathways. In addition, activation of mGluR5 results in an increased 
production of toxic Aβ species via blockade of the repressive effect of FMRP on the 
translation of APP mRNA. Finally, competition between mGluR5 and mAChR for shared 
signalling molecules is a potential mechanism by which cholinergic function is impaired in 
AD pathology.  Dashed arrow indicates unknown mechanism. ER: Endoplasmic reticulum, 
APP: Amyloid-precursor protein, AMPAR: α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor, NMDAR: N-methyl-D-aspartate receptor, mGluR5: 
metabotropic glutamate receptor 5, mAChR: muscarinic acetylcholine receptor, ACh: 
acetylcholine, IP3: inositol 1,4,5-triphosphate, PKC: protein kinase C, DAG: diacylglycerol, 
PIP2: phosphatidylinositol 4,5-bisphosphate, PrPC: cellular prion protein, GKAP: guanylate 
kinase-associated protein, FMRP: Fragile X mental retardation protein. 
In summary, compelling evidence positions synaptic GPCRs dysregulation as a 
key to understand the pathophysiology of AD. Specifically, mGluR5 and mAChR1 
have become very attractive targets in AD therapeutics. However, a better 
understanding of the mechanisms mediated by these receptors in disease is 
required in order to develop efficient treatments for AD. 
1.4 Hypothesis and aims 
Based on (1) evidence showing a role of synaptic GPCRs, mGluR5 and mAChR1, 
in the synaptic impairments that characterise AD pathophysiology (Wang 2004; Hu 
et al. 2014; Caccamo et al. 2006) and (2) preliminary data from this lab showing 
 




an impairment of mAChRs function mediated by mGluR5 (unpublished results), 
the general hypothesis of this thesis is that: 
Aberrant activation of mGluR5 has detrimental effects on synaptic function and can 
lead to the impairment of mAChR receptor function, and these effects are 
enhanced in AD pathology.   
Specific hypotheses are stated within each aim below. 
Aim 1: Characterise the role of mGluR5 in synaptic plasticity in non-pathogenic 
conditions. It was hypothesised that agonist activation of mGluR5 causes the 
following effects: (1) depression of baseline recordings and blockade of LTP 
induction in acute hippocampal slices, (2) reduction of mAChR-mediated calcium 
increase elicited by application of the mAChR agonist carbachol (CCh) in primary 
hippocampal cultured neurons and (3) activation of GSK3β in acute hippocampal 
slices. 
Aim 2: Characterise the expression of synaptic proteins over AD progression in 
post-mortem human brain samples. It was hypothesised that (1) mGluR5 protein 
expression was increased in brains from patients with severe AD and that (2) 
mAChR1 protein expression was decreased in brains from patients with severe AD 
compared to control brains. 
Aim 3: Characterise the effect of AD pathology in the form of hyperphosphorylated 
human tau on synaptic GPCRs function. Based on results from human brain work, 
it was hypothesised that expression of P-hTau in cultured hippocampal slices (1) 
reduces the mAChR-mediated change in holding current elicited by CCh and (2) 
does not reduce the mGluR-mediated change in holding current elicited by the 
mGluR agonist, DHPG. 
1.5 Summary 
The general aim of this thesis is to investigate the roles of mGluRs and mAChRs 
in AD pathology. Chapter 3 is focused on understanding whether mGluR5 
activation is sufficient to cause effects related to AD pathology, such as the 
impairment of LTP and mAChR function and the activation of GSK3β. Chapter 4 
looks at the state of receptors in AD brains, to evaluate whether the findings from 
 




Chapter 3 may be relevant in disease. Chapter 5 then explores if tau 
hyperphosphorylation, a hallmark of AD brains, can affect synaptic GPCR function. 
Finally, Chapter 6 provides an overall discussion about how these results can be 
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Male Wistar rats at postnatal day (P) 24-30 (Charles River, UK) were used for the 
preparation of acute hippocampal slices. Animals were housed in groups of 4-5 
per cage with water and food ad libitum. Cages were maintained at 21 ± 2°C and 
relative humidity of 55 ± 10%. Animals were exposed to a 14 h light/10 h dark cycle 
with the light phase starting at 5:00 h and finishing at 19.00h. P7 male Wistar rats 
were used for the preparation of organotypic hippocampal slice cultures and P0 
male Wistar rats were used for the preparation of primary neuronal cultures. Adult 
female Wistar rats were used for a maximum of 6 litters and they were time mated 
by checking for plugs. Females were kept alone until they had their litter. All efforts 
were made to minimize numbers of animals used as well as animal suffering.  All 
procedures involving animals were performed in accordance with the UK Animals 
Scientific Procedures Act of 1986.  
2.2 In vitro preparations 
2.2.1 Acute hippocampal slices preparation from rat brain 
Acute hippocampal slices were prepared from P24-30 male Wistar rats. Animals 
were sacrificed between 10:00 a.m. and 11:00 a.m. by cervical dislocation and then 
decapitated with scissors. The skull was cut following the longitudinal fissure and 
each part was separated. The brain was rapidly removed and placed in ice-cold 
artificial cerebrospinal fluid (aCSF) bubbled with 95% O2/5% CO2, which comprised 
124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4, 2 mM CaCl2, 1 mM 
MgSO4 and 10 mM D-glucose. The two hemispheres were then separated by 
performing a midsagittal cut of the brain and one hemisphere was placed back into 
the ice-cold aCSF to be dissected subsequently. The hippocampus was micro-
dissected from the whole hemisphere. First, the hemisphere was placed with the 
dorsal side facing down so the ventral side could be observed. Gentle pressure 
was applied to the front part of the hemisphere to hold it in place while the 
cerebellum was folded back with forceps. Next, a spatula was placed in the lateral 
ventricle and swept underneath each end of the hippocampus to separate it from 
adjacent cortex tissue. With the spatula underneath the hippocampus, a 180° turn 
was performed to lift it out. Finally, the hippocampus was cut away from remaining 
cortex tissue by applying pressure with the spatula while moving it along the dorsal 
edge of the hippocampus. The hippocampus was then placed on a filter paper and 
transversely sliced using a McIlwain tissue chopper (The Mickle Laboratory 
 




Engineering Co. Ltd., Gomshall, UK) to obtain 400 μM thickness hippocampal 
slices. Slices were re-submerged in ice-cold aCSF bubbled with 95% O2/5% CO2 
and separated. Finally, slices were placed in a submerged chamber containing 
aCSF at room temperature (RT: ~21°C) and allowed to recover for at least 1 hour.  
2.2.2 Organotypic cultured hippocampal slices preparation from rat brain 
Organotypic hippocampal slice cultures were prepared from P7 Wistar rats. 
Dissection areas and sterilised surgical tools were sprayed with 70% ethanol to 
ensure sterile conditions before starting the procedure. Rats were sacrificed by 
dislocation of the neck and then decapitated with scissors. The skull was cut 
following the longitudinal fissure and each part was separated. The brain was 
rapidly removed and placed in ice-cold cutting solution (previously filtered in sterile 
conditions) that contained: 238 mM sucrose, 2.5 mM KCl, 26 mM NaHCO3, 1 mM 
NaH2PO4, 11 mM D-glucose, 5 mM MgCl2 and 1 mM CaCl2. At this point, the 
procedure was performed in sterile conditions in a laminar-flow hood. The two 
hemispheres were separated by performing a midsagittal cut of the brain and one 
hemisphere was placed back into the ice-cold cutting solution to be dissected 
subsequently. The hippocampus was micro-dissected from the whole hemisphere 
in accordance to the method described for acute hippocampal slices. The 
hippocampus was transversely sliced using a McIlwain tissue chopper (The Mickle 
Laboratory Engineering Co. Ltd., Gomshall, UK) to obtain 350 μM thickness 
hippocampal slices. To remove cutting solution, slices were washed four times in 
cultured medium (previously filtered in sterile conditions) comprising: 78.8% 
minimum essential medium, 20% heat-inactivated horse serum, 30 mM HEPES, 
26 mM D-glucose, 5.8 mM NaHCO3, 2 mM CaCl2, 2 mM MgSO4, 70 µM ascorbic 
acid, 0.1% 1 mg/ml insulin, pH 7.3 and 320-330 mOsm. Slices were then placed 
on semi-permeable membrane inserts (Millipore Corporation, Bedford, MA, USA) 
in a six-well plate and the excess of culture medium on the membrane insert was 
removed with a pipette. On initial plating, each well contained 950 μL of culture 
medium pre-warmed at 37°C. Medium was changed every 2 days without 
antibiotics with a pipette, avoiding direct application of medium on the slices. First 
change of medium was done with 900 μL of fresh medium and subsequent 
changes with 850 μL. Six-well plates were kept in the incubator at 37°C with 20% 
O2, 5% CO2.  
 




2.2.3 Primary neuronal culture preparation from rat brain  
Primary neuronal cultures were prepared as described in (Brewer & Torricelli 2007) 
with some variations. Hippocampal and cortical neurons were dissected from P0-
1 Wistar rats (Charles River, UK) using sterile surgical tools. Rats were sacrificed 
by decapitation and the brain was removed and transferred to Hibernate-A medium 
(A1247501, Thermo Fisher) supplemented with B-27 Supplement serum-free 
(17504044, Thermo Fisher) and GlutaMAX (35050038, Thermo Fisher), hereafter 
termed HABG medium. The cerebellum and brainstem were removed, the cortex 
and hippocampus were isolated from the midbrain and meninges were removed. 
At this point, the procedure was performed in sterile conditions in a laminar-flow 
hood. Tissue was pulled apart into pieces of approximately 2 mm3 and digested 
with Trypsin-EDTA (25200056, Thermo Fisher) by addition to Hibernate-
A/GlutaMAX medium for 15 min at 37°C. Trypsin was inactivated by addition of 
HABG and the tissue was further dissociated by pipetting tissue into and out of a 
Pasteur pipette with a fire-polished tip. The cell suspension was added to a 
prepared OptiPrep Density Gradient Medium (D1556, Sigma-Aldrich) in HABG and 
centrifuged at 160 g for 12 minutes. OptiPrep was used for separation of cells 
according to their density. The resulting upper two fractions contained debris and 
oligodendrocytes and were discarded. The third fraction was enriched for neurons 
which were quantified using Trypan-blue exclusion in a haemocytometer. Neurons 
were transferred to Neurobasal-A medium (10888022, Thermo Fisher) 
supplemented with B-27, GlutaMAX and gentamycin (15710049, Thermo Fisher). 
Neurons were plated into 10 mm diameter glass coverslips coated with poly-D-
lysine (P7280, Sigma-Aldrich) at a density of 3 x 104 cells/cm2. Coverslips were 
placed in 12-well plates (665180, Greiner Bio-One), each well containing 1 mL of 
supplemented Neurobasal-A medium. This medium was changed at 21 days by 
replacing half of it with 500 µL of fresh medium. Neurons were kept in the incubator 
at 20% O2, 5% CO2 at 37°C. Thank you to Tom Steward for performing this 
procedure. 
2.3 Human post-mortem brain samples 
Two sets of human samples were obtained from the South West Dementia Brain 
Bank (Southmead Hospital, Bristol Medical School, Faculty of Health Sciences, 
University of Bristol). Diagnosis of patients was performed by following a combined 
clinical and neuropathological assessment according to  (Mirra et al. 1991) and the 
 




National Institute of Aging-Alzheimer’s Association (NIA-AA) (Hyman et al. 2012). 
These criteria incorporate the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) scale, which is a score system based on a series of 
standardised and validated measurements for the assessment of AD (Fillenbaum 
et al. 2008). These include clinical, neuropsychology, neuropathology, 
neuroimaging, behavioural, family history, autopsy and educational assessments. 
The semi-quantitative evaluation of the frequency of age-related plaque score 
(Table 2) together with the clinical history, results in a score used as an indication 
of the certainty of the diagnosis of AD, i.e. definite, probable AD, possible AD, no 
evidence of AD (Hyman et al. 2012) (Table 3). The progression of AD was 
measured according to the Braak staging method, which is a topographical staging 
of the NFTs deposition in the brain. Since the spatiotemporal pattern of progression 
of NFTs is stereotypical and predictable and correlates with the severity of 
cognitive decline (Braak & Braak 1991), this system is used for the pathological 
diagnosis of AD. Broadly, the transentorhinal and hippocampal regions are first 
affected (stages I-II), then the limbic areas (stages III-IV) and finally isocortical 
areas (V-VI) (Serrano-Pozo et al. 2011).  
Table 2. Age-related plaque score. 
 Frequency of plaques 
Age of patient at death (years) None Sparse Moderate Frequent 
<50 0 C C C 
50-75 0 B C C 
>75 0 A B C 
0 = No histologic evidence of Alzheimer’s disease. 
A = Histologic findings are uncertain evidence of Alzheimer’s disease. 
B = Histologic findings suggest the diagnosis of Alzheimer’s disease. 
C = Histologic findings indicate the diagnosis of Alzheimer’s disease. 
Thank you to South West Dementia Brain Bank for providing this information. 
 
The first set of samples, hereafter referred as “AD samples”, contained temporal 
lobe cortex samples from subjects with definite AD (Braak stages V-VI, N = 10) 
and non-demented aged matched control subjects (Braak stages 0-III, N = 10). 
The second set, hereafter referred as “P-AD samples”, contained temporal lobe 
cortex samples from subjects with probable/possible AD (Braak stages III-IV, N = 
11) and non-demented aged matched control subjects (Braak stages 0-III, N = 11). 
All human tissue samples were handled according to the regulations of the Human 
Tissue Authority (HTA) of the Department of Health of the UK Government. 
 




Available clinical and neuropathological data regarding human tissue brain 
samples is shown in Table 4 and Table 5. 
Table 3. CERAD diagnostic groups. 
CERAD diagnostic group Description 
Normal (with respect to 
dementia) 
No histologic evidence of AD (0 score) and no clinical history of 
dementia, and absence of other neuropathologic lesions likely to 
cause dementia  
or 
An A age-related plaque score and no clinical history of dementia 
Definite AD 
C age-related plaque score and clinical history of dementia, and 
presence or absence of other neuropathological lesions likely to 
cause dementia 
Probable AD 
B age-related plaque score, and clinical history of dementia, and 
presence or absence of other neuropathologic lesions likely to 
cause dementia 
Possible AD 
A age-related plaque score, and clinical history of dementia, and 
presence or absence of other neuropathologic lesions likely to 
cause dementia 
or 
B or C age-related plaque score and absence of clinical 
manifestations of dementia 
Thank you to South West Dementia Brain Bank for providing this information. 
Table 4. Clinical and neuropathological data of AD human samples. 








BBN_9292 C1 73 M 35 n/a III 
BBN_9329 C2 80 M 45.75 n/a 0 
BBN_4205 C3 87 M 24 n/a II 
BBN_4229 C4 87 F 47 n/a III 
BBN_9399 C5 73 F 50 n/a II 
BBN_9407 C6 90 F 41 n/a II 
BBN_9413 C7 82 M 67 n/a II 
BBN_22625 C8 70 F 33.25 n/a II 
BBN_24312 C9 69 M 31.25 n/a II 
BBN_26009 C10 87 F 54.75 n/a II 
AD 
BBN_9371 AD1 73 F 50.5 Definite AD V 
BBN_9377 AD2 75 M 39.5 Definite AD V 
BBN_9401 AD3 86 F 45.25 Definite AD VI 
BBN_9405 AD4 88 M 28 Definite AD VI 
BBN_9435 AD5 74 M 45.5 Definite AD V 
BBN_22622 AD6 81 F 58.25 Definite AD V 
BBN_24563 AD7 67 M 36 Definite AD VI 
BBN_26011 AD8 80 M 68.5 Definite AD IV 
BBN006.26796 AD9 66 F 37.25 Definite AD VI 
BBN006.28766 AD10 87 F 40.5 Definite AD V 
 




Table 5. Clinical and neuropathological data of P-AD human samples. 








BBN_24561 C1 90 F 67.25 No AD I 
BBN_8712 C2 81 F 103 No AD II 
BBN_9353 C3 94 M 40 No AD II 
BBN_9407 C4 90 F 41 No AD II 
BBN_9408 C5 87 M 42 No AD II 
BBN_9432 C6 74 F 27.5 No AD II 
BBN_10251 C7 79 F 48 No AD II 
BBN_26009 C8 87 F 54.75 No AD II 
BBN_8949 C9 79 M 24 No AD 0 
BBN_19626 C10 81 M 35.75 No AD III 
BBN_9311 C11 93 M 37.75 No AD III 
P-AD 
BBN_9331 P-AD1 97 M 34 Possible AD IV 
BBN_9343 P-AD2 80 M 24 Probable AD IV 
BBN_4215 P-AD3 80 F 26 Probable AD IV 
BBN_4216 P-AD4 84 F 48 Probable AD IV 
BBN_9394 P-AD5 81 M 32 Probable AD IV 
BBN_9433 P-AD6 88 M 36 Probable AD IV 
BBN_9257 P-AD7 82 F 110 Probable AD IV 
BBN_4220 P-AD8 86 F 13.5 Possible AD III 
BBN_9397 P-AD9 97 F 36 Possible AD III 
BBN_22624 P-AD10 93 M 44 Probable AD III 
BBN_9217 P-AD11 93 F 53 Probable AD III 
1 Medical Research Council ID, 2 Post-mortem (PM) delay refers to the time interval in 
hours between the time of the death and the time when the brain is frozen. C: Non-
demented aged-matched control subject, AD: Alzheimer’s disease patient, P-AD: 
Possible/probable AD patient, M: Male, F: Female, n/a: not available. 
For technical purposes and to facilitate the manipulation of human samples when 
loading polyacrylamide gels (see Section 2.8.3), the Medical Research Council ID 
of each sample was randomly assigned a sample name consisting of a letter (“C” 
for non-demented aged-matched control subject, “AD” for Alzheimer’s disease 
patient and “P-AD” for possible/probable AD patient) and a number (from 1 to 10 
within the AD cohort and from 1 to 11 within the P-AD cohort).  
2.4 Total RNA extraction from human tissue 
Total RNA was extracted from post-mortem human tissue samples by acid phenol-
guanidinium-thiocyanate chloroform extraction (Chomczynski & Sacchi 1987) as 
described in (Anon 2006) with some variations. Approximately, 50 mg of tissue 
were homogenised in 1 mL of solution D (4 M guanidinium thiocyanate, 25 mM 
 




sodium citrate 2H2O, 0.5% (wt/vol) sodium lauryl sarcosinate, 0.1 M 2-
mercaptoethanol) using a polypropylene pellet pestle (Z359947, Sigma) and a 
pellet pestle motor (Kimble® Kontes, Z359971, Sigma) for 30 s. Then, 100 μL of 2 
M sodium acetate, 1 mL of phenol and 200 μL of 49:1 (wt/vol) chloroform/isoamyl 
alcohol were added per mL of solution D, mixing the contents after addition of each 
reagent by inversion of the tubes. Samples were incubated 10 min on ice and 
centrifuged at 10,000 g for 20 min at 4°C.  The aqueous phase was transferred to 
a fresh tube and an equal volume of isopropanol (~900 μL) was added to the 
extracted RNA. Tubes were then thoroughly mixed and RNA was allowed to 
precipitate for 1 h at -20°C. After this period, RNA was collected by centrifugation 
at 10,000 g for 30 min at 4°C. Isopropanol was decanted and the RNA pellet was 
dissolved in 0.3 mL of solution D for every mL of this solution added in the first 
step. An equal volume of isopropanol was added and RNA was precipitated for 1 
h at -20°C. Precipitated RNA was collected by centrifugation at 10,000 g for 10 min 
at 4°C. The resulting pellet was washed twice with 75% ethanol, carefully removing 
any remaining ethanol in the second wash. Samples were allowed to air dry for 10 
min and then dissolved in 50 μL of 0.1% diethylpyrocarbonate (DEPC)-treated 
water. Finally, they were incubated at 50°C for 10 min to fully dissolve the pellets. 
Absorbance of samples was measured at 260 and 280 nm by using a 
NanoPhotometer (IMPLEN, München, Germany) and RNA concentration was 
determined by the Beer-Lambert law. Purity of samples was assessed by the 
A260/280 ratio. RNA samples were aliquoted and stored at -80°C for further use.  
2.5 First-strand cDNA synthesis from human RNA samples 
For cDNA synthesis, 1 μg of extracted RNA was reverse transcribed using 
SuperScript™ III Reverse Transcriptase kit (18080-44, Thermo Fisher Scientific) 
following the manufacturer’s instructions. First, RNA samples were diluted in 
DEPC-treated water to obtain 1 μg of RNA in a total volume of 11 μL in a nuclease-
free reaction tube. A mixture containing 1 μL of 50 μM oligo(dT)20 (18418-020, 
Thermo Fisher Scientific) and 1 μL of 10 mM dNTP mix (18427-013, Thermo Fisher 
Scientific) was prepared (quantities indicated per RNA sample). Then, 2 μL of this 
mixture was added to the reaction tube. Reaction tubes were heated at 65°C for 5 
min and immediately incubated on ice for at least 1 min. Contents were then 
collected by brief centrifugation. A mixture of 4 μL of 5X First-Strand Buffer, 1 μL 
of 0.1 M DTT, 1 μL of RNaseOUT™ Recombinant RNase Inhibitor (10777-019, 
Thermo Fisher Scientific) and 1 μL SuperScript™ III RT (quantities indicated per 
 




RNA sample) was prepared and gently mixed by pipetting up and down. Then, 7 
μL of this mixture were added to each reaction tube and mixed by gentle pipetting. 
A minus reverse transcription (-RT) control tube in which the 1 μL SuperScript™ 
III RT was replaced by 1 μL of DEPC-treated water was prepared with one 
randomly selected sample per each cDNA synthesis procedure. This control is to 
test for contaminating DNA during the RNA extraction procedure. If there is 
amplification of product detected in the qPCR step, it is most likely derived from 
contaminating DNA, as the -RT control tube should not be amplified. In total, each 
cDNA reaction volume was 20 μL. In the thermal cycler (T100, Bio-Rad, California, 
United States), reaction tubes were incubated at 50°C for 1 h and then the reaction 
was inactivated at 70°C for 15 min. Resulting cDNA was stored at -20°C until 
required. 
2.6 Quantitative polymerase chain reaction (qPCR) with human 
cDNA 
For qPCR reactions, a master mix was prepared including (per cDNA sample): 5 
μL of Fast SYBR Green Master Mix (4385612, Thermo Fisher Scienctific), 1.5 μL 
of 2 μM forward primer, 1.5 μL of 2 μM reverse primer and 1 μL (see Table 6) of 
nuclease-free water. After a light vortex, 9 μl of this mix was added to each well of 
a MicroAmp™ Fast Optical 96-Well Reaction Plate (4346906, Thermo Fisher 
Scientific). Then, 1 μL of cDNA was added to each well and mixed by pipetting up 
and down three times. Plates were always placed on a MicroAmp™ 96-Well 
Support Base (4379590, Thermo Fisher Scientific) and never in contact with the 
bench surface to prevent dirt particles from adhering to the bottom of the wells and 
obstructing the fluorescence reading. To generate a standard curve, a serial 
dilution (Neat - 1:10 - 1:100 - 1:1000 - 1:10,000 - 1:100,000) of cDNA synthesised 
from human brain total RNA (AM7962, Life Technologies) was performed. One 
standard curve was generated per plate. Each plate included a no-RT control 
sample (see cDNA synthesis section above) and a no-template control (NTC) in 
which the 1 μL of cDNA sample was replaced by 1 μL of DEPC-treated water. The 
function of the NTC was to test for primer dimer formation and for DNA 
contamination in the reagents or the plate. The total volume of the qPCR reaction 
was 10 μL (each well) and reactions were run in triplicates. Once loaded, plates 
were covered with a MicroAmp™ Optical Adhesive Film (4360954, Thermo Fisher 
Scientific) and spun in a plate spinner for a few seconds to ensure contents were 
at the bottom of the well. qPCR reactions were performed in a StepOnePlus™ 
 




Real-time PCR System (Applied Biosystems, California, USA). The plate was 
heated at 95°C for 20 s (holding stage) followed by 40 cycles of 3 s at 95°C - 30 s 
at 60°C (cycling stage). After the last cycle was completed, melt curve stage was 
performed for 15 s at 95°C - 1 min at 60°C - 15 s at 95 °C. Data was visualised in 
real time using the StepOne v2.3 software (Applied Biosystems-Life 
Technologies©).  
Table 6. Primers used in this study. 












































Thank you to Dr. Felicity Stubbs (Lightman’s Lab) for providing GUSB primers. For: 
Forward primer, Rev: reverse primer. 
2.6.1 qPCR data analysis and statistics 
Relative product quantities were calculated using the relative standard curve 
method (Anon 2013; Larionov et al. 2005). A standard curve was generated with 
relative quantities and CT values from diluted human brain total cDNA samples. 
For the experimental samples, relative quantity values were interpolated from the 
standard curve and normalised to the endogenous control gene, ribosomal protein 
13 (RPL13). Statistically significant differences (p < 0.05) between patient groups 
were tested by using Mann-Whitney rank sum test, given the non-normal 
distribution of the data. 
2.7 Calcium imaging in primary cultured hippocampal neurons 
The following procedure was performed in sterile conditions in a laminar-flow hood. 
12-well plates were taken out of the incubator and placed in the laminar-flow hood 
and Neurobasal-A medium was removed with a pipette. Coverslips were washed 
four times with 500 µL of HBS buffer (119 mM NaCl, 5 mM KCl, 25 mM HEPES, 
 




33 mM glucose, 2 mM CaCl2, 2 mM MgCl2, 1 µM glycine, 100 µM picrotoxin, pH 
~7.4) supplemented with BSA (1 mg/mL). Fluo-4AM (F14201, Life Technologies), 
a cell-permeant calcium fluorescent dye (λEx/λEm of calcium–bound form: 
494/506 nm), was prepared at 5 µM in HBS/BSA in the dark. Neurons were loaded 
with 250 µL of Fluo-4AM-containing HBS/BSA solution at 20% O2, 5% CO2, 37°C 
in the dark for 1 h. Coverslips were subsequently washed 3 times with 500 µL of 
HBS and placed in the perfusion chamber for imaging where they were constantly 
perfused with HBS buffer (flow rate ~2 mL/min) throughout the experiment. 
Neurons were viewed through a 20X lens in an inverted microscope (Leica DM 
IRBE, Wetzlar, Germany) equipped with a stage (OptiScan II, Prior Scientific, 
Cambridge, UK) and a digital camera (ORCA 100 C4742-95, Hamamatsu 
Photonics, Hamamatsu, Japan) with a charge-coupled device (CCD) for image 
acquisition. Fields with 4 or more neurons were selected on bright-field mode and 
then Fluo-4AM fluorescence was detected on epifluorescence mode using a 
mercury lamp as a light source. Images were taken every 20 seconds and 
visualised on a computer screen using the imaging software SimplePCI 
(Hamamatsu Photonics, K.K, ©2017). An overview of the calcium imaging 
experimental procedure is depicted in Figure 2-1. 
 





Figure 2-1. Schematic diagram of calcium imaging experiments. Primary cultured cells 
were loaded with the calcium dye Fluo4-AM for 1h at 37°C in the dark. After a series of 
washes, coverslips were placed on an inverted microscope equipped with a mercury lamp 
for visualisation of fluorescent signals and a CCD camera for image acquisition.   
2.7.1 Calcium imaging data analysis and statistics 
Image analysis was performed using Icy (Institut Pasteur, ©2011). Regions of 
interest (ROIs) were selected according to soma morphology and fluorescence 
intensity values were obtained for each ROI and for a background region (a region 
with no neurons) using ROI Intensity Evolution tool. For each neuron, background 
intensity was subtracted from ROI intensity at each time point. Data were 
normalised to the average of the pre-conditioning baseline (5 min) and expressed 
as a percentage of this baseline. For each experiment (i.e. coverslip), the average 
of peak intensity values from neurons within a coverslip was obtained and data 
across experiments was pooled and plotted in the graphs. Statistically significant 
differences (p < 0.05) between treatments were tested by using Kruskal-Wallis 
one-way ANOVA on Ranks or Mann-Whitney rank sum test, given the non-normal 
distribution of the data. 
 




2.8 Protein extraction and western blot of rat slices and human tissue 
2.8.1 Protein extraction from acute hippocampal slices 
This procedure was performed at 4°C by keeping samples and lysis buffer on ice 
at all times. Acute hippocampal slices were collected in tubes with aCSF from the 
incubation chamber. Lysis buffer comprised RIPA buffer (50 mM Tris pH 7.4, 150 
mM NaCl, 1% Triton, 0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA) with the 
addition of protease inhibitor cocktail at 1:10 (05892791001, Roche), phosphatase 
inhibitor cocktail at 1:100 (P5726, Sigma) and the serine/cysteine protease inhibitor 
phenylmethanesulfonyl fluoride (PMSF) at 1:100 (P7626, Sigma). First, aCSF was 
removed as much as possible without damaging the slice, then lysis buffer (100 
μL/slice) was added and the tissue was homogenised using a polypropylene pellet 
pestle (Z359947, Sigma) and a pellet pestle motor (Kimble® Kontes, Z359971, 
Sigma) for 30 s. Samples were then centrifuged at 15,000 g for 10 min at 4°C. 
Pellets were discarded and supernatants were collected in a fresh tube. The 
protein concentration of these samples was determined using a bicinchoninic acid 
(BCA) assay (Pierce™ BCA Protein Assay Kit, 23225, Thermo Fisher Scientific). 
Absorbance of the samples was measured at 565 nm with iMark Microplate 
Absorbance Reader (Bio-Rad, California, USA). Microplate Manager v6 software 
(Bio-Rad, California, USA) was used to acquire absorbance measurements. 
Samples were stored at -80°C until required.  
2.8.2 Protein extraction from human tissue 
Human post-mortem frozen samples were lysed at RT in sucrose/SDS buffer (lysis 
buffer) containing 1% SDS, 0.1 g/mL sucrose,1 mM EDTA, protease inhibitor 
cocktail at 1:10 (05892791001, Roche), phosphatase inhibitor cocktail at 1:100 
(P5726, Sigma) and the serine/cysteine protease inhibitor phenylmethanesulfonyl 
fluoride at 1:100 (PMSF, P7626, Sigma). Approximately 100 mg of tissue were 
lysed in 500 μL of sucrose/SDS buffer, added in 3 steps. First, 200 μL of lysis buffer 
was added and samples were homogenised using polypropylene pellet pestle 
(Z359947, Sigma) and a pellet pestle motor (Kimble® Kontes, Z359971, Sigma) 
for 30 s. Then, samples were spun at 3 rpm for 1 min at RT to collect contents and 
reduce bubbling caused by the SDS. Another 200 μL was added and samples were 
homogenised again for 10 s. Finally, 100 μL was added and samples were 
centrifuged at 16 g for 20 min at 16°C. Pellets were discarded and supernatants 
were collected in a fresh tube, constituting the stock solutions. Stock solutions were 
 




diluted 1:10 in lysis buffer to generate the working concentration sample. Protein 
concentration of these samples was determined in the same manner as mentioned 
above for the acute hippocampal slices protein extraction. Samples were aliquoted 
and stored at -80°C until required. 
2.8.3 Western blot 
Protein samples (10 μg) were diluted in 6x Laemmli sample buffer to obtain a 1x 
concentration. For all samples, 10 μg of protein amount were loaded in a 10% 
polyacrylamide gel. Proteins were separated by sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE) at constant voltage (90 mV 
through the stacking gel and 120 mV through the resolving gel) for approximately 
1,5 h. 5 μL of protein marker (Color Prestained Protein Standard Broad Range 11–
245 kDa, New England Biolabs P7712) with bands of known molecular weight was 
loaded as a reference. Samples were then transferred into a polyvinylidene 
difluoride (PVDF) membrane (Immobilon-P, pore size 0.45 µm, IPVH00010, 
Millipore) by wet electroblotting at constant current (300 mA) for 1 h. A cooling unit 
was included in the tank to keep temperature low. Membranes were blocked by 
incubation with 5% skimmed dried milk (Tesco, United Kingdom) in tris-buffered 
saline-Tween 20 (TBS-T) in constant agitation for 1-2 h at RT. Membranes were 
then incubated with primary antibodies (see Table 7)  prepared in 5% milk/TBS-T 
or 5% bovine serum albumin (BSA)/TBS-T overnight at 4 °C in constant gentle 
agitation. Next day, membranes were washed with TBS-T for 30 min in constant 
agitation, changing the TBS-T every 5-10 min. Next, they were incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies prepared in 5% 
milk/TBS-T in constant agitation for 1 hour at RT. Secondary antibodies used in 
this study include anti-mouse HRP conjugate (1:4000, 12-349, Upstate) and anti-
rabbit HRP conjugate (1:4000, 12-348, Millipore). After incubation, the wash step 
was repeated and membranes were incubated with hydrogen peroxide (H2O2) and 
luminol (1:1 v/v, EZ-ECL, 20-500-120, Biological Industries) for 
chemiluminescence detection of the antibodies. The chemiluminescent signal was 
then detected by placing the membrane inside the imaging system (G:Box Chemi 
XT4, Syngene) and images were taken with GeneSys software (Syngene ©2009-
2017, Cambridge, UK). Figure 2-2 shows a schematic representation of the 
experimental procedure for human tissue and acute hippocampal slices western 
blot analysis.  
 




Table 7. Primary antibodies used in this study. 
Antibody Cat. Nº/Supplier Dilution Reference 
Anti-GSK3β-H76 Santa Cruz (sc-9166) 1:200 (Mitic et al. 2017) 
Anti-P-GSK3β Cell Signal (9336L) 1:1000 (Nagaoka et al. 2015) 
Anti-NR1 Upstate (06-31) 1:1000 (Matsuno et al. 2015) 
Anti-GluA2 Millipore (MAB397) 1:1000 
(Peng et al. 2015; Park et 
al. 2007) 
Anti-mGluR1 ProteinTech (19955-1-AP) 1:1000 (Koochekpour et al. 2012) 
Anti-mGluR5 Millipore (AB5675) 1:2000 (Deschwanden et al. 2011) 
Anti-mAChR1 Millipore (AB5164) 1:200 
(Molina et al. 2014; 
Takamori et al. 2007) 
Anti-Homer 1b/c Abcam (ab97593) 1:1000 (Matosin et al. 2016) 
Anti-PSD95 Cell Signal (3409) 1:1000 
(Martineau et al. 2018; 
Subkhangulova et al. 2018) 
Anti-
synaptophysin 
Cell Signal (4329) 1:1000 (Tiwari et al. 2016) 
 
 





Figure 2-2. Schematic diagram of western blot analysis. Tissue from post-mortem 
human brain samples or acute hippocampal slices was first homogenised. Then, samples 
were subjected to SDS-PAGE to separate proteins according to size. Finally, proteins were 
transferred to a PVDF membrane for immunodetection of proteins of interest.  
2.8.4 Western blot data analysis and statistics 
Optical densities of immune reactive bands were measured using ImageJ software 
(v1.46r, National Institute of Health, USA). Optical densities of the protein of 
interest were normalised to β-Actin to account for inaccuracies in gel loading and/or 
 




pipetting. These values were then divided by the average of control experiments 
and expressed as a percentage of control. In the case of western blot experiments 
with human samples, due to the heterogeneity of the control samples, data was 
just normalised to β-Actin. 
2.9 Co-immunoprecipitation (Co-IP) assay with human tissue 
The following procedures were conducted on ice.  
2.9.1 Tissue homogenisation 
Human post-mortem frozen samples were allowed to thaw on ice prior 
homogenisation of the tissue. The samples were lysed on ice in Co-IP lysis buffer 
containing 25 mM Tris (pH 7.6), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 
autoclaved double distilled H2O and protease inhibitor cocktail (05892791001, 
Roche) at 1:10. Approximately 100 mg of tissue were lysed in 500 μL, added in 3 
steps. First, 200 μL of Co-IP buffer was added and samples were homogenised 
using a polypropylene pellet pestle (Z359947, Sigma) and a pellet pestle motor 
(Kimble® Kontes, Z359971, Sigma) for 30 s. Next, 200 μL was added and samples 
were homogenised again for 10 s. Finally, 100 μL was added and the samples 
were placed on a rotator wheel at 4°C for 30 min. Samples were centrifuged at 
10,000 g at 4°C for 10 min. Supernatants were then collected in fresh tubes and 
the pellets were discarded or stored in case that the presence of the protein of 
interest in the supernatant was uncertain.  
2.9.2 Wash of protein-G agarose beads 
Protein-G agarose beads (16-266, Millipore) were resuspended thoroughly before 
use. A volume of approximately 100 μL of beads was washed three times by adding 
1 mL of stock Co-IP buffer (without addition of protease inhibitor cocktail) each 
time. Tubes were mixed by inversion and gentle flicking to ensure resuspension, 
beads were spun at 5,000 rpm for 30 s at RT and supernatant was aspirated 
between each wash. After final wash, beads were resuspended in a volume of Co-
IP buffer equivalent to the start volume of beads (100 μL). 
2.9.3 Pre-clearing of lysates 
This step was performed to reduce non-specific binding of proteins to protein-G 
agarose beads. A volume of 30 μL of beads was resuspended thoroughly and 
 




added to each sample. Samples were placed on the rotator wheel for 1 h at 4°C. 
Next, samples were centrifuged for 5 min at 4°C to pellet the beads. This 
supernatant (pre-cleared lysate, referred here as input) was then transferred into 
a fresh tube and quantified using the BCA assay as explained above.  At this point, 
inputs could be stored at -20°C for further use.  
2.9.4 Pull-down antibody incubation 
IP samples were prepared by diluting 500 μg of input in Co-IP buffer up to a volume 
of 500 μL, leaving the samples at a concentration of 1 μg/μL. One sample was 
randomly chosen to be incubated with an IgG antibody (Santa Cruz) of the same 
species as the pull-down antibody, as a negative control. Next, 2 μg of pull-down 
antibody were added and incubated on the rotator wheel overnight at 4°C. 
2.9.5 Protein-G agarose beads incubation 
Protein-G agarose beads were resuspended thoroughly by inversion and gentle 
flicking of the tubes. Next, 30 μL of beads were added to each IP sample, including 
the IgG control tube. Samples were placed on a rotator wheel for 1 h at 4°C. 
Samples were spinned at 5,000 rpm for 30 s. Resulting supernatant contained 
proteins that did not bind to the protein-G agarose beads, hence termed unbound 
fraction (UB). The unbound fractions were transferred to fresh tubes and stored at 
-20°C for further use.  
2.9.6 Washing steps 
Pellets from previous step containing protein-G agarose beads and bound proteins 
were washed four times. Two first washes were done by adding 1 mL of Co-IP 
buffer to each sample each time and two last washes by adding 1 mL of 1x tris-
buffered saline (TBS). Tubes were mixed by inversion and gentle flicking to ensure 
resuspension of the beads, spun at 5,000 rpm for 30 s at RT and supernatant was 
aspirated between each wash. After the final wash, supernatant was carefully 
removed as much as possible with a pipette to avoid the removal of beads. 
2.9.7 Protein elution and gel loading  
At this point samples were no longer kept on ice. Proteins were eluted by adding 
50 μL of 2x Laemmli sample buffer to each sample. For unbound fractions and 
input lysates, a 5% of the amount of input used for the antibody incubation was 
 




diluted in 6x or 2x Laemmli sample buffer. Samples were boiled at 95°C for 5 
minutes, vortexed to mix and spun at 8,000 rpm for 3 min. Samples were loaded 
into 10% polyacrylamide gels and western blot was performed as previously 
described. For IP samples, 20 µL of supernatant was loaded into the gel, carefully 
avoiding including any beads. Remaining input, unbound fractions and IP samples 
were stored at -80°C for further use. 
2.10 Biolistic transfection of organotypic cultured hippocampal slices 
Broadly, biolistic transfection involves the preparation of cartridges containing DNA 
constructs of interest. These cartridges are then used to transfect cultured 
hippocampal slices by means of a gene gun that uses compressed helium to 
transfer the DNA from the cartridge into the slice (Figure 2-3). 
2.10.1 DNA constructs for biolistic transfection 
Cultured hippocampal slices were transfected with short-hairpin RNA (shRNA) 
against rat tau protein (rTau) cloned in a pGFP-V-RS vector (OriGene 
Technologies, Md, USA) under the control of the U6 promoter. This vector also 
contains turbo GFP (tGFP) under the control of the CMV promoter to allow for 
fluorescent labelling of transfected cells. A mixture of 4 different rat tau constructs 
(see sequences in Table 8) were used in a ratio of 1:1:1:1 to knock-down 
endogenous rTau (Kimura et al. 2013; Regan et al. 2015). In addition, slices were 
transfected with one of the following human tau mutants: Wild-type human tau 
(WT-hTau) (provided by Mandelkow Lab), pseudo-phosphorylated human tau P-
hTau or hTau-AT8 (provided by Takashima Lab). These mutants were cloned in 
pNG2 vectors (derivative of the pET3a, Novagen) and the expression of the 
mutants was under the control of the AmpR promoter.  
Table 8. Rat tau shRNA sequences. 













Figure 2-3. Schematic diagram of biolistic transfection and intracellular whole-cell 
recording experiments in cultured hippocampal slices. Cultured hippocampal slices 
were biolistically transfected with the Helios Gene Gun. Bullets contained gold 
microcarriers with the attached DNA constructs of interest. In this example, one plasmid 
contained the GFP tagged rat tau shRNA and the second plasmid the human tau construct. 
Cultured hippocampal slices were left in the incubator for 3 days after transfection to allow 
expression of the constructs. Then, patch clamp was performed to obtain whole-cell 
recordings from the soma of CA1 neurons in the pyramidal cell layer. 
Pseudo-phosphorylated constructs contained serine residues replaced by 
glutamate residues to mimic constitutive phosphorylation. P-hTau was mutated at 
S199/S202/T205/T212/S214/S396/S404E residues and hTau-AT8 was mutated at 
S199/S202/T205 residues. 
 




2.10.2 Precipitation of DNA into gold microcarriers 
The total volume of DNA was 100 μl at a concentration of 1 μg/μL. DNA constructs 
of interest were mixed in a single tube in the following quantities: 15 μg of each 
rTau-shRNA plasmid (4 plasmids in total) and 40 μg of hTau plasmid of interest 
(WT-hTau, P-hTau or AT8-hTau). Separately, 100 μl of spermidine (S0266, Sigma) 
were added to 10 mg of gold microcarriers (165-2264, Bio-Rad) and the mixture 
was vortexed for 10 seconds and then sonicated for 5 seconds to avoid 
aggregation of gold microcarriers. DNA was then added to this mixture and 
vortexed for 5 seconds. Next, 100 μL of 1M calcium chloride was added dropwise 
to the mixture while vortexing at low speed. Once added, the mixture was vortexed 
briefly at high speed. The mixture was allowed to precipitate for 10 minutes at RT. 
A stock solution of polyvinylpyrrolidone (PVP, Bio-Rad) at 20 mg/mL was prepared 
in 100% ethanol. The solution was diluted with ethanol to obtain PVP working 
solution at 0.1 mg/mL in a Falcon tube. To ensure that the gold microcarriers 
remained into the precipitated pellet, the tube was centrifuged in a microcentrifuge 
for 15 seconds at 2000 g. The resulting supernatant was discarded with a pipette. 
The pellets were then washed with 1 mL of 100% ethanol, resuspended by gentle 
flicking of the tube and then spun for 5 seconds in a microcentrifuge and 
supernatant discarded. This wash step was performed three times.  After final 
wash, supernatant was discarded with a pipette and the pellet was resuspended 
in 200 μL of PVP working solution. The solution was then transferred in a dropwise 
manner to the Falcon tube containing the remaining PVP working solution. The 
microcentrifuge tube was washed a few times with PVP working solution to ensure 
all particles were collected. The Falcon tube was then vortexed to thoroughly mix 
the solution. 
2.10.3 Loading the DNA/microcarrier suspension into tefzel tubing: Tubing Prep 
Station 
First, tefzel tubing (BioRad Laboratories Ltd., Hemel Hempstead, UK) was secured 
in the Tubing Prep Station (BioRad Laboratories Ltd., Hemel Hempstead, UK) and 
dried for at least 30 minutes by perfusing nitrogen through it (0.3-0.4 litres per 
minute, LPM). After this time, nitrogen perfusion was turned off. Immediately before 
loading, the DNA/microcarrier solution was vortexed to ensure an even suspension 
of the mixture. A syringe connected to the end of the tefzel tubing was used to 
slowly pass the solution through the tubing. Pressure in the syringe was held for 2 
minutes to allow settling of the microcarriers at the bottom of the tubing. Next, the 
 




loading solution was slowly aspirated back into the syringe. Tubing was then turned 
180° and left for 30 seconds. Next, the Tubing Prep Station was set up for constant 
and slow rotation for one minute. After this, perfusion of nitrogen at a flow of 0.3-
0.4 LPM was started to dry the tubing while still rotating, for 5 minutes, and then 
turned off. 
2.10.4 Preparation of cartridges 
Tubing was visually inspected to verify that microcarriers were evenly distributed 
over the length of the tubing and to avoid clumped or bare sections. Otherwise 
some cartridges may not contain microcarriers which will affect transfection. 
Tubing was then inserted into the Tubing Cutter (BioRad Laboratories Ltd., Hemel 
Hempstead, UK) to cut the tubing into ~1.3 cm pieces (cartridges). Cartridges were 
then stored in a screw-cap tube containing drierite stones (CamLab, Cambridge, 
UK) to prevent moisture build up and stored at -20°C until required.  
2.10.5 Biolistic transfection 
The Helios Gene Gun (BioRad Laboratories Ltd., Hemel Hempstead, UK) was 
used per manufacturer’s instructions. Briefly, helium was supplied into the gene 
gun at a pressure of 180 pounds per square (PSI). This pressure was optimal to 
propel the microcarriers into the slices without damaging the tissue. Cartridges 
were loaded into the cartridge holder which was locked into place in the Helios 
Gene Gun. The barrel liner of the Helios Gene Gun was positioned ~2 cm above 
of the well containing the membrane to be transfected and in a perpendicular 
position to the base of the 6-well plate. Finally, the safety button was engaged, and 
the firing trigger pressed to fire the microcarriers into the slices. Cultured slices 
were transfected at 3 DIV and electrophysiological recordings were performed at 
3-5 days after transfection (7-12 DIV). Identification of GFP-transfected cells was 
achieved by using an LED excitation light at a wavelength of 470 nm (Figure 2-4). 
 





Figure 2-4. Transfected neuron in a cultured hippocampal slice. Image taken at 40x 
magnification showing a neuron transfected with a GFP-tagged construct surrounded by 
untransfected neurons. The gold microcarrier is usually visualised as a black dot on the 
soma of the cell.  
2.11 In vitro electrophysiological recordings in rat slices 
2.11.1 Equipment set-up 
The slice was submerged into the recording chamber and immobilized by placing 
an in-house constructed nylon mesh net on top of it. The aCSF was delivered 
through PTFE microbore tubing (0.022 inches inner diameter x 0.042 inches outer 
diameter, WZ-06417-21, Cole Parmer, Cambridgeshire, UK) which was inserted 
 




into a heated perfusion tube system (HPT, ALA Scientific Instruments Inc., USA) 
controlled by a TC-10 temperature control system (npi electronic GmbH, Tamm, 
Germany). This served to maintain the aCSF within the recording chamber at 29–
31°C. A glass bottle containing aCSF bubbled with 95% O2/5% CO2 was 
submerged into a heated water bath (Clifton, Nickel-electro, Weston-super-Mare, 
UK) to keep the aCSF at ~28 °C. The recording chamber was constantly perfused 
with aCSF at a flow rate ~ 3 mL per min. This was achieved by pumping the aCSF 
into the recording chamber through fine bore polythene tubing (1.67 mm inner 
diameter, 2.42 mm outer diameter, 800/100/460, Portex Ltd., Kent, UK) by a 
peristaltic pump (Sci-Q 323, Watson-Marlow Ltd., Falmouth, UK). aCSF was 
removed via a suction needle into a waste bottle connected to a vacuum pump 
(Dymax 5, Charles Austen Pumps Ltd, Surrey, UK). 
An anodized aluminium platform (P-1, 64-0277, Warner Instruments, CT, USA) 
provided clamping between a polycarbonate recording chamber (RC-26G, Warner 
Instruments, CT, USA) and a glass coverslip base (22 x 40 mm, 64-0707, Warner 
Instruments, CT, USA). A water tight seal was obtained by applying vacuum grease 
between the bottom of the platform and the edges of the glass coverslip. This was 
mounted upon a movable top plate (Scientifca, Sussex, UK) that allowed the 
movement of the recording chamber and therefore the slice in the X and Y axis, so 
it could be centred in the microscope field of view. The microscope and movable 
top plate were fixed to an air table (IsoStationTM, Newport, UK) to minimize 
vibration from external sources. The air table was filled with compressed air by an 
air compressor (JunAir 3-4, 1109020, MI, USA). To prevent interferences from 
external electrical fields, the air table and equipment mounted on it were covered 
by an in-house built Faraday cage. 
Slices were visualised with a fixed-stage upright microscope Olympus BX51WI 
(Olympus, Tokyo, Japan) and an attached charged-coupled device KP-M1AP 
camera (Hitachi, Tokyo, Japan). GFP fluorescence signals were visualised with an 
LED illumination system (CoolLED pE-100, Andover, UK) that permitted 
illumination of slices at a wavelength of 470 nm.  
2.11.2 Recording and stimulating electrodes 
Recording pipettes were made from borosilicate glass capillary (standard wall, 1.5 
mm outer diameter x 0.86 mm inner diameter x 100 mm long, Harvard Apparatus, 
 




Kent, UK) pulled with a P-1000 Flaming/Brown micropipette puller (Sutter 
Instrument Co., CA, USA) to a resistance of 5-7 MΩ. They were back-filled with 
the appropriate filling solution, depending on the type of recording (see sections 
2.11.3 and 2.11.4), and then secured in an electrode holder (QSW-T15P, Warner 
Instruments, CT, USA), which was connected to a headstage (CV-203BU, 
Molecular Devices, CA, USA). The movement of the recording pipette was 
precisely controlled with an electronic PatchStar micromanipulator (Scientifica, 
Uckfield, UK), which allowed fine movements in the X, Y and Z axes, permitting 
precise position of the recording pipette on the slice. 
The recording electrode was a silver wire (99.9% purity, 0.20 mm diameter, Advent 
Research Materials, Oxford, UK) coated with silver-chloride (AgCl). This coating 
allows for a smooth flow of current from the intracellular or extracellular space to 
the electrode. Importantly, current must be transformed from a flow of ions in the 
solution to a flow of electrons in the recording electrode. However, current crossing 
the interface between the filling solution and the silver wire can suffer signal 
distortion or loss. The Ag-AgCl coating prevents this by providing a reversible 
reaction that ensures the bidirectional flow of electrons. Electrons flowing from the 
wire to the Ag-AgCl interface reduce the silver (Ag+) back to silver atom (Ag), 
releasing a chloride ion (Cl–) that becomes hydrated and enters the solution. If 
electrons flow from the solution to the Ag wire, the Ag loses one electron becoming 
Ag+, which forms insoluble AgCl with a nearby Cl– staying within the coating layer 
(Dong & Graziane 2016). The current through the recording electrode was 
transmitted to the headstage through a gold pin connected to it. A reference 
electrode coated in Ag-AgCl to the point that was in contact with the bath solution 
was submerged in the bath of the recording chamber and also connected to the 
headstage through a gold pin.  
Bipolar stimulating electrodes were made of two inter-coiled nickel 80/chromium 
20 wires (0.050 mm diameter, Advent Research Materials, Oxford, UK). The 
stimulating electrode was passed through a glass capillary which was placed in a 
manual micromanipulator (LBM7, Scientifica, Uckfield, UK) that allowed fine 
positioning of the stimulating electrodes on the slice. Each stimulating electrode 
was connected to an isolated stimulating box unit (DS2A-Mk.II, Digitimer Ltd., 
Welwyn Garden City, UK).  
 




2.11.3 Extracellular field recordings 
One acute hippocampal slice was placed in the recording chamber and perfused 
with aCSF which comprised 124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 1.25 mM 
NaH2PO4, 2 mM CaCl2, 1 mM MgSO4 and 10 mM D-glucose and bubbled with 95% 
O2/5% CO2. The recording pipette was back-filled with 3 M NaCl filling solution and 
was placed on the stratum radiatum of the CA1 region of the slice. Here is where 
the axon terminals of Schaffer collaterals coming from the CA3 region establish 
synaptic connections with the apical dendrites of CA1 pyramidal neurons (Figure 
2-5). One stimulating electrode was placed on the Schaffer collaterals to deliver 
high-frequency stimulation (HFS) on this pathway, therefore termed HFS input. 
Another stimulation electrode was placed on the subiculum region, between the 
CA1 and entorhinal cortex, to function as control (i.e. non-tetanised) input. As a 
result of the stimulation delivered to the Schaffer collaterals, extracellular field 
excitatory post-synaptic potentials (fEPSPs) were evoked in the CA1 region and 
recorded throughout the experiment. Therefore, fEPSPs are the population 
synaptic response which arises from the synchronous and localised currents 
generated as a result of synaptic stimulation of pyramidal CA1 cells (Dong & 
Graziane 2016).  
The response obtained after stimulation includes components other than the 
fEPSPs. Immediately after stimulation, a stimulus artefact is generated as a result 
of the voltage pulse applied (Figure 2-6A). Subsequently, it is very common to see 
a fiber volley which is recorded by the extracellular electrode as a negative 
potential. This represents the action potential firing of axons within Schaffer 
collaterals. These activate the release of neurotransmitter at the presynaptic 
terminal and produce an EPSP in the dendrites of CA1 neurons. Consequently, 
the more fibers activated with higher stimulus intensity will result in greater fEPSPs. 
Importantly, this is not due to an enhancement of the fEPSPs at individual 
synapses, as it would happen in the case of LTP, for example. This means that the 
amplitude of the fiber volley is proportional to the number of presynaptic fibers that 
are active within the Schaffer collaterals and that changes in the fiber volley 
amplitude result in changes in the fEPSP. Therefore, only recordings with no 
change in fiber volley amplitude were counted for analysis. Finally, some fEPSP 
can be contaminated by population spikes. This represents action potential firing 
in the somata of a population of neurons. A population spike is caused by the 
antidromic propagation of dendritic EPSPs from the dendrites to the soma, which 
 




can trigger an action potential when the stimulus strength is high enough. The 
population spike is recorded as positive potential that can limit the amplitude of the 
fEPSPs, but the slope generally remains unaffected.  
At the electrophysiological level, changes in synaptic efficacy are reflected by 
changes in the fEPSP size (for instance, LTP is defined as a sustained increase in 
the fEPSP size). Accordingly, the slope of the fEPSP was used as a measure of 
synaptic efficacy to detect changes in fEPSPs size. The measurement of the slope 
was preferred to the amplitude because the latter is often contaminated with 
population spikes (explained above), population IPSPs and polysynaptic 
responses (arising from synaptic events occurring at different time points following 
an evoked stimulus). 
 
Figure 2-5. Schematic diagram of extracellular field recoding experiments in acute 
hippocampal slices. P24-30 Wistar rats were killed by cervical dislocation and brain 
dissection was performed to prepare acute hippocampal slices. Dotted lines roughly 
indicate the planes for cutting the hippocampus. Acute hippocampal slices were allowed to 
recover for 1 h in aCSF at room temperature prior starting the recordings.  Extracellular 
field recordings were obtained from the stratum radiatum of the CA1 region. One 
stimulation electrode was placed on the Schaffer collaterals (HFS input) and another one 
on the subiculum area (control input). 
 




Stimulus intensity was empirically determined as the intensity that yielded 40% of 
the maximal fEPSP amplitude, but never higher than 13 V to avoid rundown of 
responses due to overstimulation and contamination by non-synaptic signals. 
Stimuli at constant voltage were delivered alternately to the two electrodes (HFS 
and control input) every 15 seconds (0.033 Hz). This stimulation will be referred as 
basal stimulation. A stable baseline, usually between 10-30 min depending on the 
type of experiment, was first obtained before performing further experimental 
manipulations. In LTP experiments, after recording a 30 min baseline, tetanic 
stimulation was delivered to only the electrode placed on the Schaffer collaterals. 
This protocol consisted in 2 trains of 100 Hz, i.e. each train comprises 100 pulses 
in 1 second, with an interval of 30 seconds between trains. Then, basal stimulation 
was delivered for at least 60 min after tetanus.  
Each sweep had a duration of 50 milliseconds (ms) and comprised 500 voltage 
measurements (i.e. samples) in mV, with a sample interval of 0.1 ms. The slope 
start and end times were manually defined as milliseconds after stimulation for 
each experiment. Then, a linear regression line was plotted through the voltage 
data points falling in between those defined time points. The slope value (mV/ms) 
for each response was generated from the regression line. Slope values were 
averaged from 4 consecutive responses and were plotted as a single data value.  
 
Figure 2-6. Measured parameters in electrophysiological recordings. (A) Example 
fEPSP trace from extracellular field recordings showing stimulus artefact, fiber volley and 
slope measurement. (B) Series resistance (Rs) and membrane resistance (Rm) were 
measured in response to a voltage pulse (10 mV, 100 ms) in intracellular whole-cell 
recordings. 
 




2.11.4 Intracellular whole-cell patch clamp recordings 
These experiments were performed in cultured hippocampal slices bound to 
membrane inserts. For each experiment, a section of the insert membrane 
containing one slice was cut with the aid of a blade and forceps and it was placed 
in the recording chamber. The slice was perfused with aCSF comprising: 119 mM 
NaCl, 2.5 mM KCl, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM D-glucose, 4 mM 
CaCl2, 4 mM MgCl2, 0.02 mM picrotoxin, 0.002 mM 2-chloroadenosine, 10 µM MK-
801, 500 nM tetrodotoxin citrate (TTX) and gassed with 5% CO2/95% O2. The 
recording pipette was filled with potassium-gluconate filling solution containing: 10 
mM HEPES, 135 mM potassium-gluconate, 0.5 mM EGTA, 2 mM Mg2+-ATP, 0.3 
mM Na+-GTP, 8 mM NaCl (275-290 mOsm, pH 7.2).  
The CA1 region was visually located under the 5x objective and then cells within 
the pyramidal cell layer were located under the 40x objective (Figure 2-3). Positive 
pressure was applied to the recording pipette via a pneumatic system consisting 
on syringe attached to a piece of Tygon tubing which in turn was tightly connected 
to an aperture (port) in the electrode holder. The 40x objective was separated from 
the preparation and the recording pipette was placed inside the bath. The 
resistance of the recording pipette tip was checked with the amplifier on “track” 
mode and “seal test” on, by applying a rectangular voltage pulse of +5 mV and 
measuring the resulting square pulse of current. According to Ohm’s law (V = I x 
R), the amplitude of this current is inversely proportional to the resistance of the 
pipette tip. Only recording pipettes with a tip resistance between 5–7 MΩ were 
used. Next, the recording pipette was lowered to the cell layer slowly together with 
the objective. With the target cell in focus, the recording pipette was advanced to 
the surface of the cell by using the micromanipulator. As the pipette approached 
the cell soma, the positive pressure pushed the membrane generating the 
formation of a dimple. At this point, positive pressure was released to induce a 
suction effect that caused the cell membrane to form a seal around the pipette tip. 
The formation of this seal was evident by an increase in the monitored pipette 
resistance (decrease of the current through the pipette tip). Amplifier settings were 
immediately changed to voltage clamp, “V-Clamp”, and a negative holding 
potential was applied, initially at -30 mV that was slowly increased until reaching -
70 mV. The formation of a GigaOhm (GΩ) seal was evident by the reduction of the 
current pulse to around -20 pA. In this cell-attached mode, the external command 
of the amplifier was switched on and the capacitive transients of the pipette could 
 




be seen in the current pulse. These capacitive transients arise as a result of the 
capacitive properties of the pipette that generates charge separation across the 
glass. They represent the removal of anions (in this case mainly chloride ions since 
the use of Ag-AgCl electrodes and a positive voltage pulse) from the intracellular 
space. Capacitive currents were compensated with the amplifier to avoid distortion 
of the current of interest. To break into the cell, a sharp, quick negative pressure 
was applied by gentle suction with the mouth into the syringe. This was generally 
sufficient to enter whole-cell configuration and the characteristic capacitive 
transients of the membrane were monitored (Figure 2-6B).  
Once in whole-cell configuration, the resting membrane potential (RPM) of the cell 
was checked and cells with RPM below -50 mV were discarded. The holding 
current (DC), which is the current applied to the cell to hold the membrane potential 
at the commanded voltage of -70 mV, was recorded throughout the experiment. 
Additionally, a square voltage pulse of 10 mV during 100 ms was applied to monitor 
series resistance (Rs) and membrane resistance (Rm). Rs describes the pipette 
resistance and the access resistance once in whole-cell configuration, as they are 
both in series with the pipette voltage in the equivalent electrical circuit. The access 
resistance refers to the resistance between the membrane of the cell and the 
pipette tip. Since pipette resistance does not change during an electrophysiological 
recording, changes in the series resistance are caused by changes in the access 
to the cell. Therefore, series resistance was used to monitor the quality of the patch 
and only experiments with a Rs less than 23 MΩ and changes less than 20% of 
initial Rs were accepted. Rm, also termed input resistance, was used to monitor the 
condition of the cell. Only cells with a Rm bigger than 80 MΩ were considered 
healthy and therefore accepted. Each sweep had a duration of 200 ms and 
comprised 10,000 voltage measurements (i.e. samples) in mV, with a sample 
interval of 0.05 ms.  
2.11.5 Electrophysiological data acquisition, analysis and statistics 
The headstage was connected to an amplifier (Axopatch 200B, Axon Instruments 
Inc., Union City CA, USA) for signal recording. In turn, the amplifier was connected 
to a digital-to-analogue/analogue-to-digital (DAC-ADC) BNC 2120 board (National 
Instruments, Berkshire, UK) connected to a M Series data acquisition device 
(DAQ) device board (National Instruments, Berkshire, UK) in the computer. The 
 




amplifier low-pass filter was set to filter signals at 5 kHz and to amplify them 5x 
(output gain). 
Data was analysed online using WinLTP (WinLTP Ltd., University of Bristol, Bristol, 
UK, 1991-2018) software. This software allowed for automated response recording 
and stimulus delivery throughout the experiment as well as real-time monitoring of 
the recorded synaptic responses and associated parameters. SigmaPlot 13.0 
software (Systat Software Inc., San Jose, CA, USA) was used for statistical 
analysis and to graph the data. 
For field recording experiments, data were normalised to the pre-conditioning 
baseline and expressed as a percentage of the same baseline (i.e. each slope 
value was divided by the average slope value of the baseline and multiplied by 
100). For each experimental condition, i.e. control or treatment, data from one slice 
per rat were analysed (n = number of slices = number of rats). Normalised data 
were then pooled across slices for each experimental condition to obtain a mean 
slope value ± standard error of the mean (S.E.M) for each time point, which were 
plotted in the graphs shown. Statistical significance (p < 0.05) of the pooled data 
was tested using paired or unpaired two-tailed Student t-test as appropriate. For 
LTP experiments, unpaired two-tailed t-test was performed between the group of 
means generated by averaging slope values at 5 time points after HFS (86, 88, 90, 
92, 94 minutes) for the control vs. the group of means for the HFS input. When 
appropriate, the HFS inputs from two different conditions (i.e. control vs. treatment) 
were also statistically compared in the same manner. For baseline experiments, 
unpaired two-tailed t-test was performed between the population of means 
corresponding to minutes 36, 38, 40 (in 40 minutes recordings) or minutes 72, 74, 
76, 78, 80 (in 80 minutes recordings) between control and treated slices. 
For whole-cell patch clamp experiments, data was normalised to the 10 minutes 
baseline (i.e. each DC value was subtracted to the average of the baseline). 
Therefore, data shown in graphs represents the change in holding current with 
respect to the baseline. Then, the maximum holding current value for each 
experiment (i.e. slice) was taken and values were pooled across slices within the 
same condition. Statistical significance (p < 0.05) of the pooled data was tested 
using unpaired two-tailed Student t-test or Mann-Whitney rank sum test if data 
were not normally distributed.  
 




2.12 Pharmacological agents and treatments 
Pharmacological agents were bath applied by direct addition to the perfused buffer 
or incubation solution to obtain the concentration of interest. For control 
experiments, solvents at the concentration used to prepare the stock aliquots were 
applied in the same manner.  
All pharmacological agents used in this study are listed in Table 9, which 
summarizes information regarding mode of action of each agent, suppliers and 
working concentrations used. For control experiments, solvents at the 
concentration used to prepare stock solutions were used. Stock solutions were 
aliquoted and kept at -20°C.  
Table 9. Pharmacological agents used in this study. 
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In electrophysiology experiments, pharmacological agents used during the 
recordings were bath applied by direct addition to the perfused aCSF to obtain the 
concentration of interest. For incubation of pharmacological agents with slices prior 
 




to recordings, an incubation chamber comprised of a nylon mesh net fitted into a 
Petri dish (35 x 10 mm, Cellstar 627 160) was filled with 5 mL of aCSF and bubbled 
with 95% O2/5% CO2. The pharmacological agent was added to the aCSF and left 
for 5 min to reach an equilibrated concentration on the solution. Then a slice was 
placed in the incubation chamber with a glass pipette, avoiding altering the 
concentration reached in the chamber by not letting aCSF from the pipette going 
into the solution. In calcium imaging experiments, pharmacological agents were 
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Given the strong deficits in memory exhibited in AD patients, together with the 
evidence supporting synaptic plasticity as the physiological foundation for such 
cognitive processes, the disruption of synaptic plasticity has been widely studied 
in the context of the disease (Jang & Chung 2016; Skaper et al. 2017). The most 
consistent argument for this concept is the evidence showing that AD-related 
neuropathology, namely Aβ and tau, is associated with deficits in synaptic function 
and plasticity.  
The ways in which Aβ disrupts synaptic function are numerous but one well-
established finding that Aβ reduces glutamatergic synaptic transmission 
(Chapman et al. 1999; Walsh et al. 2002) by decreasing the number of surface 
AMPARs and NMDARs (Hsieh et al. 2006; Shankar et al. 2007). This occurs by 
Aβ-induced activation of LTD mechanisms that include the phosphorylation of 
GluA2 subunit of AMPARs and the actions of calcineurin and p38 MAP kinase 
activity (Hsieh et al. 2006; Shankar et al. 2007). This leads to endocytosis of 
AMPARs which in turns induces NMDARs-endocytosis and it seems to underlie 
the loss of dendritic spines (Hsieh et al. 2006). In addition, this has been proposed 
as a mechanism by which Aβ impairs LTP (Cleary et al. 2005; Walsh et al. 2002) 
and enhances LTD, causing the subsequent synaptic loss that may contribute to 
memory deficits (Li et al. 2009; Hsieh et al. 2006). These effects are thought to be 
mediated by oligomeric forms of Aβ (Selkoe 2008; Shankar et al. 2008; Tomiyama 
et al. 2010), the presence of which correlates better than Aβ plaque load with 
cognitive impairments in animal models of AD (Mucke et al. 2000) and AD patients 
(Näslund et al. 2000; McLean et al. 1999). Because synapses are the sites where 
plasticity manifests, some of the Aβ-mediated effects on synaptic plasticity may 
occur at the dendritic level. Consistent with this, Aβ acts on dendrites to reduce 
spine numbers and plasticity (Wei et al. 2010). Part of these effects may be 
mediated by Aβ preferential binding at postsynaptic sites (Lacor et al. 2004; Lacor 
et al. 2007) and multiple Aβ receptors have been proposed to mediate Aβ 
synaptotoxicity (Kam et al. 2014), including mGluRs (Um et al. 2013; Renner et al. 
2010). Through the binding to these receptors, or independently, Aβ is able to 
trigger dysregulation of dendritic ion channels that modulate neuronal excitability 
(Cochran et al. 2014). For example, Aβ can induce phosphorylation of L-voltage 
sensitive calcium channels through the activation of mitogen-activated protein 
(MAP) kinase (Ekinci et al. 1999) and increase calcium influx, generating 
 




excitotoxicity in neuronal cultures (Ho et al. 2001; Ueda et al. 1997). This is in line 
with the finding that Aβ-induced calcium dysregulation is a major component of 
synaptic dysfunction (Wang et al. 2017). In addition, excessive Aβ modifies 
dendritic excitability by disrupting the function of potassium (Ye et al. 2003; Zhang 
& Yang 2006) and probably sodium channels (Verret et al. 2012). 
Not only Aβ-mediated pathology but tau pathology can also affect synaptic 
plasticity mechanisms. Illustrating this, a transgenic mice model of pathological tau 
aggregation displays strong deficits in LTP and memory (Sydow et al. 2011) and 
administration of tau to hippocampal slices and mice impairs LTP and memory, 
respectively (Fá et al. 2016). These deficits can be rescued by removing the 
expression of the toxic tau mutant (Sydow et al. 2011), providing evidence for an 
involvement of tau-mediated pathology in the disruption of synaptic plasticity. 
Similarly to the case of Aβ, some of these effects occur at the dendrites, where tau 
is thought to mislocalise at early stages of AD pathology (Zempel et al. 2010; Braak 
et al. 1994; Braak et al. 2011), potentially as a result of tau phosphorylation (Hoover 
et al. 2010). Additionally, tau can be phosphorylated at the dendrites (Jin et al. 
2011; Zempel et al. 2010), a modification that is required for the Aβ-induced 
synaptotoxicity and dendritic spine deficits (Gu et al. 2013; Mairet-Coello et al. 
2013; Yu et al. 2012). Dendritic tau is often in the form of soluble tau and it has 
been shown that this form has a prominent pathological role (Cochran et al. 2014). 
This role involves tau-dependent trafficking of Fyn kinase to the synapse (Ittner et 
al. 2010) where it potentiates NMDARs excitotoxicity by phosphorylating the NR2B 
subunit of this receptor (Nakazawa et al. 2001; Rong et al. 2001). In addition, it has 
been proposed that tau disrupts synaptic function by mediating aberrant 
scaffolding of the postsynaptic density (Chabrier et al. 2012; Ittner et al. 2010; 
Mondragón-Rodríguez et al. 2012). 
These studies highlight the complexity of Aβ- and tau-induced synaptic dysfunction 
and the necessity of identifying molecular targets that mediate its detrimental 
effects. Over the past years, research has brought to light mGluR5 as one such 
target (Kumar et al. 2015; Piers et al. 2012). As outlined in Chapter 1, mGluR5 is 
a GPCR located in the postsynaptic terminal, preferentially to perisynaptic and 
extrasynaptic locations (Conn & Pin 1997; Shigemoto et al. 1993; Romano et al. 
1995; Lujan et al. 1996; Lopez-Bendito et al. 2002) where it can regulate and 
mediate synaptic transmission. The role of mGluR5 at glutamatergic synapses also 
 




includes the capacity to mediate long-lasting forms of synaptic plasticity including 
LTD and LTP (Lüscher & Huber 2010). For instance, activation of mGluR5 can 
result in the induction of LTD in the CA1 region of the hippocampus (Bolshakov & 
Siegelbaum 1994; Huber et al. 2000; Kemp & Bashir 2001; Manahan-Vaughan 
1997; Volk et al. 2007; Oliet et al. 1997). Importantly, this role of mGluR5 in 
mediating synaptic plasticity may be related to the role of the receptor in memory. 
This is supported by in vivo studies where pharmacological blockade or genetic 
knock out of mGluR5 result in impaired spatial learning and LTP in the 
hippocampus (Lu et al. 1997; Balschun et al. 1999; Balschun & Wetzel 2002; Naie 
& Manahan-Vaughan 2004; Manahan-Vaughan & Braunewell 2005), implying the 
requirement of mGluR5 for memory processes. 
Considering the physiological synaptic functions of mGluR5, it is not surprising that 
dysregulation of its expression or function in disease may result in disruption of 
synaptic function. Indeed, there is strong evidence to support the emerging 
concept that aberrant mGluR5 activation may mediate Aβ-related pathology in AD 
(Kumar et al. 2015; Wang 2004; Hu et al. 2014; Um et al. 2013; Hamilton et al. 
2014; Renner et al. 2010; Haas et al. 2016). First, studies have shown that the 
enhancement of LTD (Hsieh et al. 2006; Li et al. 2009) and suppression of LTP 
(Walsh et al. 2002; Shankar et al. 2008; Jo et al. 2011) triggered by Aβo can be 
reproduced by activating mGluR5 with agonists but also inhibited by blocking the 
receptor with antagonists (Wang 2004; Shankar et al. 2008; Hu et al. 2014; 
Rammes et al. 2011). Second, pharmacological blockade or genetic deletion of 
mGluR5 reversed the Aβ-induced deficits in learning, memory and spine density 
(Um et al. 2013; Hamilton et al. 2016; Hamilton et al. 2014). Third, it has been 
reported that mGluR5 antagonists protect from NMDAR-induced excitotoxic 
degeneration (Kingston et al. 1999; O’Leary et al. 2000; Movsesyan et al. 2001). 
This is relevant since Aβ-mediated dysregulation of NMDARs is thought to be a 
mechanism in the pathology of AD (Texidó et al. 2011; Miguel-Hidalgo et al. 2002; 
Molnár et al. 2004; Li et al. 2011). According to this hypothesis, antagonism of 
mGluR5 protects against Aβ-induced toxicity in cortical cultures (Bruno et al. 2000) 
and also in primary hippocampal neurons from double transgenic mice models of 
Parkinson’s disease and AD, in which lentiviral transfection of mGluR5 in the 
hippocampus results in neurodegeneration (Overk et al. 2014).  
 




Although a central role of mGluR5 in Aβ-like pathological processes is undeniable, 
the mechanisms by which it becomes detrimental for neuronal function have not 
been fully characterised. To understand such mechanisms, two important 
questions must be considered. First, whether these mechanisms involve mGluR5-
mediated regulation of other key molecules in AD. Second, whether this regulation 
occurs only in pathological conditions or conversely arises from physiological 
interactions that are enhanced or reduced in pathology.  
A critical effect of AD pathology on synaptic function is the impairment of 
cholinergic transmission, due to the depletion of cholinergic neurons in the basal 
forebrain (Whitehouse et al. 1982) and their projection to the hippocampus and 
cerebral cortex (Davies & Maloney 1976; Parent et al. 2013) (see Chapter 1). 
Further supporting this, mAChR1 levels are reduced in brains of AD patients 
(Shiozaki et al. 2001), which may indicate that reductions in mAChRs function are 
involved in the pathology of AD. Supporting this, agonism of these receptors 
rescued impairments in hippocampal-dependent memory in an AD mouse model, 
indicating that hypofunction of mAChRs negatively affects cognitive processes 
(Caccamo et al. 2006). In addition, mAChRs deletion results in disruption of LTP 
and cognitive performance in behavioural tasks (Anagnostaras et al. 2003). 
Furthermore, genetic deletion or inhibition of mAChR1 results in exacerbation of 
Aβ and tau pathologies in vivo (Davis et al. 2010; Caccamo et al. 2006) whereas 
its activation down-regulates Aβ production (Hung et al. 1993; Fisher et al. 2003). 
Therefore, mAChR is a key molecule in the pathology of AD and understanding 
their regulation will help to elucidate disease mechanisms.  
Since mAChR is a synaptic GPCR, its regulation may be mediated by other 
GPCRs, as this is a common mechanism of regulation in this superfamily of 
proteins (Hur & Kim 2002; Cordeaux & Hill 2002). For example, stimulation of the 
PLC-coupled P2Y2 receptor inhibits β2-adrenergic receptor-mediated cAMP 
production via Gi proteins (Suh et al. 2001). Furthermore, mAChRs and mGluRs 
can also participate in cross-talk signalling with other receptors. Illustrating this, 
activation of mAChR3 results in heterologous PKC-mediated phosphorylation of 
β2-adrenergic receptor, causing its desensitisation (Budd et al. 1999; Pera & Penn 
2014). In addition, mGluR7 activation can inhibit β-adrenergic receptor-mediated 
adenylyl cyclase activation (Ferrero et al. 2016). Therefore, it is possible that 
inhibitory regulation of mAChRs may be exerted by mGluR5 activity. This concept 
 




is supported by evidence showing mGluR5-mediated inhibition of mAChR1 in the 
perirhinal cortex (Jo et al. 2006). In addition, preliminary data from our lab supports 
the inhibition of mAChRs by group I mGluRs in stress- and Aβ-related pathologies 
(unpublished results) in the same brain region. However, whether this functional 
interplay occurs in the hippocampus is unknown. 
Another key molecule in AD pathology that may be regulated by mGluR5 is 
glycogen synthase kinase 3β (GSK-3β). GSK-3β is a constitutively active kinase 
(Woodgett 1990; Eldar-Finkelman & Martinez 2011) that originally emerged as a 
critical mediator of neurodegeneration due to its ability to phosphorylate tau 
(Mandelkow et al. 1992; Wagner et al. 1996; Li & Paudel 2006; Sperber et al. 
1995). Since the phosphorylation state of tau is known to regulate its aggregation 
(Pérez et al. 2002), it has been proposed that GSK-3β-induced tau phosphorylation 
is responsible for the formation of tau aggregates (Cho & Johnson 2004; Ando et 
al. 2016; Hernández et al. 2010; Busciglio et al. 1995). This is supported by studies 
showing that inhibition of GSK-3β results in reduced tau aggregation and 
degeneration in vivo (Noble et al. 2005; Pérez, Hernández, et al. 2003) and in vitro 
(Alvarez et al. 1999). This finding is relevant to AD given the known neurotoxic 
effect of tau aggregates (Iqbal et al. 1989; Lee et al. 1989). 
The importance of GSK-3β for AD further relies in its involvement in synapse 
weakening pathways. Indeed, GSK-3β regulates synaptic function and long-term 
plasticity (Peineau et al. 2007) and therefore its dysregulation in pathology could 
lead to impairments in synaptic function. Consistent with this concept, the Aβ-
inhibition of LTP requires the activity of GSK-3β (Jo et al. 2011), an effect that may 
be due to the activation of GSK-3β in an Aβ-dependent manner (Baki et al. 2004; 
Takashima et al. 1998). Although it is clear that GSK-3β critically regulates 
synapse dysfunction, the molecular determinants of its activation remain poorly 
understood. GPCR regulation of GSK-3β is a potential mechanism that may be 
relevant to AD pathology as mAChR activation results in inactivation of GSK-3β 
(Ma et al. 2013) and neuroprotective effects from Aβ neurotoxicity (Farías et al. 
2004). In line with this, activation of mAChRs reduced glutamate-induced 
overactivation of GSK-3β (Ma et al. 2013). In addition, a peptide derived from prion 
protein (PrP), which mediates Aβ-effects through synaptic mGluR5 (Um et al. 
2013; Haas et al. 2016; Hamilton et al. 2015), triggers neuronal cell death via 
increased GSK-3β activity (Pérez, Rojo, et al. 2003). The regulation of GSK-3β by 
 




synaptic GPCRs coupled to PKC activation, such as mAChRs and mGluRs, is in 
agreement with studies showing that PKC activity can regulate GSK-3β function in 
vitro (Goode, N.; Hughes, K.; Woodgett, J. R. ; Parkeri 1992; Shin et al. 2002; 
Tejeda-Muñoz et al. 2015; Christian et al. 2002). Therefore, synaptic GCPRs may 
regulate GSK-3β activity and this regulation may be altered under 
neurodegenerative circumstances, having synaptotoxic effects that impair synaptic 
plasticity.  
In summary, deficits in synaptic function are a clear hallmark of AD pathology. 
Several studies point towards disease-triggered aberrant activation of mGluR5 as 
a mechanism by which such deficits may occur. However, these studies are based 
on the effects of blockade of mGluR5 in in vitro or in vivo Aβ models of AD and on 
the evidence showing that mGluR5 blockade rescues the Aβ-inhibition of LTP. Why 
mGluR5 blockade is beneficial in these conditions and how it contributes to Aβ-
mediated effects on synaptic plasticity is not fully understood. In this thesis, it was 
hypothesised that activation of mGluR5 is sufficient to cause deficits in synaptic 
function, and particularly that it causes depression of baseline recordings and 
inhibition of LTP induction in acute hippocampal slices. Furthermore, as a possible 
mechanism by which mGluR5 activation may be detrimental for synaptic function, 
it was hypothesised that mGluR5 activation inhibits mAChR function, as it is 
unknown whether this functional interaction occurs in the hippocampus. 
Specifically, the hypotheses tested were that mGluR5 activation (1) reduces 
mAChR-mediated depression of fEPSPs elicited by CCh in acute hippocampal 
slices and (2) reduces mAChR-mediated calcium increase elicited by CCh in 
primary hippocampal neuronal cultures. Finally, another key molecule involved in 
AD pathology is GSK-3β and there are reasons to think that this kinase is regulated 
by GPCRs activity, such as mGluR5. Whether this is a potential mechanism in the 
hippocampus that may contribute to Aβ pathology is unknown. Accordingly, it was 
hypothesised that activation of mGluR5 results in the activation of GSK-3β in acute 
hippocampal slices. Altogether, results in this chapter will clarify whether mGluR5 
activation is sufficient to cause similar effects on synaptic function as those seen 
in AD models (where mGluR5 is activated) and therefore will help to evaluate 
whether mGluR5 is a good therapeutic target in AD. 
 





3.2.1 mGluR5 activation does not affect baseline recording or LTP induction 
Evidence suggests that an excessive activation of mGluR5 could serve as a 
possible molecular mechanism underlying Aβ-induced pathology, including 
disruption of synaptic plasticity (Kumar et al. 2015). It was first sought to determine 
whether agonist activation of mGluR5 can alter synaptic plasticity in non-disease 
(i.e. physiological) conditions that may lead to similar synaptic effects to those seen 
in the Aβ-induced pathological state. If mGluR5 activation is sufficient to cause Aβ-
induced synaptic deficits, targeting mGluR5 itself rather than Aβ pathology may be 
more effective when designing therapeutic strategies to treat AD. To this purpose, 
field recordings in acute hippocampal slices were carried out to assess the effect 
of mGluR5 activation on baseline recording and LTP induction. Healthy slices are 
known to exhibit LTP and stable baseline recordings, therefore these were used 
as a measurement of synaptic function (Abrahamsson et al. 2016). In the first set 
of experiments, CHPG, which has been shown to act as a selective mGluR5 
agonist (Doherty et al. 1997) was used. A concentration range of CHPG (EC50 = 
7.3 µM) (Fazal et al. 2003) was tested consisting in 1, 10 and 50 µM applied for 20 
minutes. These concentrations were chosen based on previously published work 
(Doherty et al. 1997; Neyman & Manahan-Vaughan 2008; Izumi & Zorumski 2012)   
to activate mGluR5 without eliciting LTD as this could affect LTP induction. 
Stimulation of Schaffer collaterals was used to evoke fEPSPs in the CA1 region 
that were recorded throughout the experiment. As explained in Chapter 2 (section 
2.11.3), fEPSPs were used as a measure of synaptic efficacy. No differences were 
found between the fEPSPs elicited in CHPG-treated slices and control slices, 
showing that CHPG did not have an effect on baseline recording at any of the 
concentrations used (1 μM: p-value = 0.474, 10 μM: p-value = 0.146, 50 μM: p-
value = 0.0927, Figure 3-1).  
 





Figure 3-1. The selective mGluR5 agonist, CHPG, does not affect baseline recording 
in acute hippocampal slices. (A) Comparison between Schaffer inputs from control slices 
(N = 7) and CHPG 1 μM-perfused slices (N = 7) showed no effect of CHPG on basal 
recording of fEPSPs. (B) Comparison between Schaffer collateral inputs from control slices 
(N = 5) and CHPG 10 μM-perfused slices (N = 5) showed no effect of CHPG on basal 
recording of fEPSPs. (C) Comparison between Schaffer collateral inputs from control slices 
(N = 6) and CHPG 50 μM-perfused slices (N = 7) showed no effect of CHPG on basal 
recording of fEPSPs. In all graphs, data were normalised to first 20 minutes. Circles 
represent the mean and error bars the standard error of the mean (S.E.M.). Significance 
level (*p < 0.05) was determined by using an unpaired Student t-test between data points 
corresponding to minutes 36, 38, 40 between control and CHPG-perfused slices. 
Given the role of mGluR5 on synaptic plasticity (Huber et al. 2000; Francesconi et 
al. 2004), it would be expected that agonist stimulation of mGluR5 impacts LTP 
induction. This hypothesis was tested by using CHPG, which was perfused at 
different concentrations (1, 10, 50 µM) for 20 minutes prior to delivery of HFS on 
 




the Schaffer collateral input. CHPG was perfused for 10 minutes more after HFS 
delivery to ensure the treatment was effective during induction of LTP. No 
difference was found between fEPSP slopes recorded after HFS delivery from 
control slices and CHPG-perfused slices at any of the concentrations used (1 μM: 
p-value = 0.931, 10 μM: p-value = 0.811, 50 μM: p-value = 0.964, Figure 3-2). 
Therefore, CHPG perfusion did not affect LTP induction. 
 
 





Figure 3-2. The selective mGluR5 agonist, CHPG, does not affect LTP induction in 
acute hippocampal slices. (A) LTP was induced in control slices (N = 7) and CHPG 1 
μM-perfused slices (N = 7) (B) LTP was induced in control slices (N = 5) and CHPG 10 
μM-perfused slices (N = 5). (C) LTP was induced in control slices (N = 5) and CHPG 50 
μM-perfused slices (N = 6). In all graphs, data before the break were normalised to the first 
20 minutes. Data after the break were normalised to the 20 minutes prior to HFS delivery. 
Top panel shows representative fEPSPs before and after HFS and the superposition of 
both. Circles represent the mean and error bars the standard error of the mean (S.E.M.). 
Significance level (*p < 0.05) was determined by using an unpaired Student t-test between 
data points corresponding to minutes 86, 88, 90, 92, 94 between control and CHPG-
perfused slices. 
 




To verify these data, mGluR5 was activated using a different protocol. A 
combination of DHPG (20 µM), a group I mGluR agonist that activates both 
mGluR5 and mGluR1 (Palmer et al. 1997; Wisniewski & Car 2002) together with 
JNJ (1 µM), which is an mGluR1 negative allosteric modulator  (Lavreysen et al. 
2004) was used. Concentrations of pharmacological agents were selected to 
provide 5x of the half maximal response in the case of JNJ (IC50 = 0.019 µM) 
(Fukunaga et al. 2007) and 40x of the half maximal response in the case of DHPG 
(EC50 = 0.5 µM) (Fazal et al. 2003). These concentrations were selected based on 
previously published work (Fitzjohn et al. 1999; Palmer et al. 1997) to avoid eliciting 
mGluR-dependent LTD as this would interfere with LTP induction. This treatment 
should serve as an alternative pharmacological approach to selectively activate 
mGluR5. In the second set of experiments, field recordings in acute hippocampal 
slices were carried out to assess the effects of DHPG+JNJ treatment on baseline 
recording and LTP induction. Similarly to the data obtained with CHPG, no 
differences were observed between control slices and DHPG+JNJ-perfused slices 
neither in baseline recording (p-value = 0.0754, Figure 3-3A) nor in LTP induction 
(p-value = 0.603, Figure 3-3B).  
 
 





Figure 3-3. Selective activation of mGluR5 does not affect baseline recording or LTP 
induction in acute hippocampal slices. (A) Co-perfusion of slices (N = 6) with 
DHPG+JNJ (20 min) did not affect baseline recording as compared to control slices (N = 
5). Data were normalised to first 20 minutes. (B) LTP was normally induced in control slices 
(N = 5) and DHPG+JNJ-perfused slices (N = 6). Data before the break were normalised to 
first 20 minutes. Data after the break were normalised to 20 minutes prior to HFS delivery. 
Top panel shows representative fEPSPs before and after HFS and the superposition of 
both. Circles represent the mean and error bars the standard error of the mean (S.E.M.). 
Significance level (*p < 0.05) was determined by using an unpaired Student t-test between 
data points corresponding to minutes 36, 38, 40 in A, or minutes 86, 88, 90, 92, 94 in B, 
between control and DHPG+JNJ-perfused slices. 
Taken together, these data indicate that selective activation of mGluR5 does not 
affect synaptic transmission as assessed by baseline recording and LTP induction 
experiments. 
3.2.2 Selective mGluR5 activation does not affect CCh-induced depression  
Loss of cholinergic function is a hallmark of AD pathogenesis (Fisher 2012). The 
potential mGluR5-dependent inhibition of mAChR function could further lead to a 
deficiency in cholinergic signalling and contribute to AD pathology. This concept is 
supported by a study showing that aberrant expression of mGluR5 leads to the 
 




inhibition of mAChR-mediated LTD in the perirhinal cortex (Jo et al. 2006) and by 
preliminary data in our lab (unpublished results). 
First, it was sought to test whether a functional interaction between mGluR5 and 
mAChRs may exist in the hippocampus. To do this, the muscarinic agonist 
carbachol (CCh) in combination with CHPG were used. It is well established that 
perfusion of CCh during field recordings causes a long-lasting depression of the 
fEPSPs, an effect termed CCh-LTD (Kumar 2010; Massey et al. 2001; Volk et al. 
2007; Kirkwood et al. 1999; Mccoy & Mcmahon 2007; McCutchen et al. 2006; 
Scheiderer et al. 2006). Although CCh activates both muscarinic and nicotinic 
receptors (Akay et al. 2009; Brenner & Stevens 2013), in the hippocampus this 
effect has been shown to be specifically mediated by mAChRs expressed 
postsynaptically and in particular by the mAChR1 subtype (Scheiderer et al. 2006; 
Kumar 2010; McCutchen et al. 2006). Therefore, CCh-induced depression was 
used as a readout of mAChR function. In agreement with these studies, all 
concentrations of CCh (50, 25, 10 µM) tested induced a depression of fEPSPs 
when perfused for 10 minutes during baseline recording experiments in acute 
hippocampal slices (Figure 3-4). It was next hypothesised that if mGluR5 could 
inhibit mAChR function, activation of mGluR5 with CHPG would have an effect on 
CCh-induced depression. However, no effect of CHPG on CCh-induced 
depression of fEPSPs was detected at any of the concentration tested (50 and 500 
µM)  as this depression was equally observed in CHPG+CCh-perfused slices and 
CCh alone-perfused slices (50 μM: p-value = 0.553, 25 μM: p-value = 0.35, 10 μM: 
p-value = 0.0756) (Figure 3-4). 
 





Figure 3-4. Perfusion of the selective mGluR5 agonist, CHPG, does not affect CCh-
induced depression of fEPSPs in acute hippocampal slices. (A) Perfusion of CCh (50 
μM, 10 min) resulted in the depression of fEPSPs slopes (N = 6) and this effect was not 
prevented by co-perfusion with CHPG (50 μM, 10 min) (N = 5). (B) Perfusion of CCh (25 
μM, 10 min) resulted in the depression of fEPSPs (N = 5) and this effect was not prevented 
by co-perfusion with CHPG (50 μM, 10 min) (N = 6). (C) Perfusion of CCh (10 μM, 10 min) 
resulted in the depression of fEPSPs slopes (N = 5) and this effect was not prevented by 
co-perfusion with CHPG (500 μM, 10 min) (N = 6). Top panel shows representative fEPSPs 
before and after treatments and the superposition of both. Data normalised to first 30 
minutes. Circles represent the mean and error bars the standard error of the mean (S.E.M.). 
Significance level (*p < 0.05) was determined by using an unpaired Student t-test between 
data points corresponding to minutes 72, 74, 76, 78, 80 between CCh alone and 
CCh+CHPG-perfused slices. 
 




To exclude the possibility that activation of mGluR5 was required prior mAChRs 
activation to reduce CCh-induced depression, two alternative protocols were used. 
The first one involved perfusion of CHPG (50 µM) for 20 minutes prior CCh 
perfusion (10 µM for 10 minutes) and until the end of CCh application (a total of 30 
minutes). Under these circumstances, CHPG did not affect CCh-induced 
depression (p-value = 0.965) (Figure 3-5A).  The second protocol involved the 
incubation of acute hippocampal slices with an increased concentration of CHPG 
(100 µM) for 1-1.5 hours prior field recordings to ensure mGluR5 activation. Then 
CHPG was perfused from the start of recordings until the end of CCh application 
(total of 40 minutes). In these experiments, CHPG treatment had no effect on CCh-









Figure 3-5. Pre-incubation or previous perfusion of acute hippocampal slices with 
the selective mGluR5 agonist, CHPG, do not affect CCh-induced depression. (A) 
Perfusion of CCh (10 μM, 10 min) resulted in the depression of fEPSPs slopes in acute 
hippocampal slices (N = 5). Perfusion of CHPG (50 μM) for 20 minutes prior perfusion of 
CCh (10 μM, 10 min) did not affect CCh-induced depression of fEPSPs (N = 5). (B) Pre-
incubation of acute hippocampal slices with CHPG (100 μM, 1-1.5 h) and subsequent 
perfusion of CHPG during the recording for 30 minutes prior perfusion of CCh did not affect 
CCh-induced depression of fEPSPs (N = 7) compared to CCh alone-perfused slices (N = 
7). Top panel shows representative fEPSPs before and after treatments and the 
superposition of both. Data normalised to first 30 minutes. Circles represent the mean and 
error bars the standard error of the mean (S.E.M.). Significance level (*p < 0.05) was 
determined by using an unpaired Student t-test between data points corresponding to 
minutes 72, 74, 76, 78, 80 between CCh alone and CCh+CHPG-perfused slices. 
Taken together, these data indicate that activation of mGluR5 does not inhibit CCh-
induced depression of fEPSPs in acute hippocampal slices, suggesting that 
mGluR5 does not inhibit mAChR function under these experimental conditions. 
 




3.2.3 Effects of transient agonist activation of mGluRs on mAChR-mediated 
calcium increase 
Electrophysiology data showed that agonist activation of mGluRs does not inhibit 
CCh-induced depression of fEPSPs in acute hippocampal slices. This suggests 
that mGluR5 may not inhibit mAChRs function under these experimental 
conditions. The activation of mAChRs by CCh involves the activation of the G-
protein mediated pathway (Kelly et al. 1996) that results in an increase in 
intracellular levels of calcium (VanDeMark et al. 2006). Therefore, measuring the 
CCh-induced calcium increase would be a complementary approach to confirm the 
electrophysiology data.  
According to this, the effects of agonist activation of mGluRs on mAChR-mediated 
calcium increase were assessed. Fluo4-AM is a cell-permeant calcium fluorescent 
dye that emits at 494/506 nm in its calcium-bound form and was used to load 
primary hippocampal neurons and detect changes in calcium concentration. First, 
it was established whether CCh treatment could produce an increase in 
intracellular calcium levels. As expected, acute activation of muscarinic receptors 
by CCh produced the characteristic increase in intracellular calcium (VanDeMark 
et al. 2009), that was significantly higher at 100 µM (160.02 ± 26.81, p = 0.011) 
and 200 µM (138.22 ± 15.02, p = 0.026) compared to 10 µM (91.59 ± 0.49) 
(Kruskal-Wallis one way ANOVA on ranks, p = 0.007, Dunn’s method for all 
pairwise multiple comparison procedures, Figure 3-6).  
 





Figure 3-6. Effect of muscarinic agonist, CCh, on calcium concentration in primary 
hippocampal neurons. Acute application of muscarinic agonist, CCh, at the following 
concentrations: (A) 10 µM (N = 5 coverslips, 39 cells), (B) 100 µM (N = 7 coverslips, 54 
cells), (C) 200 µM (N = 5 coverslips, 36 cells) caused an increase in the calcium 
concentration. Arrow indicates the addition of 5 mL of CCh prepared in HBS buffer. Right 
panel shows representative images of calcium imaging experiments. Differences in colour 
represent differences in Fluo-4AM fluorescence intensity (i.e. calcium concentration). 
Baseline and after-treatment images were taken at minute 3 and 8 of recordings, 
respectively. (D) Peak calcium fluorescence intensity for each condition. Circles represent 
averaged peak intensity of cells within one experiment (i.e. coverslip). Error bars represent 
the standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by 
using a Kruskal-Wallis one-way ANOVA on ranks and a Dunn’s test for multiple 
comparisons. 
 




Next, the effect of agonist activation of mGluRs by DHPG on CCh-induced calcium 
increase was assessed. The perfusion of 20 µM DHPG throughout the experiment 
resulted in a reduction of the CCh-induced calcium increase (p = 0.039, Figure 
3-7A). DHPG was perfused for 15 min before starting the recording to acquire a 
stable baseline as DHPG also caused an increase in intracellular calcium levels 
(Figure 3-7B). Neurons were depolarised after experiments with 90 mM KCl to 
confirm their viability (Gómez-Ramos et al. 2008) (Figure 3-7C). Taken together, 
these data show that activation of mAChRs by CCh results in an increase in 
intracellular calcium levels in primary hippocampal neurons and that this increase 
is reduced by activation of group I mGluRs with DHPG. 
 
 





Figure 3-7. Perfusion of group I mGluRs agonist, DHPG, reduces CCh-induced 
calcium increase in primary hippocampal neurons. (A) Comparison between CCh 100 
µM-perfused cells (N = 7, 54 cells) and CCh-perfused cells in combination with DHPG 20 
µM (N = 6, 32 cells). DHPG was perfused for 10 min prior to starting the recording. (B) 
Application of DHPG 20 μM for 3 min (N = 4 coverslips, 17 cells). (C) Application of KCl 90 
mM for 3 min (N = 4 coverslips, 30 cells). Right panel shows representative images of 
calcium imaging experiments. Differences in colour represent differences in Fluo-4AM 
fluorescence intensity (i.e. calcium concentration). Images were taken at the indicated 
times. (D) Peak calcium fluorescence intensity for each condition. Circles represent 
averaged peak intensity of cells within one experiment (i.e. coverslip). Error bars represent 
the standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by 
using a Mann-Whitney rank sum test. 
 




3.2.4 mGluR5 protein expression in acute hippocampal slices 
Since electrophysiology data showed no effect of mGluR5 activation on baseline 
recordings or synaptic plasticity elicited in acute hippocampal slices (Figure 3-1, 
Figure 3-2, Figure 3-3), the possibility that this was due to relatively low 
expression of mGluR5 in this in vitro preparation was tested. To this purpose, 
various protein extraction conditions were tested and mGluR5 expression was 
analysed by western blot in acute hippocampal slices. Radioimmunoprecipitation 
assay (RIPA) buffer is a commonly used buffer for the lysis of cells in protein 
extraction protocols (Peach et al. 2012). However, the extraction of membrane-
bound proteins such as mGluR5 may require harsher buffers that contain ionic 
detergents such as sodium dodecyl sulfate (SDS).  According to this, two different 
buffers for cell lysis were used: RIPA buffer and sucrose/SDS buffer (see Chapter 
2, section 2.8.1). It was also tested whether leaving samples with RIPA buffer for 
1 hour improves the protein yield after tissue homogenization. Out of these three 
conditions, the sucrose/SDS buffer showed the best protein yield for mGluR5 (132 
kDa) as revealed by western blot (Figure 3-8). These results indicate that mGluR5 
protein is expressed in acute hippocampal slices. They do not demonstrate that 
mGluR5 is specifically expressed in CA1 pyramidal cells, where mGluR5 was 
expected to be activated in electrophysiology experiments. However, there is 
evidence supporting that mGluR5 is most abundant in the CA1 region of the 
hippocampus (Lujan et al. 1996). Considering this, findings here likely indicate that 
the absence of mGluR5 expression in the CA1 region of acute hippocampal slices 
used in this study does not explain the lack of effects of mGluR5 activation 
observed in field recording experiments. 
 
Figure 3-8. Optimization of mGluR5 total protein extraction from acute hippocampal 
slices. Conditions of protein extraction are as follows: lanes A and B: RIPA buffer, lanes C 
and D: Sucrose/SDS buffer, lanes E and F: RIPA buffer and samples left in rotating wheel 
at 4ºC for 1 h after tissue homogenization. 
3.2.5 Agonist activation of mGluRs does not affect GSK3β activation 
Work from our group and others have shown that GSK-3β is involved in synaptic 
weakening pathways underlying neurodegeneration (Eldar-Finkelman & Martinez 
 




2011; Jo et al. 2011; Noble et al. 2005; Pérez, Hernández, et al. 2003). Regulation 
of GSK-3β may be controlled by synaptic GPCRs activation (Ma et al. 2013; Farías 
et al. 2004) likely via PKC activation (Goode, N.; Hughes, K.; Woodgett, J. R. ; 
Parkeri 1992; Shin et al. 2002; Tejeda-Muñoz et al. 2015; Christian et al. 2002). 
Importantly, this regulation may have an impact in neurodegenerative mechanisms 
(Farías et al. 2004). Because overactivation of mGluR5, a synaptic GPCR coupled 
to PKC activation, also contributes to synaptotoxicity (Kumar et al. 2015), the 
mGluR5-mediated regulation of GSK-3β is a potential mechanism of synaptic 
dysfunction. Accordingly, the hypothesis that activation of mGluR5 can result in the 
activation of GSK-3β in physiological conditions was tested. GSK-3β is a protein 
kinase that is activated upon dephosphorylation of the serine 9 (Ser9) residue 
(Sutherland et al. 1993; Stambolic & Woodgett 1994). Therefore, its activation can 
be determined by assessing protein levels of phosphorylated GSK-3β (P-GSK-3β) 
by western blot. First, acute hippocampal slices were incubated with 10 or 50 µM 
of DHPG for 30 minutes to activate group I mGluRs. None of these concentrations 
of DHPG influenced the levels of GSK-3β phosphorylation on Ser9 residue 
(control: 1.00 ± 0.14, DHPG 10 µM: 0.86 ± 0.15, DHPG 50 µM: 0.87 ± 0.12, p = 
0.718, Figure 3-9A). Second, a time course of 50 µM DHPG was used to ensure 
that the absence of effect was consistent over time. Indeed, DHPG did not trigger 
activation of GSK-3β (Control: 1.00 ± 0.19, 10 min: 1.08 ± 0.19, 30 min: 0.99 ± 
0.19, 2 h: 0.88 ± 0.07, 4 h: 0.83 ± 0.12, p = 0.521, Figure 3-9B). This data suggests 
that activation of group I mGluRs does not result in the activation of GSK-3β. 
 





Figure 3-9. Incubation of acute hippocampal slices with DHPG does not affect GSK3β 
activation. (A) Concentration range of DHPG incubation (N = 6 for all groups). (B) Time 
course of DHPG 50 µM incubations (N = 5 for all groups). Insets show representative 
immunoblots. C: Control (aCSF only). Circles represent the mean and error bars the 
standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by using 















3.3.1 Activation of mGluR5: what makes it detrimental?  
A main physiological role of mGluR5 is the regulation of synaptic transmission and 
plasticity (Lüscher & Huber 2010). Accordingly, excessive activation of mGluR5 
may lead to synaptic impairments and this appears to be a plausible mechanism 
for Aβ-mediated effects on synaptic plasticity. However, whether mGluR5 
activation is sufficient to cause Aβ-like impairments on synaptic function is 
unknown. It was therefore hypothesised that agonist activation of mGluR5 in non-
disease conditions may lead to the same detrimental effects. To test this, field 
recordings in acute hippocampal slices perfused with the mGluR5 selective agonist 
CHPG were performed. At the concentration range used, CHPG did not cause any 
alterations on baseline recording (Figure 3-1) or LTP induction (Figure 3-2). To 
further corroborate this data, a different protocol was used to achieve mGluR5 
activation. A treatment in which the combination of DHPG, a group I mGluR agonist 
that activates both mGluR5 and mGluR1, and the mGluR1 negative allosteric 
modulator mGluR1, JNJ, served as means of selectively activating mGluR5. This 
set of experiments yielded similar results to those obtained with CHPG, as no effect 
on fEPSPs was detectable on baseline recording or LTP experiments after co-
perfusion of DHPG + JNJ (Figure 3-3). Together, this data suggests that, contrary 
to the initial hypothesis, agonist activation of mGluR5 does not lead to impairments 
in synaptic plasticity as per the measurements taken in this study. 
One possibility to be considered is that the lack of effect on synaptic plasticity 
observed is due to a relatively low expression of mGluR5 in these experimental 
conditions. It has been shown that the amount mGluR5 protein reaches a peak 
during the first and second weeks of life followed by a decrease to the adult plateau 
level (Romano, van den Pol, et al. 1996). Rats used in this study were P24-P30, 
therefore the effect of agonist activation of mGluR5 with CHPG could be rather 
small as mGluR5 expression may not be high enough to see a clear functional 
effect. However, this is very unlikely because although the levels decrease after 
two weeks, this is in comparison to the levels at birth, which does not mean that 
expression after two weeks is non-existent or irrelevant for functional effects. 
Indeed, mGluR5 is highly localized in hippocampal dendritic fields of the stratum 
radiatum in the adult rat brain (Lujan et al. 1996). In agreement, western blot of 
acute hippocampal slices showed that mGluR5 was strongly expressed in this 
 




preparation (Figure 3-8), eliminating its lack of expression as an explanation for 
the lack of effect of CHPG and DHPG on electrophysiological recordings. 
Another consideration regarding the effects of activation of mGluR5 with agonists 
is that developmental differences in its expression are isoform-dependent. Three 
splice variants of mGluR5 mRNA have been described to date, namely mGlu5a, 
mGlu5b and mGlu5d, of which mGluR5a and mGluR5b are the best characterised 
(Joly et al. 1995; Minakami et al. 1995; Romano, Yang, et al. 1996; Malherbe et al. 
2002). Studies have consistently shown that mGluR5a is predominantly expressed 
during postnatal stages while mGluR5b expression is higher in adult stages 
(Minakami et al. 1993; Romano, Yang, et al. 1996), with a similar dynamic 
distribution for protein and mRNA levels (Minakami et al. 1995; Joly et al. 1995; 
Romano, van den Pol, et al. 1996). Although agonist compounds that selectively 
activate one isoform are not available yet, the pharmacological characterisation of 
CHPG was done in mGluR5a-expressing cells (Doherty et al. 1997), the isoform of 
which expression is expected to decrease at the post-natal age studied here. 
Therefore, it could be possible that by using CHPG part of the activation within the 
population of mGluR5 is missing, specifically the mGluR5b variant, which precisely 
is thought to have a higher expression. However, this does not seem to be the case 
since no pharmacological differences have been described between mGluR5a and 
mGluR5b (Joly et al. 1995). In addition, data presented here shows that an 
alternative treatment to activate mGluR5 consisting in co-perfusion with DHPG, a 
group I mGluR orthosteric agonist that has no reported isoform preference, and 
JNJ, similarly showed no effects on field recordings (Figure 3-3). Therefore, this 
indicates that the lack of effect of mGluR5 activation is not related to preferential 
isoform activation by the compounds used in these experiments.  
The above evidence shows that mGluR5 is abundantly expressed in the 
hippocampus, with higher levels than its group I counterpart, mGluR1 (Lujan et al. 
1996). Given the role of the hippocampus in cognition, the expression of mGluR5 
in this brain region has been linked to a role of the receptor in physiological 
mechanisms that mediate cognitive processes. Indeed, one of the main roles of 
mGluR5 in physiological conditions is the regulation of NMDARs, which are key 
mediators of higher cognitive functions (Riedel et al. 2003). Supporting this, 
pharmacological activation of group I mGluRs triggers the potentiation of 
NMDARs-induced depolarisations in CA1 (Fitzjohn et al. 1996) and this action 
 




occurs via mGluR5 (Doherty et al. 1997; Mannaioni et al. 2001). Given the role of 
NMDARs in learning and memory (Riedel et al. 2003), the enhancement of 
NMDAR function by mGluR5 may be related to positive effects of mGluR5 
activation on cognitive processes in physiological conditions (Homayoun et al. 
2004; Stefani & Moghaddam 2010). It may be then the case that only when 
pathology is present that mGluR5 function is aberrantly engaged and consequently 
activation of the receptor is detrimental. In fact, much of the evidence supporting a 
role of mGluR5 in the pathology of AD is based on the neuroprotective effects of 
mGluR5 blockade, which are assessed under pathological conditions. For 
instance, Aβ peptides are commonly used to resemble AD-like brain pathology, 
and it is under these conditions when mGluR5 seems to participate in various Aβ-
mediated pathological effects such as the facilitation and enhancement of LTD (Hu 
et al. 2014; Shankar et al. 2008) and impairment of LTP (Wang 2004; Rammes et 
al. 2011) as well as NMDAR-induced excitotoxicity (Movsesyan et al. 2001). In 
these studies, different forms of AD-related pathology are present in the 
experimental conditions where the effects of activation or inactivation of mGluR5 
are assessed. A similar scenario is extended to in vivo evidence showing that 
genetic deletion (Hamilton et al. 2014) and pharmacological inhibition (Hamilton et 
al. 2016) of mGluR5 prevents memory deficits and Aβ pathology in an AD mice 
model. Therefore, this evidence suggests that mGluR5 activation mediates 
pathological effects in circumstances where the receptor is already in a diseased 
environment, such as the presence of toxic Aβ (Hu et al. 2014; Wang 2004) or 
overactivated NMDARs (Kingston et al. 1999; O’Leary et al. 2000). These 
molecules and/or pathways may interfere with mGluR5 signalling preventing its 
physiological actions with neurotoxic consequences. The results obtained in the 
present study support this concept by showing that activation of mGluR5 in non-
pathological conditions does not affect synaptic plasticity, particularly LTP 
induction in the hippocampus (Figure 3-2 and Figure 3-3). In agreement with the 
above evidence, this may be because the absence of AD-related pathological 
events renders mGluR5 activation as a harmless event for the neuron.  
This knowledge is valuable to our understanding of molecular mechanisms 
operating in AD because it indicates that the involvement of mGluR5 is more 
complex than an on/off situation. Rather than this, a combination of pathology-
triggered actions and/or molecules are simultaneously required for mGluR5 to 
become a detrimental insult for synaptic function. Importantly, this may mean that 
 




although activation of mGluR5 alone is not sufficient to cause pathology in a 
healthy neuronal environment, inhibition of the receptor may be sufficient to restore 
normal synaptic function. This is in accordance with the central role of played by 
mGluR5 once the pathology is triggered. Therefore, identification of additional 
pathological events that accompany mGluR5 activation in AD will be crucial to 
successfully design therapeutic strategies aimed at this receptor. 
3.3.2 mGluRs and mAChRs interplay 
A synaptic hallmark of AD pathology is the reduction of cholinergic transmission 
(Whitehouse et al. 1982; Davies & Maloney 1976; Parent et al. 2013), which may 
be related to the observed reduction of mAChRs in the brains of AD patients 
(Shiozaki et al. 2001; Flynn et al. 1995). Supporting this, loss of mAChR1 results 
in increased Aβ-pathology in a mouse model of AD (Davis et al. 2010). This can 
potentially relate to the cognitive impairments that characterise AD, as blockade of 
mAChR1 results in cognitive impairment in mice (Anagnostaras et al. 2003) and 
agonism of mAChR1 rescues cognitive deficits in a mice model of AD (Caccamo 
et al. 2006). Therefore, identification of mechanisms by which activity or expression 
of mAChRs is reduced is of interest for the development of therapeutics aimed to 
restore mAChRs function in AD. 
The impairment of mAChRs function mediated by mGluRs has been shown in the 
perirhinal cortex (Jo et al. 2006) and it is supported by preliminary data from our 
group (unpublished results). According to this, it was hypothesised that mGluR5 
may also regulate mAChRs function in the hippocampus. To examine this, acute 
hippocampal slices were perfused with the muscarinic agonist CCh, which elicits a 
well-established depression of fEPSPs through the action of mAChRs (Kumar 
2010; Massey et al. 2001; Volk et al. 2007; Kirkwood et al. 1999; Mccoy & 
Mcmahon 2007; McCoy et al. 2008; McCutchen et al. 2006; Scheiderer et al. 
2006), in combination with the mGluR5 agonist CHPG. In these experiments, 
CHPG did not prevent the observed CCh-induced depression (Figure 3-4), even 
when slices were perfused or pre-incubated with CHPG for long periods of time (1-
1.5 h) (Figure 3-5). The possibility that the concentration of CCh was too high that 
masked the effect of CHPG was considered. For this reason, a decreased 
concentration of CCh from 50 µM down to 10 µM was tested, as well as increasing 
concentrations of CHPG (up to 500 µM) (Figure 3-4). In none of these conditions, 
CHPG perfusion affected the CCh-induced depression by CHPG. Together these 
 




data suggest that under these experimental conditions, activation of mGluR5 does 
not inhibit mAChR-mediated depression of fEPSPs in acute hippocampal slices.  
These experiments may indicate that the interplay between mGluRs and mAChRs 
may not occur under these experimental circumstances or may not be of 
competitive nature. For instance, not competitive but cooperative signalling via 
mAChRs and group I mGluRs has been shown to increase the excitability of 
hippocampal CA1 pyramidal neurons when both receptors are synergistically 
activated (Park & Spruston 2012). In the experimental conditions of this study, 
however, a bigger magnitude CCh-induced effect when mAChRs and mGluR5 
were co-activated was not observed. This suggests a lack of cooperative signalling 
for this particular functional aspect of mAChRs.  
It is well established that both mAChRs (Levey et al. 1995) and mGluR5 (Lujan et 
al. 1996) are highly expressed in the CA1 region of the rat hippocampus, 
particularly in the dendritic fields. Nonetheless, the perisynaptic distribution of 
mGluR5 to the lateral margin of synapses and extrasynaptic locations have been 
well described (Lujan et al. 1996), whereas mAChRs are very likely enriched in the 
postsynaptic region of specific synapses (Levey 1996). Therefore, differential 
subcellular expression may potentially affect reciprocal interactions between 
receptors. This concept has been previously suggested as an explanation for how 
signalling pathways activated by GPCRs coupled to the same G proteins can exert 
different functional effects depending on their location (Moore et al. 2009; Ostrom 
& Insel 2004). For instance, activation of mGluRs and mAChRs results in the 
activation of extracellular signal-regulated kinase (ERK) in distinct compartments 
within the cell (Berkeley et al. 2001). In addition, there is evidence showing that 
GCPRs are specifically located in microdomains within the membrane, such as 
caveolae and lipid rafts (Insel et al. 2005). Illustrating this, Gq-coupled GPCRs and 
specifically group I mGluRs (Francesconi et al. 2009) and mAChRs (Gosens et al. 
2007; Keshavarz et al. 2018), can localise to these domains where their signalling 
is enhanced (Calizo & Scarlata 2012). According to this, a plausible consideration 
regarding results presented here is that spatial separation of synaptic GPCRs 
located in different cellular compartments could result in the absence of 
competition for G-proteins and possibly other shared intracellular molecules. 
In addition, GPCRs can signal through G-protein-independent pathways. For 
example, mGluRs can regulate brain function through non-GPCR mediators, such 
 




as the non-receptor tyrosine kinases (Heuss & Gerber 2000; Ireland et al. 2004). 
In the experiments presented here, it could be possible that agonist activation of 
mGluR5 may trigger a G-protein independent pathway that may not interfere with 
the mAChR intracellular signalling that is involved in CCh-induced depression. One 
way to address whether there is an interaction between mGluRs and mAChRs at 
the level of intracellular signalling is to study changes in intracellular concentration 
of calcium induced by these receptors. It is very well-characterised that the 
activation by mAChRs by CCh results in an increase in intracellular calcium levels 
as a result of its release from intracellular stores (Gómez-Ramos et al. 2008; 
Haraguchi & Rodbell 1991; VanDeMark et al. 2009; Luo et al. 2001; Montiel et al. 
2001; Mayerhofer et al. 1992) through the activation of the coupled G-protein 
(Caulfield & Birdsall 1998). Accordingly, calcium imaging in primary hippocampal 
neurons was carried out to test the hypothesis that mGluRs activation may impair 
calcium release triggered by mAChRs. Treatment of primary neurons with CCh 
induced the well-established increase in intracellular calcium levels, which was 
used as a readout of mAChRs function (Figure 3-6). Perfusion of group I mGluRs 
agonist DHPG caused a reduction in the CCh-mediated calcium increase (Figure 
3-7), indicating that mGluRs may regulate mAChRs function under these 
experimental conditions.  
The regulation of GPCRs function is exerted at many levels within the cell, 
including GPCR trafficking to the membrane, agonist binding, G-protein coupling, 
desensitisation and endocytosis of the receptor (Magalhaes et al. 2012). Out of 
these, receptor desensitisation can be seen as a central mechanism that is 
influenced by all other processes, resulting in a complex regulation of GCPRs 
signalling. GPCR desensitisation is triggered by various molecular mechanisms 
that have been classified as heterologous or homologous (Chuang et al. 1996). 
Homologous refers to agonist-dependent receptor desensitisation that generally 
involves the actions of GPCR kinases (GRKs) and arrestin proteins (Smith & 
Rajagopal 2016). These interactions generally result in the internalisation of the 
GPCR (Kelly et al. 2008). In opposition, heterologous desensitisation is agonist-
independent, and it is triggered by the activation of other receptors rather than 
agonism of the GPCR that undergoes desensitisation (U. Klein et al. 2001; 
Cordeaux & Hill 2002). This latter mechanism of desensitisation could apply to data 
presented here, where mGluRs-activation results in the reduction of mAChRs-
mediated calcium signalling. 
 




One plausible mechanism of heterologous desensitisation is the competition for 
intracellular signalling complexes shared between group I mGluRs and mAChRs 
(Hur & Kim 2002; Hippe et al. 2013). Both receptors are coupled to Gq/11 and the 
generation of IP3, which results in the release of calcium from intracellular stores 
(Huang & Thathiah 2015). Therefore, it is possible that application of DHPG 
activates this pathway through group I mGluRs that recruit part of the G-protein 
signalling complexes used by mAChRs. This mechanistic pathway would be further 
influenced by relative receptor abundance, since receptor density may be different 
for mGluRs and mAChRs. This can be a factor in determining the extent to which 
the more abundant GPCR sequesters G-proteins required by another GPCR 
present in lesser quantity (Willars et al. 1999; Bundey & Nahorski 2001). If mGluRs 
occupies a great part of the available GPCR signalling machinery, the later 
activation of mAChRs by CCh causes a smaller increase in intracellular calcium 
than if all downstream signalling molecules were available. Heterologous 
desensitisation of mAChRs can also occur as a result of uncoupling from Gq/11 
proteins, a process reported to be triggered by α1B-adrenoceptor activation 
(Bundey & Nahorski 2001). Since coupling of mAChRs to Gq/11 is required for the 
CCh-mediated effects on intracellular calcium (Gómez-Ramos et al. 2008; 
VanDeMark et al. 2009; Montiel et al. 2001; Lanzafame et al. 2003), mGluR-
induced uncoupling of mAChRs would explain a reduction in the calcium response 
triggered by CCh.  
Alternatively, it could also be the case that previous sustained activation of mGluRs 
results in the depletion of intracellular calcium stores so that less calcium is 
available to be released when mAChRs are later activated by CCh. The relevance 
of this effect would depend on two factors. First, whether there is a common 
intracellular calcium store shared between the receptors. This seems plausible 
since a cell contains many stores of calcium rather than one large reservoir and 
that movement of calcium in discrete stores is GPCR-driven by different agonists, 
allowing cross-talk between receptors (Blaustein & Golovina 2001). Second, the 
temporal dynamics of the intracellular store to replace the released calcium before 
further release is triggered (Werry et al. 2003). Interestingly, activation of group I 
mGluRs may result in the refilling of intracellular calcium stores through a L-type 
calcium channel-mediated mechanism (Fagni et al. 2000). Therefore, in the 
present experiments calcium stores could be replenished by the time mAChRs are 
activated, although this would depend on the timing of these two processes. In the 
 




case that intracellular calcium stores are replenished shortly after calcium is 
released due to mGluR activation, calcium would be available for further mAChR-
induced release. If this release is decreased by DHPG, as shown by data 
presented here, it may mean that mGluRs activation is causing the reduction of 
mAChRs available to mediate CCh-induced calcium increase. The loss of 
functional mAChR in the plasmatic membrane could occur through an increased 
desensitisation of the receptor induced by mGluRs. Interestingly, it has been 
shown that mAChRs activation can result in the heterologous internalisation of 
mGluRs in a CCh dependent manner (Mundell et al. 2002; Mundell et al. 2004). 
Therefore, a similar mechanism but in the opposite direction could be triggered by 
prior activation of mGluRs, resulting in mAChRs internalisation. This would result 
in a reduced number of mAChRs expressed in the plasmatic membrane that are 
available to bind CCh.  
Overall, calcium imaging data supports an interplay between mGluRs and 
mAChRs that was not observed at the electrophysiological level. However, these 
results may not necessarily contradict each other. They may simply reflect 
differences in the mechanisms that produce the outcome used to asses mAChRs 
function, i.e. fEPSPs or calcium release. In field recording experiments, the 
generation of fEPSPs requires extracellular calcium (Error! Reference source not 
found.) in addition to intracellular calcium as well as other mechanisms that alter 
membrane excitability (Dong & Graziane 2016). In calcium imaging experiments, 
mobilisation of intracellular calcium accounted for the effect of mAChRs activation. 
Therefore, the interplay between mGluRs and AChRs could still happen in acute 
hippocampal slices although a functional effect was not seen by the specific 
measure of fEPSPs. 
3.3.3 mGluRs and GSK3β 
Finally, another possible mechanism by which mGluRs contributes to AD 
pathological processes is the activation of GSK-3β, a kinase involved in synapse-
weakening pathways leading to neurodegeneration (Jo et al. 2006; Baki et al. 
2004; Takashima et al. 1998; Hernández et al. 2010; Busciglio et al. 1995; Pérez, 
Rojo, et al. 2003). To test the hypothesis that mGluRs can regulate GSK-3β 
activity, acute hippocampal slices were incubated with different concentrations of 
DHPG to activate group I mGluRs. This set of experiments showed that regardless 
the concentration or incubation time, DHPG had no effect on GSK-3β activation as 
 




assessed by the phosphorylation state of the protein in physiological conditions 
(Figure 3-9).  
As outlined before, the pathological relevance of mGluR5 activation may only 
emerge in the situation where pathology is present and engages aberrant 
signalling of the receptor. Therefore, mGluR5-induced activation of GSK-3β may 
only occur in neurodegenerative conditions but not under physiological conditions, 
such as those of this study. This concept is supported by studies showing that 
pharmacological inhibition of mGluR5 results in increased inhibitory 
phosphorylation of GSK-3β at Ser9 in a mice model of FXS but not in wild-type 
mice (Min et al. 2009; Yuskaitis et al. 2010). This indicates that in conditions where 
mGluR5 is aberrantly activated, such as in FXS (Bear et al. 2004; Ronesi et al. 
2012), the receptor can trigger the activation of GSK-3β. A possible link between 
GSK-3β and mGluR5 is the activation of NMDARs. It is known that NMDARs can 
regulate GSK-3β function, as blocking NMDARs results in increased inhibitory 
phosphorylation of GSK-3β (De Sarno et al. 2006). In addition, the regulation of 
NMDARs by mGluRs is well-established (Awad et al. 2000; Fitzjohn et al. 1996; 
O’Connor et al. 1994; Attucci et al. 2001), so excessive activation of mGluR5 could 
lead to NMDAR-induced activation of GSK-3β in disease conditions. Therefore, 
although data presented here does not support that activation of mGluR5 induces 
activation of GSK-3β in non-disease conditions, the possibility that this is still a 
plausible mechanism in AD pathology cannot be excluded.  
3.3.4 Summary 
In summary, according to data presented in this chapter, activation of mGluRs in 
physiological conditions does not seem to have detrimental effects on synaptic 
plasticity mechanisms such as LTP. Neither it affects the activation of synapse-
weakening pathways mediated by GSK-3β. This does not exclude that in AD-like 
conditions, when the receptor is aberrantly activated and non-physiological 
mechanisms may be triggered, the activation of mGluR5 is harmful for the neuronal 
environment. Evidence provided here supports that group I mGluRs may inhibit 
mAChR function in physiological conditions. The relevance of this interplay for AD 
pathological mechanisms can be speculated based on deficits in cholinergic 
transmission and pathological activation of mGluR5 described in disease 
conditions. Therefore, the mGluR-mediated inhibition of mAChRs function would 
be particularly important if the expression or function of mGluRs is affected in AD. 
 




For this reason, the next chapter is aimed to explore the changes in synaptic 
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Alzheimer’s disease is a neurodegenerative disorder characterised by a long 
pathological progression that starts many years before the clinical diagnosis of 
dementia (Sperling et al. 2011; Price & Morris 1999). This pathology includes the 
accumulation of the two AD-defining molecules, Aβ and hyperphosphorylated tau, 
in the form of amyloid plaques and NFTs in the brains of AD patients, respectively 
(Perl 2010). The anatomical distribution of these lesions is characterised by 
following a specific pattern and selectively affecting some neuronal populations 
(Braak & Braak 1991; Braak et al. 1993; Braak et al. 2006; Thal et al. 2000; Thal 
et al. 2002). Importantly, once triggered, the neuropathological process progresses 
relentlessly for decades until cognitive dysfunction is observable in the form of 
clinical symptoms (Vickers et al. 2016). Since gradual brain deposition of 
pathological Aβ and hyperphosphorylated tau aggregates occurs in a predictable 
sequence, its use as a diagnostic tool to determine the stage of pathology has 
been proposed (Sperling et al. 2011). Although the therapeutic importance of 
detecting AD at early stages is undeniable (Korolev 2014), even more relevant is 
to identify the molecular changes occurring at different stages, so therapeutic 
interventions can be tailored to these specific phases.  
The fact that AD pathology gradually takes over brain structures has led to think 
that neuronal dysfunction in affected regions also occurs progressively, hence the 
definition of AD as a “progressive” neurodegenerative disorder (Vickers et al. 
2016). Therefore, the need to understand how factors underlaying 
neurodegeneration evolve during the course of AD has become essential. It is 
widely believed that neurodegeneration results in deterioration of synaptic function 
that eventually leads to synaptic loss, and this has been linked to the severe 
impairments in cognitive abilities in AD (Masliah & Terry 1993; Masliah et al. 1989; 
Scheff & Price 1998; Scheff et al. 2006; Scheff et al. 2001; Terry et al. 1991; 
DeKosky et al. 1996; DeKosky & Scheff 1990). Support for this comes from studies 
showing a correlation between synaptic loss in AD brains and cognitive decline (De 
Wilde et al. 2016; Terry et al. 1991; DeKosky et al. 1996; DeKosky & Scheff 1990). 
In fact, synapse loss has become a hallmark not only for AD but for multiple types 
of dementia (Scheff et al. 2014). Notably, the integrity of synapses relies to a great 
extent on the correct functioning of neurochemical communication (Mckinney 
2010), which depends on different neurotransmitter systems across brain regions 
(Kandimalla & Reddy 2017). In the hippocampus, one of the first brain regions 
 




affected in AD (Braak & Braak 1991; Braak et al. 2006), glutamatergic transmission 
plays a key role in memory processing (Squire & Zola-morgan 1991; Bird & 
Burgess 2008) and glutamate receptors are critically involved in the maintenance 
of dendritic spines (McKinney et al. 1999; Ultanir et al. 2007; Mateos et al. 2007). 
Therefore, understanding the vulnerability of glutamate receptors in AD may hold 
important insights regarding disease mechanisms and identification of new 
therapeutic targets. 
As outlined in Chapter 1, glutamatergic transmission is mainly mediated by two 
types of receptors, ionotropic and metabotropic. The involvement of these 
receptors in the pathology of AD is widely accepted and has been the object of 
intense research, but how they operate in pathologies is not fully understood yet. 
The involvement of NMDARs in AD has been linked, among other things, to their 
ability to mediate calcium excitotoxicity. It is well-established that chronic activation 
of NMDAR leads to a prolonged calcium influx into the postsynaptic neuron (Choi 
1987; Greenamyre et al. 1988; Dong et al. 2009). Importantly, calcium 
excitotoxicity has been proposed as a mechanism for Aβ-mediated neuronal death 
(Demuro et al. 2005; Mattson et al. 1992; Alberdi et al. 2010; Arias et al. 1995; Le 
et al. 1995). Indeed, NMDAR-dependent calcium influx causes a rise in intracellular 
calcium levels that activates various intracellular cascades resulting in cell death 
(Alberdi et al. 2010; Kelly & Ferreira 2006; Harkany et al. 2000). This aberrant 
activation of NMDAR can be triggered by glutamate excessively accumulated at 
the synapse (Parpura-Gill et al. 1997; Fernández-Tomé et al. 2004). Excessive 
accumulation of glutamate in turn can occur by Aβ-induced decrease in glutamate 
clearance (Li et al. 2009; Parpura-Gill et al. 1997; Fernández-Tomé et al. 2004). 
This process involves Aβ-mediated impairment of the function or expression of 
glutamate transporters located in neurons and glia, resulting in increased 
extracellular levels of glutamate (Li et al. 2009; Fernández-Tomé et al. 2004). In 
addition, Aβ can induce synaptic glutamate release in a potassium- and calcium-
dependent manner (Kabogo et al. 2010; Arias et al. 1995; Abramov et al. 2009). 
Crucially, these findings are supported by human studies showing reductions in 
glutamate transporters in AD brains (Lauderback et al. 2001; Li et al. 1997; Jacob 
et al. 2007; Scott et al. 2011; Kashani et al. 2008; Kirvell et al. 2006). In addition to 
elevated glutamate levels, NMDAR can also be activated in pathological conditions 
in a more direct way. Illustrating this, Aβ can interact with NMDAR (De Felice et al. 
2007; Texidó et al. 2011; Alberdi et al. 2010) to induce neurotoxic effects that are 
 




detected preferentially on glutamatergic neurons (Deshpande et al. 2009; Sokolow 
et al. 2012). Further supporting a central role for NMDARs in AD, one of the FDA-
approved treatments for AD is the NMDAR blocker memantine (Alzheimer’s 
Association 2018). This evidence therefore indicates that NMDARs are 
dysregulated in the presence of AD-like pathology. 
Synaptic dysfunction is associated with impairments in cognitive processes such 
as memory. Therefore, pathological alteration of synaptic plasticity mediators such 
as AMPARs (Shankar et al. 2008) is likely to have an impact on cognition. In 
support of this, Aβ-mediated enhancement of LTD involves the removal of 
AMPARs from postsynaptic membranes in a NMDAR-dependent manner (Hsieh 
et al. 2006; Shankar et al. 2007). This may be related to the Aβ-mediated 
impairment of AMPAR trafficking (Gu et al. 2009) and may be relevant for synaptic 
function since blocking AMPAR endocytosis prevents the Aβ-mediated loss of 
dendritic spines (Hsieh et al. 2006). In addition to amyloid pathology, tau pathology 
also contributes to the disruption of AMPAR function.  For instance, there is 
evidence for a reduction of AMPAR expressed in the postsynaptic membrane in a 
tau model of AD (Hoover et al. 2010) which may be related to the ability of tau to 
interfere with AMPAR trafficking (Jurado et al. 2018). Furthermore, tau can also 
disrupt AMPAR-dependent synaptic plasticity (Fá et al. 2016; D’Amelio et al. 2011) 
in AD models. Overall, this evidence shows that dysregulation of ionotropic 
glutamate receptors, AMPARs and NMDARs, plays a key role in pathological 
mechanisms associated with AD.  
mGluRs also contribute to glutamatergic transmission and memory processing. As 
explained in Chapter 3, compelling evidence supports that mGluRs and 
particularly the mGluR5 subtype are important mediators of AD-related 
pathological effects (Kumar & Singh 2015). Part of this evidence is based on the 
positive effects of mGluR5 activation on the Aβ-precursor APP secretion (Lee et 
al. 1995; Sokol et al. 2011). In addition, mGluR5 has been shown to mediate the 
detrimental effects of Aβ on synaptic function, including the blockade of LTP 
(Walsh et al. 2002; Shankar et al. 2008; Jo et al. 2011; Rammes et al. 2011) and 
the enhancement of LTD (Hu et al. 2014; Hsieh et al. 2006; Li et al. 2009; Shankar 
et al. 2008). Importantly, this may have behavioural effects as suppression of 
mGluR5 activity rescued deficits in learning, memory and spine density triggered 
by Aβ (Um et al. 2013; Hamilton et al. 2016; Hamilton et al. 2014). As in the case 
 




of NMDARs, mGluR5 can also behave as a receptor of Aβ in the synaptic 
membrane which may provide a mechanistic explanation for how Aβ triggers 
aberrant activation of mGluR5 (Um et al. 2013; Haas et al. 2016; Hamilton et al. 
2015; Renner et al. 2010). These studies highlight the importance of glutamate 
receptors in mediating AD-associated neuropathology such as Aβ-toxicity.  
Most of the evidence presented above relies on animal models of disease, which 
have several limitations and do not reflect the true complexity of the disease 
(Franco & Cedazo-Minguez 2014). Although these models allow for useful 
manipulations to study molecular disease mechanisms, they are imperfect in 
mimicking disease pathology in human patients (King 2018). For instance, synapse 
loss and dysfunction, which are now believed to be a core triggering factor for early 
memory impairment, are not often observed in transgenic models of AD (Hu et al. 
2003; King & Arendash 2002). This may be a main difficulty when translating pre-
clinical findings into successful treatments for patients. Furthermore, animal 
models are usually generated from genetic mutations and may not reflect the 
complex multifactorial origin of the most common form of AD, the sporadic variant. 
In addition, animal models tend to exhibit just a few aspects of AD pathology, 
hampering a comprehensive assessment of how receptors are affected by 
pathological mechanisms and also the effects of drugs in the 
symptomatology/progression of the disease (Franco & Cedazo-Minguez 2014). 
Moreover, disease progression in AD animal models occurs in a very different time 
window than in AD patients (Dam & De Deyn 2011; Franco & Cedazo-Minguez 
2014). These hurdles may explain why pharmacological agents designed 
according to beneficial changes (of molecular or cognitive nature) in animal models 
may behave differently when tested in humans. In this regard, a main consideration 
is that human brains have been subjected to a much more heterogeneous 
pathology for longer periods of time.  
Therefore, AD remains being a disorder that affects humans only and consequently 
research towards the study of AD patient’s brains is gaining importance (Perl 
2010). For example, in vivo receptor binding studies with positron emission 
tomography (PET) probes in human brains provide information about the specificity 
and dose requirements of new drugs during clinical trials (Ametamey et al. 2007; 
Terbeck et al. 2015; Pillai & Tipre 2016). They also help to study the mechanism 
of action of drugs and receptor density in the diseased brain (DeLorenzo et al. 
 




2011; Treyer et al. 2008; Akkus et al. 2014; Deschwanden et al. 2011; Albasanz 
et al. 2005). In addition, protein and gene expression studies in post-mortem tissue 
can provide direct information of the state of receptors at different stages of the 
disease (Albasanz et al., 2005; Gomez-Nicola & Boche, 2015; Gylys, 2004; Haas 
et al., 2016a; Scarr, McLean, & Dean, 2016; Sokolow et al., 2012; Tiwari et al., 
2016).  
As previously outlined, Aβ and tau pathologies and associated neuronal 
dysfunction are thought to gradually develop in AD. Therefore, it can be 
hypothesised that glutamate receptors with a demonstrated involvement in these 
pathologies, at least in AD models, may also be progressively affected as disease 
develops in the human brain. Accordingly, it is reasonable to hypothesise that 
glutamate receptor expression may change over the course of AD as a 
consequence of differential regulation by pathological mechanisms. Although 
synapses and thus synaptic receptors may be particularly vulnerable at early 
stages of AD (Selkoe 2002; Revett et al. 2013), it is unknown whether this 
represents an overall loss of total protein levels and whether this loss in maintained 
throughout disease progression. This is important because successful 
pharmacological manipulation of synaptic glutamate receptors made in animal 
models of AD may not necessarily be an efficient approach in humans if overall 
receptor proteins are lost in AD brains. Moreover, since data from Chapter 3 has 
shown that mGluRs can inhibit mAChRs function, the relevance of this functional 
interplay in AD may be subject to changes in protein expression. The hypotheses 
being that (1) upregulation of mGluR5 protein levels and (2) downregulation of 
mAChRs protein levels occur in the brains of patients with severe AD. The aim of 
this chapter is to test these hypotheses by analysing protein levels of glutamate 
and mAChRs receptors in post-mortem brain samples from human AD patients at 
two stages of AD pathology. These stages are defined as possible/probable AD 
(P-AD cohort) and severe AD (AD cohort). Findings from this study will help to 
understand how receptor expression may change over disease progression and 
why some pharmacological manipulations may be more effective in certain phases 
of AD. Hopefully, it will also lead to more representative models of AD and therefore 
better therapeutics designs. 
 





4.2.1 Synaptic protein expression in post-mortem human brain from AD patients 
Samples from AD patients (Braak stages V-VI) and control subjects were received 
from the South West Dementia Brain Bank. There were no significant differences 
in age (C: 79.80 ± 2.52, AD: 77.70 ± 2.52, p-value = 0.563) and post-mortem delay 
(C: 1.04 ± 0.10, AD: 0.75 ± 0.09, p-value = 0.715) between control and AD groups 
(Figure 4-1), indicating that this will likely not account for any differences detected 
in the analysis. Protein levels of ionotropic glutamate receptor subunits were first 
analysed. To assess protein levels of AMPAR, an antibody against the GluA2 
subunit of these receptors was used. Western blot analysis showed a significant 
decrease in GluA2 protein levels in AD samples compared to control samples (C: 
79.80 ± 2.52, AD: 77.70 ± 2.52, p-value = 0.043, Figure 4-2A). Protein levels of 
NMDAR were assessed by using an antibody against the NR1 subunit, which is an 
obligated subunit to form a functional NMDAR heteromeric complex. Western blot 
analysis with this antibody showed a significant decrease in NR1 protein levels in 
AD patients compared to control subjects (C: 0.97 ± 0.11, AD: 0.54 ± 0.07, p-value 
= 0.005, Figure 4-2B). Overall, these findings suggest a loss of GluA2-containing 
AMPARs and NR1-containing NMDARs in AD. 
 
Figure 4-1. Age and post-mortem delay distribution of post-mortem AD samples. (A) 
No significant differences in age were found between the control (C) group (N = 10) and 
the Alzheimer’s disease (AD) group (N = 10) (B) No significant differences in post-mortem 
delay were found between the C group (N = 10) and the AD group (N = 10). Circles 
represent the value for each subject and error bars represent the standard error of the 
 




mean (S.E.M.). Significance level (*p < 0.05) was determined by using an unpaired Student 
t-test. (C) Table summarising characteristics of human AD samples. 
 
Figure 4-2. Ionotropic glutamate receptor protein expression in post-mortem AD 
samples. (A) GluA2 protein levels are significantly reduced in the Alzheimer’s disease (AD) 
group (N = 10) compared to the control (C) group (N = 10). (B) NR1 protein levels are 
significantly reduced in the AD group (N = 10) compared to the C group (N = 10). Circles 
represent the value for each subject and error bars represent the standard error of the 
mean (S.E.M.). Significance level (*p < 0.05) was determined by using an unpaired Student 
t-test. A.U.: Arbitrary units. Insets show representative immunoblots. For technical 
purposes, samples were loaded in numerical order to facilitate the work, but not due to 
scientific reasons. See Appendix for examples of full-length immunoblots for each 
antibody and for immunoblots corresponding to the rest of the samples. 
Changes in protein levels of group I metabotropic glutamate receptors, mGluR1 
and mGluR5, were then examined. Quantification of mGluR1 protein amounts 
showed no differences between control and AD groups (C: 0.89 ± 0.08, AD: 0.97 
± 0.08, p-value = 0.457, Figure 4-3A). On the contrary, mGluR5 protein levels were 
markedly decreased in AD brains compared to controls (C: 1.72 ± 0.22, AD: 0.85 
± 0.15, p-value = 0.004, Figure 4-3B). These results suggest that AD pathology 
specifically affects mGluR5, whereas protein levels of a closely related receptor, 
mGluR1, remain unaffected. Since data from Chapter 3 showed the mGluRs-
mediated inhibition of mAChRs, and a previous study has outlined that mGluR5 
can negatively impact on mAChRs (Jo et al. 2006), it was possible that decreased 
mGluR5 levels would lead to an alteration in mAChRs levels. Therefore, protein 
amounts of mAChR1 were evaluated by western blot. This analysis showed no 
 




significant changes in protein levels between control and AD brains (C: 1.06 ± 0.16, 
AD: 1.03 ± 0.17, p-value = 0.915, Figure 4-3C).  
 
Figure 4-3. Synaptic GPCR protein expression in post-mortem AD samples. (A) 
mGluR1 protein levels are not significantly different in the Alzheimer’s disease (AD) group 
(N = 10) compared to the control (C) group (N = 10). (B) mGluR5 protein levels are 
significantly reduced in the AD group (N = 10) compared to the C group (N = 10). (C) 
mAChR1 protein levels are not significantly different in the AD group (N = 10) compared to 
the C group (N = 10). Circles represent the value for each subject and error bars represent 
the standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by 
using an unpaired Student t-test. A.U.: Arbitrary units. Insets show representative 
immunoblots. For technical purposes, samples were loaded in numerical order to facilitate 
the work, but not due to scientific reasons. See Appendix for examples of full-length 
immunoblots for each antibody and for immunoblots corresponding to the rest of the 
samples. 
 




The location and signalling of mGluR5 is affected by its interaction with Homer 1 
b/c, a scaffold protein located in the postsynaptic density (Roche et al. 1999; Tu et 
al. 1999; Sergé et al. 2002; Mao et al. 2005). In addition, Homer 1b/c and mGluR5 
interaction can be disrupted by Aβ pathology, having pathological consequences 
(Roselli et al. 2009; Ronesi et al. 2012; Haas et al. 2016). Therefore, a decrease 
in the levels of mGluR5 could be associated with a decrease in Homer 1b/c levels. 
Western blot analysis with Homer 1b/c antibody showed that Homer 1b/c protein 
levels were significantly decreased in AD brains compared to controls (C: 0.72 ± 
0.07, AD: 0.37 ± 0.05, p-value = 0.001, Figure 4-4A). Since this decrease was 
detected in the same AD samples that showed a reduction in mGluR5 protein 
levels, this suggests that reduced Homer 1b/c levels may be related to the reduced 
expression of mGluR5. 
Finally, changes in protein expression levels may be explained by an overall loss 
of neurons and/or synapses, which can be estimated by measuring levels of 
synaptic markers. To measure postsynaptic changes, an antibody against 
postsynaptic density 95 (PSD95) was used. PSD95 is an integral scaffold protein 
located in the postsynaptic region of synapses that is classically used as a 
postsynaptic marker (Dorostkar et al. 2014; Kurbatskaya et al. 2016). Analysis of 
immunoblots incubated with PSD95 antibody revealed no significant differences in 
protein expression between AD and control groups (C: 1.50 ± 0.18, AD: 1.11 ± 
0.18, p-value = 0.121, Figure 4-4B). Since synapses are composed of pre- and 
postsynaptic elements and presynaptic inputs are necessary for clustering of 
glutamate receptors in the postsynaptic element (Rao et al. 2000), changes in 
presynaptic terminals were assessed. To do this, an antibody against 
synaptophysin (SYP) was used. Synaptophysin is a glycoprotein found in 
presynaptic vesicles whose expression serves as a measurement of presynaptic 
abundance (Jahn et al. 1985; Wiedenmann & Franke 1985; Navone et al. 1986). 
Analysis of synaptophysin protein expression in AD patient samples showed no 
differences in protein levels between control and AD samples (C: 1.67 ± 0.19, AD: 
1.33 ± 0.16, p-value = 0.192, Figure 4-4C). Altogether these results show that no 
loss of pre- and postsynaptic markers could be detected in temporal lobe samples 
from AD patient brains as measured by western blot analysis of total protein 
homogenates. 
 





Figure 4-4. Synaptic markers protein expression in post-mortem AD samples. (A) 
Homer 1b/c protein levels are significantly reduced in the Alzheimer’s disease (AD) group 
(N = 10) compared to the control (C) group (N = 10). (B) PSD95 (shift in band corresponding 
to sample AD10 is due to the gel being broken during the transfer step) and (C) SYP protein 
levels are not significantly different in the AD group (N = 10) compared to the C group (N = 
10). Circles represent the value for each subject and error bars represent the standard error 
of the mean (S.E.M.). Significance level (*p < 0.05) was determined by using an unpaired 
Student t-test. A.U.: Arbitrary units. Insets show representative immunoblots. For technical 
purposes, samples were loaded in numerical order to facilitate the work, but not due to 
scientific reasons. See Appendix for examples of full-length immunoblots for each 








4.2.2 Co-immunoprecipitation between mGluR5 and Homer 1 b/c 
Since a reduction in both mGluR5 and Homer 1b/c levels was observed, the study 
next aimed to determine whether their interaction was also affected in disease 
conditions. This would be relevant as Homer 1 b/c can influence mGluR5 location 
and function, as previously mentioned (Roche et al. 1999; Sergé et al. 2002; Mao 
et al. 2005). To do this, co-immunoprecipitation with protein samples from AD and 
control brain tissue was attempted. However, this presented a technical difficulty 
that could not be easily overcome. As shown in Chapter 3  (see section 3.2.4), 
extraction of mGluR5 protein could only be achieved by the use of sucrose/SDS 
buffer. This is a very stringent buffer and the presence of SDS causes denaturing 
of proteins and hence can disrupt protein-protein interactions. However, in co-
immunoprecipitation techniques, maintaining the interaction complex intact is a key 
requirement for successful detection of the interaction. For this reason, buffers 
containing non-denaturing components with low ionic strength are generally used 
in co-immunoprecipitation techniques (Thermo Scientific 2010). Therefore, the 
possibility of using sucrose/SDS buffer for protein extraction in the co-
immunoprecipitation protocol was discarded. A buffer that was less likely to disrupt 
protein-protein interactions was used instead and co-immunoprecipitation was 
performed using an antibody against Homer 1b/c as the IP antibody. This resulted 
in no extraction of mGluR5 protein in the input fractions, although Homer 1 b/c 
could be detected in western blot (Figure 4-5). Due to the limitation imposed by 
the necessity of using a denaturing buffer to obtain mGluR5 bands by western blot, 
co-immunoprecipitation of mGluR5 and Homer 1b/c was not pursued further.  
 





Figure 4-5. Co-immunoprecipitation of Homer 1b/c and mGluR5 in post-mortem AD 
samples. (A) Membrane incubated with anti-mGluR5 (B) Membrane incubated with anti-
Homer 1b/c. Input sample refers to the lysate resulting after tissue homogenisation that is 
pre-cleared by incubation with protein-G agarose beads. Immunoprecipitation (IP) sample 
refers to the fraction taken from the input tube that is incubated with the pull-down antibody, 
in this case anti-Homer, or the control antibody, anti-IgG. Unbound fraction (U.B.) refers to 
the fraction of the IP sample that has not bound to the antibody. Pellet refers to the material 
accumulated at the bottom of the tube after tissue homogenisation. Western blot (WB) 
antibody indicates the antibody used for immunoblotting. For details of the procedure see 
Section 2.9. 
4.2.3 Gene expression of synaptic proteins in post-mortem human brain from AD 
patients 
Following the results of protein expression in human AD brains, the study aimed to 
investigate the causes of mGluR5 decrease. One plausible cause for this decrease 
is a reduction in mGluR5 transcripts, which may result in a decrease in protein 
 




translation (Bauernfeind & Babbitt 2017). To measure gene expression levels, 
quantitative polymerase chain reaction (qPCR) was used. This is a very sensitive 
technique for which the identification of valid endogenous controls for data 
normalisation is essential (Coulson et al. 2008). Therefore, the first step was to 
identify an appropriate endogenous control gene in the set of post-mortem human 
brain samples. This selection was made according to (Rydbirk et al. 2016) and 
resulted in three candidate endogenous genes: ACTB (β-actin), GUSB (β-
Glucuronidase) and ribosomal protein large 13 (RPL13). qPCR analysis of these 
transcripts confirmed that the most stably expressed gene across all samples was 
RPL13 (Figure 4-6). Therefore, this gene was selected as endogenous control for 
data normalisation in qPCR analysis. Next, levels of mGluR5 gene expression 
were analysed by qPCR. This showed that mGluR5 gene expression was 
significantly reduced in AD brain samples compared to control samples (C: 14.97 
± 9.85, AD: 0.005 ± 0.002, p-value = 0.010, Figure 4-7A). As a comparison to other 
postsynaptic proteins, levels of GluA2 and PSD95 gene expression were also 
measured. The levels PSD95 were also significantly decreased in AD brains (C: 
0.07 ± 0.05, AD: 0.0 ± 0.01, p-value = 0.011, Figure 4-7B). Levels of GluA2 
however were not significantly different between control and AD groups (C: 0.40 ± 
0.17, AD: 0.20 ± 0.11, p-value = 0.186, Figure 4-7C). This data suggests that a 
reduction in gene expression levels of mGluR5 could account for a reduction in 
protein levels in AD brain samples. In the case of PSD95 and GluA2, changes in 
protein expression did not correlate with changes in gene expression, suggesting 
that post-translational modifications may affect the expression of these proteins. 
 





Figure 4-6. Gene expression of candidate endogenous control genes in post-mortem 
AD samples and age-matched control samples. Raw Ct values for (A) ACTB (β-actin), 
(B) GUSB (β-glucuronidase) and (C) RPL13 (ribosomal protein large 13). 
 
 





Figure 4-7. Gene expression in human post-mortem AD samples. Gene expression 
levels of (A) GRM5b (mGluR5b) and (B) DLG4 (PSD95) are significantly reduced in AD (N 
= 10) group compared to C (N =11) but not (C) GRIA2 (GluA2). Circles represent the mean 
and error bars the standard error of the mean (S.E.M.). Significance level (*p < 0.05) was 
determined by using a Mann-Whitney rank sum test. A.U.: Arbitrary units. 
4.2.4 Synaptic protein expression in post-mortem human brain from P-AD 
patients 
Given the progressive nature of neuropathological changes in AD, alterations in 
protein expression observed in severe AD cases may not be the same at earlier 
stages of the disease. Therefore, the same western blot analysis was undertaken 
in a set of samples from patients diagnosed with possible/probable AD (Braak 
stages III-IV) and aged-matched controls (Braak stages 0-III). Clinically, these 
 




patients may or may not show manifestation of dementia as assessed by cognitive 
score systems but their neuritic plaque score suggests the diagnosis of AD, 
according to CERAD criteria (see Chapter 2, section 2.3). No differences in age 
(C: 85 ± 1.97, P-AD: 87.36 ± 2.00, p-value = 0.410, Figure 4-8A) or post-mortem 
delay (C: 47.36 ± 6.63, P-AD: 41.50 ± 7.63 p-value = 0.324, Figure 4-8B) were 
detected between control and P-AD groups, indicating that these were not likely to 
have an effect on further analysis. 
 
Figure 4-8. Age and post-mortem delay distribution of post-mortem P-AD samples. 
(A) No significant differences in age were found between the control (C) group (N = 11) 
and the probable/possible Alzheimer’s disease (P-AD) group (N = 11) (B) No significant 
differences in post-mortem delay were found between the C group (N = 11) and the P-AD 
group (N = 11). Circles represent the value for each subject and error bars represent the 
standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by using 
an unpaired Student t-test. (C) Table summarising characteristics of human P-AD samples. 
Same pattern of analysis to that performed with AD samples was applied to P-AD 
samples. Western blot analysis of GluA2 levels showed a significant reduction in 
protein amounts in P-AD brain samples compared to control samples (C: 0.96 ± 
0.07, P-AD: 0.65 ± 0.12, p-value = 0.042, Figure 4-9A). On the contrary, protein 
levels of NR1 we not significantly changed in the P-AD group compared to the 
control group (C: 0.82 ± 0.10, P-AD: 0.71 ± 0.13, p-value = 0.508, Figure 4-9B). 
This data suggests that NMDARs may be less affected than AMPARs at early 
stages of AD pathology. 
Levels of mGluRs were then assessed. Western blot analysis showed no 
significant changes in protein levels of mGluR1 (C: 0.78 ± 0.08, P-AD: 0.80 ± 0.08, 
 




p-value = 0.875, Figure 4-10A) and mGluR5 (C: 1.55 ± 0.39, P-AD: 0.88 ± 0.20, 
p-value = 0.139, Figure 4-10B) between the P-AD group and the control group. 
However, levels of the synaptic GPCR, mAChR1 were significantly reduced in the 
brains of P-AD patients compared to control subjects (C: 2.09 ± 0.25, P-AD: 0.82 
± 0.14, p-value = 0.001, Figure 4-10C). This data indicates that mAChR1 
decreases at early stages of AD but that this decrease is not detected at late 
stages. 
 
Figure 4-9. Ionotropic glutamate receptor protein expression in post-mortem P-AD 
samples. (A) GluA2 protein levels are significantly reduced in the probable/possible 
Alzheimer’s disease (P-AD) group (N = 11) compared to the control (C) group (N = 11). (B) 
NR1 protein levels are not significantly different in the P-AD group (N = 11) compared to 
the C group (N = 11). Circles represent the value for each subject and error bars represent 
the standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by 
using an unpaired Student t-test. A.U.: Arbitrary units. Insets show representative 
immunoblots. For technical purposes, samples were loaded in numerical order to facilitate 
the work, but not due to scientific reasons. See Appendix for examples of full-length 
immunoblots for each antibody and for immunoblots corresponding to the rest of the 
samples. 
As in the case of the previous analysis for the set of AD samples, loss of synaptic 
terminals was assessed to check whether it could account for changes in protein 
expression. Homer 1b/c protein levels did not differ significantly between P-AD and 
control brains (C: 0.79 ± 0.07, P-AD: 0.56 ± 0.12, p-value = 0.10, Figure 4-11A). 
 




This was also the case for protein levels of postsynaptic marker PSD95 (C: 1.04 ± 
0.13, P-AD: 0.90 ± 0.17, p-value = 0.529, Figure 4-11B) as well as for the 
presynaptic marker SYP (C: 1.34 ± 0.11, P-AD: 1.06 ± 0.18, p-value = 0.187, 
Figure 4-11C). These results suggest that in the samples analysed in these study, 
synaptic marker protein expression is not significantly altered at any stage of AD 
pathology. 
 
Figure 4-10. Synaptic GPCR protein expression in post-mortem P-AD samples. (A) 
mGluR1 protein levels are not significantly different in the probable/possible Alzheimer’s 
disease (P-AD) group (N = 11) compared to the control (C) group (N = 11). (B) mGluR5 
protein levels are not significantly different in the P-AD group (N = 11) compared to the C 
group (N = 11). (C) mAChR1 protein levels are significantly reduced in the P-AD group (N 
= 8) compared to the C group (N = 8). Circles represent the value for each subject and 
error bars represent the standard error of the mean (S.E.M.). Significance level (*p < 0.05) 
was determined by using an unpaired Student t-test. A.U.: Arbitrary units. Insets show 
representative immunoblots. For technical purposes, samples were loaded in numerical 
 




order to facilitate the work, but not due to scientific reasons. See Appendix for examples 
of full-length immunoblots for each antibody and for immunoblots corresponding to the rest 
of the samples. 
 
 
Figure 4-11. Synaptic markers protein expression in post-mortem P-AD samples. (A) 
Homer 1b/c, (B) PSD95 and (C) SYP protein levels are not significantly different in the 
probable/possible Alzheimer’s disease (P-AD) group (N = 11) compared to the control (C) 
group (N = 11). Circles represent the value for each subject and error bars represent the 
standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by using 
an unpaired Student t-test. A.U.: Arbitrary units. Insets show representative immunoblots. 
For technical purposes, samples were loaded in numerical order to facilitate the work, but 
not due to scientific reasons. See Appendix for examples of full-length immunoblots for 










In this study, the expression of a select group of synaptic proteins relevant to AD 
was analysed in post-mortem temporal lobe samples from patients diagnosed with 
definite AD and probable/possible AD (P-AD), according to CERAD principles (see 
Chapter 2, section 2.3). Considering data from Chapter 3 showing an mGluRs-
mediated inhibition of mAChRs function, it was of interest to assess whether the 
expression of these receptors was affected in AD, as it could have functional 
implications for pathological mechanisms. In addition, other synaptic proteins 
analysed included ionotropic glutamate receptors, to evaluate how the 
glutamatergic system is affected in AD, and synaptic markers, as they are good 
indicators of the state of synapses. 
First, the levels of ionotropic glutamate receptors were analysed. A significant 
reduction in GluA2 and NR1 proteins in AD brains (Figure 4-2) suggested that 
GluA2-containing AMPARs and NR1-containing NMDARs are affected at late 
stages of AD pathology. In the case of GluA2, this decrease seemed to start at 
earlier stages of the pathology as protein levels were also reduced in samples from 
P-AD patients (Figure 4-9A).  
Presumably, protein extraction performed in this study reflects total protein levels, 
including protein expressed intracellularly and at the plasma membrane. 
Therefore, the reduction in GluA2 levels observed here corresponds to overall 
protein levels. Interestingly, it has been shown that a reduction in AMPARs 
expressed at postsynaptic membranes is driven by Aβ (Hsieh et al. 2006; Shankar 
et al. 2007) and tau (Hoover et al. 2010) in in vitro models of AD. Since both 
pathologies are present in the AD brains studied here, it is reasonable to think that 
the reduction observed in this study may reflect a reduction in GluA2-containing 
AMPARs expressed at the plasma membrane. This could occur by increased 
receptor internalization or disruption of receptor trafficking to the membrane (Gu et 
al. 2009; Jurado et al. 2018). However, because protein internalised to endocytic 
vesicles would also be included in the analysis here, the reduction in overall GluA2 
levels may reflect a reduction in its synthesis or an increased degradation of the 
receptor. The former seems not to be the case, at least at late stages of AD, as 
GluA2 mRNA levels were not significantly changed in AD samples compared to 
controls (Figure 4-7C). Degradation of AMPARs is governed by numerous factors 
that may be relevant to this study. For instance, GluA2-containing AMPARs are 
 




degraded in the proteasome as a result of reduced activity of sodium-potassium 
ATPase (Zhang et al. 2009). A reduction in activation of sodium-potassium ATPase 
activity and expression has been previously shown to occur in AD brains (Chauhan 
et al. 1997; Hattori et al. 1998) and could be driven by Aβ present in these brains 
(Petrushanko et al. 2016; Ohnishi et al. 2015). In addition, proteasomal 
degradation of GluA2-containing AMPARs requires NMDAR activity (Hou et al. 
2011) and it is specifically regulated by activity-dependent sorting mechanisms 
(Lussier et al. 2011; Lee et al. 2004). Supporting that NMDAR activity is a strong 
regulator of AMPARs degradation, it has been shown that NMDARs activation 
selectively diverts GluA2 from the recycling pathway toward degradation via 
lysosomal pathway (Lee et al. 2004). Since an increase in NMDARs activity 
(Texidó et al. 2011; Alberdi et al. 2010; Molnár et al. 2004) and a decrease in 
sodium-potassium ATPase activity (Wei et al. 2016; Hattori et al. 1998) have been 
shown to occur in AD-related pathology, it is plausible that the combination of both 
mechanisms operating in the brain samples studied here contributes to the 
reduced levels of GluA2 observed via enhanced degradation. In addition, other 
studies showed that loss of GluA2 subunits was not due to neuronal loss in the 
entorhinal cortex of AD patients by immunohistochemical and western blot 
techniques (Armstrong et al. 1994; Yasuda et al. 1995). It has also been suggested 
that loss of GluA2 subunits may be an early sign of AD pathology as it was shown 
to occur prior to neuronal loss (Armstrong et al. 1994) and NFT formation 
(Ikonomovic et al. 1997). This is supported by a study showing loss of GluA2 
immunoreactivity in brains from AD patients at Braak stages III-IV (Ikonomovic et 
al. 1997) as well as by results presented here showing a reduction in GluA2 levels 
occurring at early stages of the pathology (in P-AD brain samples) (Figure 4-9A).  
The presence of GluA2 subunits in the AMPAR complex substantially reduces 
calcium permeability of the receptor (Hollmann et al. 1991). Given the role of 
calcium excitotoxicity in the pathological mechanisms of AD (LaFerla 2002), it has 
been proposed that GluA2-lacking calcium permeable AMPARs (CP-AMPARs) 
may play key roles in some of these mechanisms (Whitehead et al. 2017). Indeed, 
increased expression of CP-AMPARs has been reported in AD transgenic mice 
(Megill et al. 2015). A role of CP-AMPAR in AD is further supported by the finding 
that intracellular administration of Aβ oligomers in CA1 hippocampal neurons 
results in the insertion of CP-AMPARs in the plasma membrane (Whitcomb et al. 
2015). Importantly, intracellular accumulation of Aβ has been reported in AD brains 
 




(Wegiel et al. 2007; Aoki et al. 2008; Nagele et al. 2002; D’Andrea et al. 2002) and 
this seems to be an early event of the pathology as it precedes formation of Aβ 
plaques and NFTs (D’Andrea et al. 2001; Gouras et al. 2000). Therefore, the 
reduction in GluA2 levels reported in the present study is consistent with a 
mechanism involving a pathological increase in CP-AMPARs starting at early 
stages of disease progression.  
While the reduction in GluA2-containing AMPARs started markedly at early stages 
of AD, this was not the case for the other group of ionotropic glutamate receptor 
analysed, as NR1-containing NMDARs were only reduced at late stages (Figure 
4-2B and Figure 4-9B). This result is in agreement with findings of others (Sze et 
al. 2001; Ikonomovic et al. 1999; Hynd et al. 2004b), and suggests that at early 
stages of AD, NMDAR protein expression is somehow maintained at similar levels 
than in control brains. It has been proposed that this may occur by virtue of 
compensatory mechanisms, including dendritic sprouting (Masliah et al. 1991). 
This involves the growth of dendritic spines into denervated areas, a process 
shown to occur in presenile dementia (Scheibel & Tomiyasu 1978). Therefore, 
NMDARs levels may be maintained at early stages of AD pathology by action of 
dendritic sprouting mechanisms that eventually cannot counterbalance the loss of 
NMDARs at late stages.  
Another proposed mechanism of maintaining NMDAR levels in P-AD brains is the 
upregulation of these receptors by specific phosphorylation at this stage of the 
pathology (Raymond et al. 1994; Sze et al. 2001; Farber et al. 1998; Olney et al. 
1997). This is in line with the well-established feature of AD pathology consisting 
of increased NMDAR function (Vosler et al. 2008; Alberdi et al. 2010; Kelly & 
Ferreira 2006; Harkany et al. 2000). Accordingly, data presented here could be 
explained by an initial upregulation of NMDAR function at early stages of 
pathology. Then, cumulative overactivation of NMDARs by glutamate built up 
during the progression of AD could eventually lead to Aβ-induced endocytosis of 
NMDARs (Snyder et al. 2005) and reduction of overall levels at late stages. In 
addition, because NR1-expressing cells may be selectively vulnerable to toxicity 
associated with AD (Hynd et al. 2004b), the effect of this vulnerability could become 
more evident as neurodegeneration progresses and neurons die. This could 
eventually lead to a significant overall loss of NR1-containing cells at late stages, 
when neurons can no longer face neurotoxicity. The possibility that reduced 
 




translation of NR1 mRNA underlies the reduction in protein levels cannot be 
discarded. However, the correlation between changes in NR1 mRNA and protein 
levels in AD brains seems to be variable depending on the brain areas (Panegyres 
et al. 2002). Nonetheless, the findings presented here are relevant to the clinical 
impact of AD pathology since the severity of alterations in NR1 subunits seemed 
to strongly correlate with the magnitude of cognitive impairments associated with 
AD (Sze et al. 2001). This is not surprising given that the molecular mechanism 
thought to underlie memory processes relies to a great extent on the function of 
NMDARs (Martin et al. 2000; Lissin et al. 1998; Lu et al. 2001; Shi et al. 1999; 
Malenka 2003), for which the presence of NR1 subunits is required (Wang et al. 
2009).  
In addition to ionotropic glutamate receptors, the glutamatergic system includes 
mGluRs, which are also mediators of AD-related neuropathological mechanisms 
(Revett et al. 2013). Radioligand binding studies have shown a general reduction 
in the levels of mGluRs in the hippocampus and cortex of AD patients (Dewar et 
al. 1991; Albasanz et al. 2005). This is in agreement with results presented here 
showing a specific reduction of mGluR5 but not mGluR1 levels in the brains of AD 
patients (Figure 4-3 and Figure 4-10).  
The reduction in mGluR5 protein levels is entirely consistent with the finding that 
mGluR5 gene expression is downregulated in brains of AD patients (Figure 4-7A). 
Therefore, it seems plausible that a reduction in mGluR5 transcription contributes, 
at least in part, to the observed reduction in protein levels. Additionally, it is well-
described that chronic glutamate exposure can lead to down-regulation and 
desensitization of mGluRs (Albasanz et al. 2005; Doherty et al. 1999; Catania et 
al. 1991). Since glutamate clearance mechanisms may be impaired in AD brains 
(Jacob et al. 2007; Scott et al. 2011; Masliah et al. 1996; Li et al. 1997), it is possible 
that the levels of glutamate in these brains are very high. This could lead to an 
excessive activation of mGluR5, a process that has been reported to play a role in 
AD-related pathologies (Hsieh et al. 2006; Hamilton et al. 2016; Hamilton et al. 
2014; Shankar et al. 2008; Wang 2004; Um et al. 2013; Bruno et al. 2000). This in 
turn could result in its desensitisation and reduced levels at the plasma membrane 
(Dhami & Ferguson 2006; Albasanz et al. 2005). Furthermore, internalisation could 
lead to increased receptor degradation. Proteasomal degradation of mGluR5 is 
induced by Siah1A (Moriyoshi et al. 2004) and a complex including Siah1A has 
 




been shown to alter its location in brains from AD patients (Wasik et al. 2013). 
Therefore, it is possible that the rate of mGluR5 degradation is increased in AD 
brains as a result of dysregulation of degradation mechanisms. 
Considering results from Chapter 3 showing an inhibition of mAChR function by 
agonism of group I mGluRs, the reduction in mGluR5 levels could influence other 
synaptic proteins, including mAChR and its expression in pathology. It has been 
reported that a decrease in cholinergic projections and activity of cholinergic 
enzymes occurs in individuals with AD (Davies & Maloney 1976; Bowen et al. 1982; 
Quirion et al. 1986; Davis et al. 1999). Moreover, reduction in the coupling between 
mAChR1 receptors and G-proteins seems to happen in AD brains (Shiozaki & Iseki 
2004; Smith et al. 1987; Flynn et al. 1991; Warpman et al. 1993; Ferrari-DiLeo et 
al. 1995). However, whether these effects are due to a reduction in mAChR1 levels 
is not clear yet. In the present study, a prominent reduction of mAChR1 levels was 
detected at earlier stages of the pathology but no significant changes were found 
at late stages (Figure 4-3C and Figure 4-10C). These results are in agreement 
with evidence showing unchanged muscarinic binding in AD brains (Araujo et al. 
1988; Svensson et al. 1992) and indicate that mAChR1 receptors are firstly 
affected by pathological mechanisms occurring in AD. Since this reduction seems 
to occur relatively early in the progression of the disease, it is possible that neurons 
are still healthy enough to activate compensatory mechanisms to counterbalance 
this loss at late stages. Given the severity of the loss of cholinergic afferents and 
enzymes in AD (Perry et al. 1977; Spillane et al. 1977; White et al. 1977), it has 
been proposed that neurons may respond by upregulating mAChRs levels 
(Nordberg et al. 1983). Indeed, upregulation of receptor expression as a response 
to afferent depletion has been reported (Levey 1995), indicating that is a plausible 
response in AD. This is supported by a prominent increase in mRNA levels of 
mAChR1 in the brains of AD patients, which may indicate that levels of protein also 
increase during disease (Harrison et al. 1991). In addition, compensatory 
increases in the levels of choline acetyltransferase (ChAT), the enzyme that 
synthesises ACh, have been reported in the brains of patients with MCI (DeKosky 
et al. 2002). Furthermore, it has been shown that destruction of the performant 
path in animal models results in sprouting of cholinergic afferents (Lynch et al. 
1972; Storm-Mathisen 1974; Cotman et al. 1973; Savaskan & Nitsch 2001). This 
is consistent with reinnervation of acetyl cholinesterase (AChE) terminals in the 
hippocampus of AD brains in response to disease triggered cellular damage in the 
 




entorhinal cortex (Hyman et al. 1987). Therefore, data presented here supports 
that after an initial loss of mAChR proteins, the cholinergic system may be capable 
of compensatory responses to counterbalance the consequences of 
neurodegeneration, which presumably manifest at later stages of the pathology. 
Finally, an obvious reason for the decrease in receptor levels observed here is an 
overall decrease in synaptic terminals. To estimate the extent of loss of synaptic 
terminals in the samples analysed here, changes in synaptic markers were 
assessed. Western blot analysis of brain samples with an antibody against the 
postsynaptic marker PSD95 revealed no significant changes at any stage of AD 
progression (Figure 4-4B and Figure 4-11B). This agrees with results from a study 
that showed no differences in PSD95 levels by western blot analysis of association 
neocortex samples from AD subjects (Gylys et al. 2004). Regarding presynaptic 
terminals, no significant changes were detected in the levels of presynaptic marker 
synaptophysin in the AD or P-AD groups compared to controls (Figure 4-4C and 
Figure 4-11C), in agreement with other studies (Tannenberg et al. 2006; Harigaya 
et al. 1996; Hatanpää et al. 1999). Taken together these results indicate there is 
no significant loss of synaptic terminals in the samples analysed in this study. This 
may seem surprising considering that loss of synaptic connections has been widely 
correlated with early cognitive deficits in AD (Terry et al. 1991; DeKosky & Scheff 
1990; Sze et al. 1997). However, this has not been consistently linked to a 
decrease in synaptic markers. For example, a significant increase in PSD95 in AD 
frontal cortex was reported (Leuba et al. 2008) which was also observed at the 
level of the postsynaptic density fraction (Gong et al. 2009). In the case of 
synaptophysin, levels were shown to be both reduced in the frontal cortex of early-
AD brains (Masliah et al. 2001) and increased in frontal and temporal cortices  
(Mukaetova-Ladinska et al. 2000). In relation to this, a detailed analysis of post-
mortem studies has shown that the degree to which changes in synaptic markers 
affect different brain areas is variable (De Wilde et al. 2016), which may explain 
the heterogeneity in the results. These findings support the concept that synapse 
loss and loss of synaptic markers may not be equivalent in AD. In line with this, 
results presented here support that numbers of pre- and postsynaptic terminals are 
unchanged over the course of AD but synapses may still be affected. Indeed, it 
cannot be excluded that actual synaptic connections are lost although pre- and 
postsynaptic terminals are present. However, these results suggest that rather 
 




than a structural loss of synaptic connections, weakening of synaptic function may 
arise from loss of synaptic receptors in AD. 
In summary, results from this chapter have shown that the expression of selected 
synaptic receptors is affected during AD progression. From a therapeutic 
perspective, it is very useful to know whether pathological changes observed in 
severe cases of AD occur at early stages of the pathology. This is because it is 
widely believed that treatments should be administered at early stages of 
pathology to be most effective. In this regard, this study has provided new insights 
into identifying receptors that are firstly affected in AD. In addition, since data from 
Chapter 3 showed a functional interaction between mGluRs and mAChRs and 
these synaptic GPCRs are selectively affected in AD brains, the study next aimed 
to assess the functional consequences of AD pathology on these receptors. 
Therefore, Chapter 5 is focused on the effects of human hyperphosphorylated tau, 






















5.2.1 CCh-induced holding current change is increased in P-hTau transfected 
neurons 
5.2.2 CCh-induced holding current change is not altered in WT-hTau transfected 
neurons 
5.2.3 CCh-induced holding current change is not altered in AT8E-hTau transfected 
neurons 
5.2.4 DHPG-induced holding current change is not altered in P-hTau transfected 
neurons 



















Since the identification of tau as a central component of neurofibrillary tangles 
(NFTs) in AD brains (Kosik et al. 1989; Grundke-Iqbal, Iqbal, Quinlan, et al. 1986) 
and the importance of these structures in defining the neuropathology of the 
disease (Braak & Braak 1991), tau pathology has been in the spotlight of AD 
research for many years. Importantly, the so called “tauopathy” correlates strongly 
with the extent of cognitive decline (Nelson et al. 2012) and it is common to several 
neurodegenerative disorders, including frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17) and Pick’s disease (PiD), 
among others (Williams 2006). This indicates that tauopathy is a critical feature of 
neurogenerative processes.  
Tau was first characterised as a microtubule binding protein with a clear function 
in promoting and stabilising microtubule assembly (Drechsel et al. 1992; 
Weingarten et al. 1975). This function is intrinsically linked to the role of tau in 
axonal transport (Dixit et al. 2008) and elongation through the establishment of 
neuronal polarity (Caceres & Kosik 1990; Esmaeli-Azad et al. 1994). The gene that 
codes for tau, MAPT, contains 16 exons that are transcribed into a pre-mRNA 
(Andreadis et al. 1992). This pre-mRNA undergoes alternative splicing to generate 
six tau protein isoforms, all of them expressed in the human central nervous system 
(CNS) and raging from 352 to 441 amino acids  (Drubin et al. 1984; Himmler 1989; 
Himmler et al. 1989; Kosik et al. 1989; Andreadis et al. 1992). Tau proteins contain 
a microtubule-binding domain that includes a proline-rich region, a C-terminal 
flanking region and at least three amino acid repeat regions, although some tau 
isoforms contain four repeats (Lee et al. 1989; Lee et al. 1988; Goedert, Spillantini, 
Potier, et al. 1989). In the N-terminus there is a projection domain that contains 
amino acid sequences coded by exon 2 or by exons 2 and 3. Therefore, depending 
on the number of N-terminal inserts and C-terminal repeats, six possible 
combinations give name to the six tau isoforms existing in the human brain: 0N3R, 
0N4R, 1N3R, 1N4R, 2N3R and 2N4R (full-length) tau (Goode et al. 2000). These 
isoforms differ in their expression across the CNS which may be linked to 
differential susceptibility of brain regions to tau pathology in AD (Boutajangout et 
al. 2004). 
The function of tau is highly regulated by its phosphorylation state which influences 
its ability to bind microtubules (Biernat et al. 1993; Lindwall & Cole 1984) and other 
 




interacting partners and to self-aggregate (A. del C. Alonso et al. 2001). Thus, 
hyperphosphorylated tau disassembles from microtubules and aggregates in 
paired helical filaments (PHFs), one of the main pathological hallmarks in AD 
brains (Grundke-Iqbal, Iqbal, Tung, et al. 1986; Iqbal et al. 1986; Grundke-Iqbal, 
Iqbal, Quinlan, et al. 1986; Goedert et al. 1992). One obvious consequence of this 
is the destabilisation of microtubules (Alonso et al. 1994; Li et al. 2007; Alonso et 
al. 1996) and the resulting impaired axonal transport and loss of dendritic spines 
(Thies & Mandelkow 2007). Additionally, abnormal phosphorylation of tau confers 
the protein resistance to proteolytic cleavage by proteases (Wang et al. 1995; 
Wang et al. 1996) which results in a slower turnover of pathological tau compared 
to that of normal tau (Poppek 2006). This is supported by evidence showing that 
the levels of tau in AD brain are increased compared to controls (Khatoon et al. 
1992). Part of tau expressed in AD brains is located to neurofibrillary tangles 
(NFTs), a pathological feature of these brains (Crowther et al. 1992; Crowther et 
al. 1994; Crowther et al. 1989; Goedert 1993) that correlates with severity of 
cognitive impairments (Arriagada et al. 1992; Braak & Braak 1991). Tau within 
extracellular NFTs specifically binds to antibodies directed to phosphorylated 
epitopes (serine o threonine residues), including AT8 (S199/S202/T205), AT100 
(T212/S214), and PHF-1 (S396/S404), which corroborates that tau has a 
phosphorylation signature that characterises AD pathology (Augustinack et al. 
2002; Duka et al. 2013). 
The role of P-tau on synaptic damage goes beyond the disruption of microtubule 
stability (Jadhav et al. 2015). For instance, it can affect the function of postsynaptic 
receptors and therefore synaptic transmission. In relation to this, it was shown that 
P-tau localises to dendritic spines where it impairs the function of NMDARs and 
AMPARs located at the postsynaptic membrane by reducing their trafficking or 
anchoring to the PSD (Hoover et al. 2010). Another study showed that tau is 
required for the trafficking of Fyn kinase to the postsynaptic compartment (Ittner et 
al. 2010). This is relevant to pathology because Fyn forms a complex with PSD95 
and phosphorylates the NR2B subunit of NMDARs (Ittner et al. 2010). This 
increases NMDARs stability at the PSD and it has been proposed as a mechanism 
that increases NMDAR-triggered excitotoxicity (Ittner et al. 2010; Mondragón-
Rodríguez et al. 2012). Calcium influx through NMDARs can in turn activate tau 
kinases such GSK3β (Lesort et al. 1999) and Cdk5 (Hernandez et al. 2009) that 
further increase tau phosphorylation (Revett et al. 2013). In addition to NMDARs, 
 




tau can exert pathological effects on AMPARs function. Illustrating this, there is 
evidence that pathological forms of tau can reduce AMPARs surface expression in 
cultured neurons (Hoover et al. 2010; Yu et al. 2012) and in animal models of 
tauopathy (Kopeikina et al. 2013). These effects on ionotropic glutamate receptors 
function may be related to the disruption of synaptic plasticity mediated by aberrant 
tau (Polydoro et al. 2009; Fá et al. 2016).  This has been supported by studies 
showing a preferential accumulation of phosphorylated tau in the dendritic 
compartment where plasticity occurs (Hoover et al. 2010; Zempel et al. 2010). 
Altogether, this evidence supports a critical role of pathological tau in the regulation 
of synaptic structure and function with implications for AD.  
One essential characteristic for the neuropathological diagnosis of AD is the 
presence of P-tau-containing NFTs in the autopsied brains. Consequently, the 
progression of AD is measured according to the anatomical distribution of NFTs 
on post-mortem brain, following the Braak staging procedure (Braak & Braak 
1991). In the present study, patient cases were sorted according to Braak staging 
and divided into two groups: P-AD (Braak stages III-IV) and AD (Braak stages V-
VI). As shown in Chapter 4, changes in the protein expression of GPCRs were 
observed in these brains. Therefore, it was of interest to test something unknown 
to date: whether P-human tau (P-hTau), a hallmark of AD brains and a critical 
marker of neuropathological progression, could affect the function of these 
receptors. The hypothesis being that P-hTau can disrupt the function of synaptic 
GPCRs as it does with other synaptic receptors (i.e. AMPARs and NMDARs) 
(Hoover et al. 2010). In particular, a reduction in the levels of mAChRs was 
observed in P-AD brains, suggesting that these receptors are susceptible at earlier 
stages of pathology. Therefore, it seems reasonable to think that an early effect of 
P-hTau expression in the neuron may be the disruption of mAChRs function. In 
relation to this, the effects of early P-hTau expression have been characterised to 
some extent in animal models. These studies are based on the principle that P-
hTau can be functionally relevant when it is not part of NFTs. Supporting this, 
inhibition of P-hTau delayed motor dysfunction but did not change NFT numbers 
in tau transgenic mice (Le Corre et al. 2006). In addition, accumulation of P-hTau 
appears to be an early event occurring before NFTs formation in a transgenic 
mouse model of tauopathy (Berger et al. 2007). Importantly, this early 
accumulation of P-hTau may specifically happen in postsynaptic sites, suggesting 
that P-hTau may alter synaptic function. Indeed, P-hTau sorting to dendritic spines 
 




is thought to be an early pathological feature of tauopathies (Gendron & Petrucelli 
2009) and one early event associated with P-hTau localisation to dendrites is the 
disruption of synaptic function, particularly the reduction of miniature EPSCs 
(mEPSCs) (Hoover et al. 2010). This study also demonstrated that dendritic P-
hTau was associated with decreased expression of AMPARs and NMDARs, 
suggesting that these molecular changes may underlie tau-mediated synaptic 
dysfunction at early stages of tau accumulation (Hoover et al. 2010).  
In summary, there is evidence that P-Tau can affect the function of AMPARs and 
NMDARs in AD models but the effects on other receptors important for synaptic 
function, such as GPCRs, remain unknown. Therefore, experiments presented in 
this chapter aim to fill this gap in our current knowledge and assess whether P-
hTau affects the function of synaptic GPCRs whose expression is affected in AD 
pathology. According to the above evidence and previous data from this thesis 
showing a reduced expression of mAChR1 observed at early stages of AD, it was 
hypothesised that expression of P-hTau reduces mAChR-mediated change in 
holding current elicited by CCh in cultured hippocampal neurons. In addition, since 
it was shown that mGluR5 levels are reduced at late stages of AD pathology but 
not at early stages, it was hypothesised that P-hTau expression does not reduce 
mGluR-mediated change in holding current elicited by DHPG in cultured 
hippocampal neurons. This study will help to understand the vulnerability of 
synaptic GPCRs to tau pathology and will provide valuable information regarding 














5.2.1 CCh-induced holding current change is increased in P-hTau transfected 
neurons 
To assesses the effects of phosphomimetic human tau (P-hTau) on mAChRs 
function, cultured hippocampal slices were transfected with P-hTau and rat tau 
shRNA (rTau-shRNA). This rTau-shRNA has been previously shown to 
successfully knock-down endogenous tau expressed in cultured hippocampal 
slices (Kimura et al. 2013; Regan et al. 2015). Analogously to field recording 
experiments (see Chapter 3), CCh was used to pharmacologically activate 
mAChRs. CCh produces a characteristic change in holding current during whole-
cell recordings that can be used as a readout of mAChRs function (Fiszman et al. 
1991; Haj-Dahmane & Andrade 1996; Hsu et al. 1996). This was corroborated in 
the present study as perfusion of CCh (50 µM, 5 minutes) resulted in a change in 
holding current with a peak of approximately 45 picoamperes (Untransfected: -
44.86 ± 8.95, Figure 5-1). This change was significantly increased in P-hTau 
transfected neurons (P-hTau: -84.00 ± 11.11, p-value = 0.013, Figure 5-1). This 
data indicates that mAChRs activation in P-hTau transfected cells triggers a bigger 
holding current change, suggesting a tau-induced facilitation of mAChRs function. 
 





Figure 5-1. CCh-induced holding current change is increased in P-hTau transfected 
neurons. (A) Holding current change in untransfected (N = 11) and P-hTau transfected 
neurons (N = 11). (B) P-hTau transfected neurons have significantly higher peak in holding 
current change than untransfected neurons. Circles represent the mean and error bars the 
standard error of the mean (S.E.M.). Significance level (*p < 0.05) was determined by using 
an unpaired Student t-test. 
5.2.2 CCh-induced holding current change is not altered in WT-hTau transfected 
neurons 
The enhancement of CCh-induced holding current change could be due to the 
effect of tau but not specifically due to its phosphorylation state. To test this 
possibility, cultured hippocampal slices were transfected with wild-type human tau 
(WT-hTau) in addition to rTau-shRNA. WT-hTau construct encodes for full-length 
(2N4R) human tau but does not mimic phosphorylation. Perfusion of CCh resulted 
in a change in holding current in untransfected neurons that was not significantly 
altered in WT-hTau transfected neurons (untransfected: -63.90 ± 8.13, WT-hTau: 
63.10 ± 6.76, p-value = 0.944, Figure 5-2). These data suggest that the 
enhancement of CCh-induced holding current change in P-hTau neurons is 
specifically due to the phosphorylation state of tau and not solely due to the 
presence of human tau. 
 





Figure 5-2. CCh-induced holding current change is not altered in WT-hTau 
transfected neurons. (A) Holding current change in untransfected (N = 14) and WT-hTau 
transfected neurons (N = 10). (B) No significant differences in peak holding current change 
between WT-hTau transfected neurons and untransfected neurons. Circles represent the 
mean and error bars the standard error of the mean (S.E.M.). Significance level (*p < 0.05) 
was determined by using an unpaired Student t-test. 
5.2.3 CCh-induced holding current change is not altered in AT8E-hTau 
transfected neurons 
Previous results showed that the CCh-induced holding current change was 
increased in P-hTau transfected neurons and that this effect was not due to the 
presence of tau itself but very likely due to its phosphorylation state. In the P-hTau 
construct, serine residues are mutated to glutamate so they mimic constitutive 
phosphorylation at three epitopes: AT8 (S199/S202/T205), AT100 (T212/S214), 
and PHF-1 (S396/S404). The term “epitope” is used for these sites as they are 
recognised by the antibodies AT8, AT100 and PHF1, respectively. Therefore, it 
was unknown whether the increase in CCh-induced holding current change 
involved phosphorylation at all epitopes or if there was a specific epitope 
responsible for this effect. To further clarify this, cultured hippocampal slices were 
transfected with AT8E-hTau construct in addition to rTau-shRNA. In these slices, 
CCh induced a holding current change in untrasfected neurons that was not altered 
in AT8E-hTau transfected neurons (Untransfected: -69.67 ± 5.50, AT8E-hTau: -
 




61.50 ± 11.67, p-value = 0.163, Figure 5-3). Therefore, this data suggests that the 
increase in CCh-induced holding current change observed in P-hTau transfected 
neurons is not due to phosphorylation of the AT8 epitope of human tau. 
 
Figure 5-3. CCh-induced holding current change is not altered in AT8E-hTau 
transfected neurons. (A) Holding current change in untransfected (N = 8) and AT8E-hTau 
transfected neurons (N = 9). (B) No significant differences in peak holding current change 
between AT8E-hTau transfected neurons and untransfected neurons. Circles represent the 
mean and error bars the standard error of the mean (S.E.M.). Significance level (*p < 0.05) 
was determined by using Mann-Whitney rank sum test. 
5.2.4 DHPG-induced holding current change is not altered in P-hTau transfected 
neurons 
The aim of this study was to understand the effects of hyperphosphorylated tau on 
synaptic GPCR function. Since P-tau clearly affected mAChRs function, it was next 
aimed to test whether it could also affect the function of mGluRs, as they are 
synaptic GPCRs coupled to the same signalling pathway as mAChRs. Therefore, 
it was hypothesised that the effect of P-tau could be specific to a GPCR-mediated 
mechanism. To test this hypothesis, cultured hippocampal neurons were 
transfected with P-hTau and rTau-shRNA and perfused with the group I mGluRs 
agonist DHPG (20 µM, 5 min). These experiments showed that DHPG triggers a 
holding current change of similar magnitude to that elicited by CCh in untransfected 
 




cells and that this effect was not altered in P-hTau transfected cells (Untransfected: 
-45.32 ± 7.11, P-hTau: -46.65 ± 5.20. p-value = 0.884, Figure 5-4). These results 
indicate that P-hTau does not affect group I mGluRs function as assessed by 
alteration of DHPG-induced holding current change. 
 
Figure 5-4. DHPG-induced holding current change is not altered in P-hTau 
transfected neurons. (A) Holding current change in untransfected (N = 6) and P-hTau 
transfected neurons (N = 6). (B) No significant differences in peak holding current change 
between P-hTau transfected neurons and untransfected neurons. Circles represent the 
mean and error bars the standard error of the mean (S.E.M.). Significance level (*p < 0.05) 
was determined by using an unpaired Student t-test. 
5.2.5 DHPG-induced holding current change is not altered in WT-hTau 
transfected neurons 
Although no effect was observed in DHPG-induced holding current change in P-
hTau transfected neurons, it remained possible that tau itself could have an effect 
on the function of group I mGluRs. In support of this, full-length hTau is able to 
regulate GPCRs function  (Gómez-Ramos et al. 2006; Gómez-Ramos et al. 2008; 
Gómez-Ramos et al. 2009). To test this possibility, cultured hippocampal slices 
were transfected with WT-hTau and rTau-shRNA and perfused with DHPG as in 
the previous experiment. This showed that DHPG-holding current change was not 
significantly different between untransfected neurons and WT-hTau transfected 
 




neurons (Untransfected: -39.11 ± 5.20, WT-hTau: -48.37 ± 4.23, p-value = 0.125, 
Figure 5-5). In combination with the previous result, this data suggests that hTau, 
either constitutively phosphorylated or in its wild-type form, does not affect the 
function of group I mGluRs in the experimental conditions tested here.  
 
Figure 5-5. DHPG-induced holding current change is not altered in WT-hTau 
transfected neurons. (A) Holding current change in untransfected (N = 6) and WT-hTau 
transfected neurons (N = 7). (B) No significant differences in peak holding current change 
between WT-hTau transfected neurons and untransfected neurons. Circles represent the 
mean and error bars the standard error of the mean (S.E.M.). Significance level (*p < 0.05) 











A wide body of evidence supports the role of tau pathology as a potential cause of 
neurodegenerative diseases (Hutton et al. 1998; Nelson et al. 2012). However, the 
precise mechanisms by which it contributes to degeneration in these disorders are 
not fully understood. While NFTs are considered a neuropathological hallmark 
required for the post-mortem diagnosis of AD (Braak & Braak 1991), it is becoming 
clear that early synaptic dysfunction results from tau hyperphosphorylation 
(Ballatore et al. 2007). This aberrant post-translational modification of tau very 
likely results in synapse loss (Thies & Mandelkow 2007), defects in microtubule 
assembly and axonal transport (Alonso et al. 1994; Li et al. 2007; Alonso et al. 
1996), and enhancement of Aβ-mediated toxicity (Roberson et al. 2007; Ittner et 
al. 2010; Rapoport et al. 2002; Shipton et al. 2011). In addition, tau-mediated 
disruption of function of receptors pivotal for memory, such as ionotropic glutamate 
receptors (Ittner et al. 2010; Mondragón-Rodríguez et al. 2012; Yu et al. 2012; 
Kopeikina et al. 2013), may provide a molecular basis for the cognitive decline 
associated with the degree of tauopathy (Polydoro et al. 2009; Fá et al. 2016; 
Nelson et al. 2012). However, the effects of P-Tau on other synaptic receptors also 
important for memory, such as metabotropic receptors, are much less understood. 
As shown in Chapter 4, the molecular analysis of post-mortem brain samples 
revealed multiple alterations in the expression of synaptic receptors at different 
stages of AD progression. Such alterations may be driven by the presence of P-
Tau in these brains and may have a functional impact on these receptors. 
Therefore, it was hypothesised that P-Tau could disrupt the function of synaptic 
GPCRs. In the case of mAChRs, CCh was perfused to the slices to induce a 
change in holding current measured in whole-cell recordings that was used as a 
readout of mAChRs function. In P-hTau transfected neurons, the CCh-induced 
holding current change was significantly increased (Figure 5-1) whereas no 
change was observed in WT-hTau transfected neurons (Figure 5-2). These results 
indicate the potential of P-hTau as a modulator of mAChRs function.  
Interestingly, Tau-mediated modulation of cholinergic receptors has been 
previously reported (Simón et al. 2013). For example, intracellular accumulation of 
hTau can result in the calcium-dependent degradation of nicotinic receptors, 
causing a reduction in receptor expression (Yin et al. 2016). Another well-
documented example is that extracellular hTau can interact with mAChRs, 
 




particularly neuronal mAChR1 and mAChR3 receptors, to potentiate the 
intracellular calcium increase mediated by these receptors (Gómez-Ramos et al. 
2006; Gómez-Ramos et al. 2008). In this study, the authors identified the C-
terminal region comprising residues 391-407 of the full-length hTau as the one 
required for the interaction with mAChRs (Gómez-Ramos et al. 2008). Whether 
there is a direct interaction between P-hTau and mAChRs in the experimental 
model used here remains to be investigated. However, this may not to be the case 
as it was shown that tau phosphorylation prevents its interaction with mAChRs 
(Díaz-Hernández et al. 2010). Therefore, the mechanism that accounts for tau-
mediated regulation of mAChRs in the present study may not require a direct 
interaction. 
In the experimental conditions of the present study, the change in holding current 
observed by perfusion of CCh in cultured hippocampal slices is presumably due to 
an activation of mAChRs (Fiszman et al. 1991; Haj-Dahmane & Andrade 1996; 
Hsu et al. 1996). Receptor activation results in the depolarisation of the cell, an 
effect thought to be mediated by activation of voltage-dependent non-selective 
cation currents (Haj-Dahmane & Andrade 1996) in combination with inhibition of 
potassium currents (Hsu et al. 1996). As a consequence of membrane 
depolarisation, a higher current is applied to the cell in voltage clamp mode to keep 
it at the commanded voltage of -70 mV. If the presence of P-hTau results in a 
bigger holding current change, this could mean that P-hTau itself causes cell 
depolarisation, so the later activation of mAChRs by CCh occurs in an already 
depolarised state and the CCh-mediated effects on holding current add on to those 
of P-hTau. One potential way in which P-hTau may increase cell depolarisation is 
through indirect actions on NMDARs. As previously mentioned, it has been shown 
that hTau can induce the translocation of Fyn kinase to the dendritic compartment 
where it triggers Fyn-dependent phosphorylation of the NR2B subunit of NMDARs 
(Ittner et al. 2010). This facilitates the interaction of NMDARs with the PSD-95 
(Rong et al. 2001) and couples the receptor to excitotoxic mechanisms (Ittner et 
al. 2010). NMDAR-mediated excitotoxicity involves the increase of intracellular 
calcium and cell depolarisation (Dong et al. 2009) that leads to cell death through 
activation of calpain (Vosler et al. 2008) and mitochondrial apoptotic pathways 
(Alberdi et al. 2010). Importantly, dendritic accumulation of hTau occurs in a 
phosphorylation dependent manner (Hoover et al. 2010). Therefore, it is possible 
that in the present study, the presence of P-hTau leads to an increased 
 




depolarisation of neurons mediated by NMDARs, further increasing the CCh-
induced depolarisation mediated by mAChRs. 
To further investigate what phosphorylation sites are involved in the effect of P-
hTau on CCh-induced holding current change, a phosphomimetic mutant for the 
AT8 site was used. Notably, neuropathological classification of human brain 
samples studied in Chapter 4 was made according to AT8 immunostaining of the 
tissue, in accordance with the standardized Braak staging of NFTs distribution 
(Braak et al. 2006). In addition, phosphorylation at this epitope causes tau 
missorting to the dendritic region and subsequent neurotoxic effects (Zempel et al. 
2010), leading to the idea that this epitope may be relevant for tau pathological 
effects. If the same change in holding current was observed in AT8E-hTau 
transfected cells than in P-hTau transfected cells, this would indicate that this site 
is involved in the regulation of mAChRs. This experiment showed that CCh-
induced holding current change was not significantly different between 
untransfected and AT8E-transfected neurons (Figure 5-3). This data indicates that 
phosphorylation at the AT8 site is not required for the regulation of mAChRs 
function by P-hTau but does not discount the involvement of other sites. The 
hyperphosphorylated mutant form of tau used in this study (P-hTau) corresponds 
to the full-length hTau containing mutations in amino acid residues that mimic 
constitutive phosphorylation at three different sites: AT8, AT100 and PHF1. 
Therefore, the possibility that AT100 and/or PHF1 are involved in the CCh-
mediated change in holding current cannot be excluded. This would not be 
surprising since phosphorylation tightly regulates tau function and specific effects 
of the protein are mediated by phosphorylation at specific sites (Augustinack et al. 
2002).  
Although phosphorylation is considered the major post-translational modification 
of tau, other post-translational modifications play a role in its pathological effects 
(Martin et al. 2011). These include glycosylation, nitration, truncation, 
polyamination and ubiquitination, among others. Likely, interactions between 
several post-translational modifications take place to drive tauopathy. For example, 
glycosylation may induce conformational changes in tau structure that expose 
phosphorylation sites, partially explaining why glycosylation precedes 
hyperphosphorylation (Liu et al. 2002; Yuzwa et al. 2008). In the experimental 
model presented here, tau mutants already include the residues substitutions that 
 




mimic phosphorylation. Therefore, this limits the physiological relevance of these 
mutants as some post-translational modifications that would normally occur after 
the protein is transcribed may not happen due to steric hindrance by modified 
residues. In addition, the temporal sequence in which post-translational 
modifications occur may also have pathological implications. Illustrating this, 
sequential phosphorylation of tau at specific residues generates the AT100 epitope 
and this affects the microtubule-binding capacity of tau (Yoshida & Goedert 2006). 
According to this evidence, it cannot be excluded that other post-translational 
modifications occur in this experimental model and therefore contribute to the 
effect of P-hTau on mAChRs function.  
Results from this study support that P-hTau differentially regulates the function of 
mAChRs and mGluRs. Since experiments were carried out 3 days after biolistic 
transfection of tau mutants into cultured hippocampal slices, they are more likely 
to reflect early effects of P-hTau expression. This would mean that P-hTau alters 
the function of mAChRs in the first place but other receptors resist this insult. This 
is potentially consistent with data from Chapter 4 showing a reduced expression 
of mAChRs at earlier stages of AD pathology and mGluRs being reduced at late 
stages. This may mean that mGluRs are more resilient to the effects of tau 
pathology and consequently become affected when P-hTau has been present for 
longer periods of time in the brain.  
The differential regulation of mGluRs and mAChRs by P-hTau rises yet again the 
question of what the reasons for this difference may be, given that both GPCRs 
couple to the Gq/11 pathway. As discussed in Chapter 3, different functional effects 
of activation of GPCRs coupled to the same pathway may relay on differential 
location (Moore et al. 2009; Ostrom & Insel 2004) or different signalling cascades 
being activated in response to the same G-protein mechanism (Berkeley et al. 
2001). According to data presented here, it is only possible to speculate that P-
hTau firstly affects mAChRs, consistent with early impairments in cholinergic 
function in the presence of AD pathology. It remains to be elucidated why mAChRs 
are particularly vulnerable to early signs of pathophysiological changes and why 
mGluRs may be spared at this stage (see Chapter 6). 
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6.1 Summary of results 
The present thesis has provided the following findings: 
1. Activation of mGluRs does not affect baseline recording or LTP induction. 
 
2. Activation of mGluRs does not affect mAChRs-induced depression of 
fEPSPs triggered by CCh. 
 
3. Activation of mGluRs reduces mAChRs-induced calcium increase triggered 
by CCh. 
 
4. Activation of mGluRs does not affect the activation of GSK3β. 
 
5. Protein expression of mAChRs and GluA2 is reduced in P-AD brains 
whereas mGluR5, NR1 and Homer 1b/c are reduced in AD brains. 
 
6. Expression of P-hTau enhances mAChRs-induced holding current change 
triggered by CCh but not by DHPG. 
6.2 mGluR5 is not an isolated player in AD pathology 
Compelling evidence supports that synapses are the initial target of 
pathophysiology in AD (Selkoe 2002). Although this targeting eventually leads to 
synapse loss and subsequent loss of whole neurons, evidence points to 
deficiencies in synaptic function occurring first (Selkoe 2002; Pooler et al. 2014; Tu 
et al. 2014). Weakening of synaptic function is mediated by several signalling 
cascades that normally operate in physiological conditions but are hijacked in the 
presence of pathological insults. As outlined in Chapter 3, this thesis has provided 
support for this concept by showing that in non-disease conditions, the activation 
of mGluR5, a mediator of Aβ-induced neurotoxicity, does not disrupt synaptic 
plasticity. As discussed before, this is relevant to AD because it indicates that 
mGluR5 activation is not sufficient to cause synaptotoxicity. Instead, other 
molecules and pathways that are altered in pathology likely contribute to make 
mGluR5 into a key pathological mediator of Aβ-induced synaptic deficits. The 
question that remains to be answered is therefore: what are the 
 




molecules/pathways activated by Aβ that may contribute to mGluR5 aberrant 
function? 
To evaluate possible answers to such a challenging question, it is necessary to 
first consider the effects of Aβ on synaptic function. These include the blockade of 
LTP (Walsh et al. 2002; Cleary et al. 2005; Jo et al. 2011) and enhancement of 
LTD (J. H. Kim et al. 2001; Li et al. 2009; Hsieh et al. 2006), among other effects. 
Importantly, these deficits in synaptic plasticity have been linked to cognitive 
impairments observed in behavioural tests (Walsh et al. 2002; Selkoe 2008) and 
occur concomitantly to reductions in spine numbers (Wei et al. 2010). These 
findings indicate that Aβ clearly targets synapses (Lacor et al. 2004) and highlight 
the relevance of Aβ-induced synaptic deficits in the pathology of AD. Obviously, 
for Aβ to induce such effects, somehow its interference with intracellular cascades 
that modulate synaptic plasticity and/or function would be required. One compelling 
mechanism by which this is very likely to occur is the binding of Aβ to synaptic 
plasma membranes through its interaction with synaptic receptors (Dinamarca et 
al. 2012). In this way, Aβ can interfere with receptor activation and downstream 
signalling which in turn are necessary for the operation of synaptic plasticity 
mechanisms. Various Aβ receptors have been proposed, and interestingly some 
of them are as well able to regulate mGluR5 signalling.  
For instance, different NMDAR subunits were co-immunoprecipitated with Aβo and 
an antibody against the NR1 subunit abolished neuronal binding of Aβo (De Felice 
et al. 2007). Another NMDAR subunit, NR2B, was co-localised with Aβo in 
hippocampal slices (Deshpande et al. 2009). Although the domain responsible for 
the interaction has not been characterised yet, it has been shown that Aβ binds in 
a NR1- and NR2B-dependent manner to hippocampal neurons (Lacor et al. 2004; 
Lacor et al. 2007). The functional relevance of this binding may be related to the 
Aβ-mediated LTP impairment that occurs in combination with activation of MAPK 
and downregulation of CREB signalling in a NR2B-dependent manner (Li et al. 
2011). In addition, a functional regulatory interplay between NMDARs and mGluRs 
may play a role in Aβ pathology. It has long been reported that activation of 
mGluR5 can enhance NMDAR responses in vitro (Fitzjohn et al. 1996; Awad et al. 
2000; Doherty et al. 1997; O’Connor et al. 1994; Attucci et al. 2001). In an animal 
model, mGluR5 antagonism potentiates the impairments in learning and memory 
in behavioural tasks caused by NMDAR blockade (Homayoun et al. 2004), 
 




indicating that mGluR5 regulation of NMDARs function may be relevant for 
NMDAR-dependent cognitive tasks.  
Importantly, this regulatory effect is not unidirectional, as NMDARs can also inhibit 
or potentiate mGluRs-mediated signalling and particularly that of mGluR5, 
depending on the NMDA concentration (Alagarsamy et al. 2002; Luthi, et al. 1994; 
Challiss et al. 1994). Illustrating this, NMDAR activation results in 
dephosphorylation of mGluR5, reversing its PKC-dependent desensitisation and 
resulting in the potentiation of mGluR5-mediated inward currents recorded in acute 
hippocampal slices (Alagarsamy et al. 1999). Furthermore, NMDA treatment of 
cortex slices results in the potentiation of mGluR-induced phosphoinositide 
hydrolysis (Challiss et al. 1994). As mentioned before, this functional interaction 
between NMDARs and mGluR5 has the potential to be relevant for AD 
mechanisms since pathological activation of NMDAR by Aβ has been well-
established (Molnár et al. 2004; Miguel-Hidalgo et al. 2002; Texidó et al. 2011; Li 
et al. 2011). This, together with findings showing the potential binding of Aβ to 
NMDARs and that NMDARs can modulate mGluR5 function, provides a solid basis 
for the idea that the widely reported aberrant activity of mGluR5 in AD-like 
pathological conditions could be partially due to the regulatory effect of Aβ-induced 
NMDAR overactivity on mGluR5. Therefore, it is plausible that the lack of 
overactive NMDARs and associated signalling spares activation of mGluR5 as an 
innocuous event for synaptic function in the physiological model used in the 
present study.  
In addition to reducing phosphorylation-dependent mGluR5 desensitisation, 
another potential mechanism by which NMDARs may cause the potentiation of 
mGluR5 signalling is an increase in intracellular calcium levels. As mentioned 
before, a well-stablished theory is that Aβ causes aberrant activation of NMDARs 
(Molnár et al. 2004; Miguel-Hidalgo et al. 2002; Texidó et al. 2011; Li et al. 2011). 
This is further supported by the fact that an FDA-approved treatment for AD is 
memantine, an NMDAR blocker (Alzheimer’s Association 2018). Pathological 
activation of NMDARs is thought to result in an increased amount of calcium influx 
entering the cell through the ion channel which triggers a variety of synaptotoxic 
mechanisms (Kelly & Ferreira 2006; Mattson et al. 1992; Dong et al. 2009; Harkany 
et al. 2000). This is not surprising considering that calcium is a crucial second 
messenger that regulates a vast amount of key neuronal processes, including 
 




neuronal growth (Henley & Poo 2004), neurotransmitter release (Südhof 2012a), 
synaptic plasticity (Fitzjohn & Collingridge 2002) (Fitzjohn 2002) and cell death 
(Zhivotovsky & Orrenius 2011). As a result, dysregulation of calcium homeostasis 
is the gateway for severe disruptions in neuronal function and structure that 
characterise neurodegeneration (Wang et al. 2017). Supporting this, incubation of 
cortical cultures with Aβ peptides results in release of calcium from the 
endoplasmic reticulum (ER), which is required for Aβ-induced neuronal death 
(Ferreiro et al. 2004). In addition, ER calcium release dependent on ryanodine 
receptor is markedly increased in hippocampal slices from an AD mouse model, 
and it is required for the disruption of synaptic transmission (Chakroborty et al. 
2009). In vivo, Aβ-induced aberrant calcium increase results in loss of spino-
dendritic calcium compartmentalisation and dystrophy of neurites (Kuchibhotla et 
al. 2008). This evidence has provided the foundations of the compelling theory that 
establishes calcium excitotoxicity as a major feature of AD-like pathology (Demuro 
et al. 2010).  
Interestingly, by a different molecular mechanism than NMDARs, activation of 
mGluR5 also leads to an increase in intracellular calcium levels. Presumably, in 
conditions where this activation is excessive, such as in the presence of Aβ (Kumar 
et al. 2015; Wang 2004; Hu et al. 2014; Um et al. 2013; Hamilton et al. 2014; Haas 
et al. 2016), this effect is exacerbated. Although there is no direct evidence 
supporting that the detrimental effects of mGluR5 activation on synaptic function 
involve mGluR5-activated calcium-dependent pathways, this is quite likely given 
that this is a prominent signalling pathway triggered by Gq/11-coupled receptors, 
such as mGluR5 (Huang & Thathiah 2015). Therefore, one may think that in 
physiological conditions, agonist activation of mGluR5 results in a calcium increase 
that is not high enough to trigger neurotoxicity. However, if this occurs in 
combination with NMDAR activation and/or Aβ-induced calcium alterations, 
intracellular calcium concentration may reach a “pathological level” over which 
toxic signalling could be engaged and pathology triggered. Indeed, it is known that 
cells maintain cytosolic calcium levels within the nanomolar range (Gleichmann & 
Mattson 2011) and that the changes induced by Aβ greatly exceed the resting 
calcium levels (Kuchibhotla et al. 2008). Therefore, in addition to the previously 
mentioned synergistic effect of NMDARs and mGluRs, summation of their calcium 
signalling may be a key intracellular change in making mGluR5 a pathological 
mediator. 
 




Another Aβ receptor that is in turn a promising candidate for turning mGluR5 into 
a key mediator of Aβ-synaptotoxicity is cellular prion protein (PrPC). Support for 
this relies on the demonstration that Aβo bound to PrPC interact with mGluR5 
(Hamilton et al. 2015; Um et al. 2013; Haas et al. 2016). This may correlate with 
the increased vulnerability of mGluR5 bearing neurons to Aβ pathology (Overk et 
al. 2014; Beraldo et al. 2016). Notably, the indirect interaction of Aβ with mGluR5 
can result in the overstabilization of mGluR5 at the postsynaptic membrane and 
subsequent aberrant activation of the receptor (Renner et al. 2010). This may 
explain why the reduction of mGluR5 activity by pharmacological (Hamilton et al. 
2016; Um et al. 2013) and genetic approaches (Hamilton et al. 2014) reverses Aβ-
induced deficits in learning and memory, as well as it ameliorates Aβ-mediated 
calcium toxicity (Renner et al. 2010; Um et al. 2013) and spine density (Um et al. 
2013). In addition, this interaction may provide a mechanistic basis for the 
involvement of mGluR5 in the in vivo Aβ-mediated facilitation of LTD, for which 
both PrPC and mGluR5 are required (Hu et al. 2014). This evidence suggests that 
Aβ binds to PrPC and this complex interferes with mGluR5 physiological signalling 
(Renner et al. 2010). 
For instance, aberrant activation of mGluR5 within the PrPC-mGluR5 complex 
results in the cytoplasmic activation of the kinase Fyn (Um et al. 2012; Um et al. 
2013; Larson et al. 2012). Fyn then phosphorylates tau and NMDARs in an Aβ-
induced manner, inducing excitotoxicity and spine loss (Um et al. 2012; Larson et 
al. 2012). This role of mGluR5 as a central transducer of Aβ-mediated effects on 
synaptic function, may explain why its blockade with antagonists may be sufficient 
to prevent pathological signalling from the complex when Aβ is present (Haas & 
Strittmatter 2016; Haas et al. 2014). Furthermore, a recent study has shown that 
specific inhibition of pathological Aβ-mediated signalling through mGluR5 can 
restore behavioural and memory deficits, synaptic depletion and tau pathology in 
an AD transgenic mice model (Haas et al. 2017). They use a specific mGluR5 silent 
allosteric modulator (BMS-984923) (Huang et al. 2016) that blocks pathological 
Aβ-induced signalling and enhancement of PrPC-mGluR5 interaction without 
altering basal glutamate-induced calcium signalling (Gregory et al. 2010; Gregory 
et al. 2011; Sheffler et al. 2011). These findings further support that there is a clear 
separation between pathological and physiological molecular roles of mGluR5  
(Haas et al. 2017). With these ideas on scope, mGluR5 activation may not be 
 




sufficient to cause synaptic impairments as those mediated by the receptor in 
disease-like conditions due to the absence of synergistic activation by PrPC. 
The fact that mGluR5 is not the only key for AD pathology has therapeutic 
implications. Importantly, drugs targeting mGluR5 may not be a successful 
intervention unless used in combination with others aimed to tackle aspects of 
synaptic pathology occurring simultaneously to mGluR5 activation. Indeed, the 
need of using combined therapies that tackle more than one neuropathological 
problem has become a reality now (Hendrix et al. 2016; Jarosz-Griffiths et al. 
2016).  
6.3 mGluR-mediated inhibition of mAChRs 
GPCRs expressed on the postsynaptic membrane play important roles in the 
regulation of synaptic function (Betke et al. 2012). As outlined extensively 
throughout this thesis, efficient synaptic transmission and the integrity of synaptic 
connections are essential for correct functioning of neuronal communication 
(Huang & Thathiah 2015). Consequently, disruption of GPCRs expression or 
function is a common feature in numerous brain disorders, including AD (Huang et 
al. 2017). As previously discussed, reduction of cholinergic transmission is a 
hallmark of AD pathology (Whitehouse et al. 1982; Davies & Maloney 1976; Parent 
et al. 2013) and functional downregulation of the synaptic GPCRs mAChR has 
been proposed as a contributing factor to molecular and cognitive deficits in AD 
models (Caccamo et al. 2006; Davis et al. 2010). The outstanding question is 
however what the mediators for mAChRs dysregulation are. In this regard, data 
presented in Chapter 3 provides evidence for a possible inhibitory effect of 
mAChRs function exerted by group I mGluRs. Considering the variety of effects 
mediated by mAChR and mGluRs in addition to the significant number of 
intracellular molecules in common, some possible molecular mechanisms for this 
interaction may be considered. 
Regulation of GCPRs activity is an orchestrated process that occurs at many 
functional levels and involves a wide variety of GPCR-interacting proteins 
(Magalhaes et al. 2012). These include GPCR kinases (GRKs) (Ribas et al. 2007), 
regulators of G-protein signalling (RGS) (Nunn et al. 2006; Stewart & Fisher 2015), 
β-arrestins (Smith & Rajagopal 2016) and receptor activity-modifying proteins 
(RAMPS) (Hay & Pioszak 2016), among many others. In addition, GPCR-cross 
 




talk mechanisms have been widely regarded as a way to control GPCRs function 
(Cordeaux & Hill 2002). This is not surprising considering that the number of GPCR 
effectors is smaller than that of receptors and this number is limited within the cell 
(Hur & Kim 2002). Therefore, one possibility is that cross-regulation between 
GPCRs occurs at points of the signalling pathway where common effectors are 
required (see Chapter 3, section 3.3.2). Alternatively, cross-regulation may occur 
as a result of one GPCR being able to regulate the above mentioned GPCR-
interacting proteins that in turn regulate another GPCR.  
Among the GPCR-interacting proteins that regulate mAChRs function, RGS 
proteins seem to have an important role. For instance, RGS2 can selectively bind 
to the third intracellular loop of mAChR1 and potently inhibit mAChR-mediated 
phosphoinositide hydrolysis (Bernstein et al. 2004). This is in agreement with the 
canonical mode of action of RGS proteins, consisting in inactivation of Gα subunits 
by accelerating the hydrolysis of GTP through stimulation of GTPase activity 
(Stewart & Fisher 2015). Although the regulation of RGS proteins is still poorly 
understood, it has been reported that PIP3 can inhibit the GTPase-activating 
function of RGS in a calcium/calmodulin dependent fashion (Popov et al. 2000). 
The physiological relevance of this regulatory mechanism has been tested in 
cardiac myocytes, where PIP3-dependent inhibition of RGS4 was reversed by 
calcium/calmodulin activation, resulting in decreased potassium channel activity 
induced by the GTPase activity of RGS4 (Ishii et al. 2002). Notably, this 
mechanism is regulated by elevation of intracellular calcium, which then binds to 
calmodulin to activate it (Ishii et al. 2002). Interestingly, calcium release from 
intracellular stores represents an intersection for signalling pathways triggered by 
Gq/11 GPCRs, including mGluRs (Werry et al. 2003). According to this, agonist 
activation of mGluRs resulting in the release of calcium from intracellular stores 
could cause the activation of RGS proteins that in turn regulate muscarinic actions.  
In addition to RGS-mediated mechanisms, mAChRs activity is regulated by 
phosphorylation events at serine and threonine residues located on the receptor 
extracellular loops (Haga et al. 1990; Kwatra & Hosey 1986). These can be 
phosphorylated by numerous kinases among which are casein kinase 1a (CK1a), 
GRKs and PKC (van Koppen & Kaiser 2003; Haga et al. 1996; Tsuga et al. 1998; 
Budd et al. 2000). Importantly, GRK2 and GRK3 have been shown to supress Gq/11 
signalling (Carman et al. 1999; Ribeiro et al. 2009; Willets et al. 2001). A more 
 




relevant aspect for brain function is that GRK2 can inhibit mAChR1-induced IP3 
formation irrespectively of its kinase activity in cultured hippocampal neurons 
(Willets 2004). This study also showed that GRK2 is expressed in hippocampal 
neurons, suggesting its role in the regulation of hippocampal GPCRs (Willets 
2004). This finding implies that GRK2 is endogenously expressed in the 
hippocampus and that it can regulate mAChR1 function in a phosphorylation 
independent manner in the hippocampus, which is in line with other study (Willets 
et al. 2003). Since the demonstration that GRK2 contains a sequence that can bind 
to Gq/11 (Sterne-Marr et al. 2003), it has been proposed that a direct interaction 
mediates its phosphorylation-independent effects on mAChR1 (Day et al. 2004; 
Lodowski et al. 2003). This does not exclude the regulation of mAChR1 by 
phosphorylation-dependent mechanisms, as this has also been demonstrated to 
occur in native neuronal conditions (Willets et al. 2005).  Interestingly, GRK2 is in 
turn regulated by phosphorylation events (Chuang et al. 1995; Winstel et al. 1996). 
Particularly, PKC phosphorylation at the N-terminus of GRK2 prevents its inhibition 
by calmodulin (Krasel et al. 2000; Levay et al. 1998). According to this evidence, 
PKC activation may exert regulatory effects on mAChRs function through the 
activation of GRK2. It is well-established that mGluR5 activation results in PKC 
activation via the G-protein activated PLC/DAG pathway (Ferraguti & Shigemoto 
2006). Therefore, this could provide another mechanism by which mGluR5 can 
induce the inhibition of mAChRs function. 
In summary, regulators of GPCR activity such as RGS and GRKs may provide a 
molecular substrate for the mGluRs-mediated inhibition of mAChRs activity. 
Although their importance in the regulation of synaptic GPCRs cross-talk is yet to 
be explored, there are reasons to think that they may play such a role and 
consequently may be considered as targets to regulate GPCRs interplay. 
6.4 Differential effects of AD pathology on synaptic GPCRs 
Although multiple neurotransmitter systems are altered over the course of AD, 
dysfunction of glutamatergic and cholinergic synapses is better correlated with 
early symptomatology (Selkoe 2002). This is supported by findings shown in 
Chapter 4, where a selective loss of mAChR1 expression was observed in the 
brains of patients at earlier stages of AD pathology (Braak stages III-IV) but not at 
later stages (Braak stages V-VI). This specific downregulation of receptor 
expression in P-AD brains may reflect a very selective targeting by pathological 
 




molecules present in this tissue, such as P-hTau. This is consistent with data 
provided in Chapter 5, showing that P-hTau, a key entity in AD brains used for 
their neuropathological evaluation, can regulate the function of mAChRs but not 
that of other synaptic GCPRs such as group I mGluRs. In the particular 
experimental conditions of this study, P-hTau was shown to upregulate the 
responses of mAChRs in conditions of receptor activation. Although the 
mechanism for this effect remains to be elucidated, it is possible to consider 
potential ways in which P-hTau may regulate mAChRs based on the reported 
effects of tau on other receptors expressed at the synapse.  
The regulation of synaptic receptor function by tau has been widely studied, 
especially in the case of ionotropic receptors, AMPARs and NMDARs. As an 
illustrative example, tau enhances the interaction between GluA2 subunit of 
AMPARs and PICK1 (Yagishita et al. 2015). The functional relevance of this has 
been related to the involvement of these proteins in AMPAR trafficking and LTD 
mechanisms (Terashima et al. 2008; Hanley 2008; Steinberg et al. 2006; C.-H. Kim 
et al. 2001; Citri et al. 2010). Further supporting this, AMPARs surface expression 
is reduced in an animal model of tauopathy (Kopeikina et al. 2013) and in neuronal 
cultures where tau is present (Hoover et al. 2010; Yu et al. 2012). Given the 
importance of AMPARs for synaptic plasticity (Henley & Wilkinson 2016), these 
effects of tau on AMPAR trafficking have been proposed as a mechanism by which 
tau disrupts synaptic plasticity (Polydoro et al. 2009; Fá et al. 2016). Further 
supporting the ability of tau to regulate synaptic receptors function, tau-mediated 
regulation of NMDARs has been reported. As mentioned before in this thesis, a 
well-characterised example is that full-length hTau can induce excitotoxic activity 
of NMDARs via promoting Fyn trafficking to the synaptic compartment (Ittner et al. 
2010). This effect is generated by Fyn phosphorylation of the NR2B subunit of 
NMDAR, resulting in enhancement of stability of the receptor at the PSD (Ittner et 
al. 2010; Mondragón-Rodríguez et al. 2012). In line with these studies, tau can 
enhance NMDARs activity with pathological consequences as full-length hTau 
resulted in NMDAR-toxicity in neuronal cultures in a NR2B-dependent manner 
(Amadoro et al. 2006). In addition, expression of tau in mouse hippocampal 
neurons resulted in increased NMDAR-induced excitotoxicity, dependent on the 
Fyn-mediated phosphorylation of tau (Miyamoto et al. 2017). Although the 
mechanisms for these regulatory effects are not clear yet, this evidence supports 
 




that tau can alter the activity of NMDAR in a way that potentiates receptor-mediated 
excitotoxicity, probably through phosphorylation.  
As previously mentioned for mGluR5, there is evidence supporting a regulatory 
interplay between NMDARs and GPCRs (Lu et al. 1999), suggesting that tau-
mediated activation of NMDARs may impact GPCR function. For instance, 
activation of mAChRs can enhance NMDAR-mediated neurotransmission (i.e. 
EPSPs) in the auditory cortex, an effect dependent on G-protein activation 
(Aramakis et al. 1997). Furthermore, CCh administration in cortical slices resulted 
in an increase in NMDAR-evoked adenosine release (Semba & White 1997). Such 
interaction seems to also take place in the hippocampus, as ACh administration in 
hippocampal neurons was able to facilitate the slow component of NMDAR-EPSPs 
generated by NMDAR activation (Markram & Segal 1990) and CCh treatment of 
hippocampal slices transiently enhanced NMDAR-mediated inward currents 
(Auerbach & Segal 1996). Although these studies provide evidence for enhancing 
effects of muscarinic regulation on NMDARs activity, this functional interaction can 
be of inhibitory nature. Illustrating this, mAChRs activation can result in 
downregulation of NMDAR-mediated inward currents in CA3 neurons through a 
mechanism involving G-protein mediated calcium release (Grishin et al. 2005). 
This heterogeneity of effects indicates the complexity of cross-talk between 
cholinergic and glutamatergic systems. Further supporting this concept, NMDAR 
can in turn downregulate the phosphoinositide response induced by mAChRs 
activation in cerebellar granule neurons (Butcher et al. 2009). In this study, the 
authors showed that activation of NMDARs results in the activation on 
calcium/calmodulin-dependent kinase II (CaMKII) and proposed that CaMKII can 
then phosphorylate mAChR causing its uncoupling from Gq/11 and subsequent 
desensitisation (Butcher et al. 2009). Moreover, antagonism of NMDARs enhanced 
the detrimental effects of mAChRs blockade in behavioural tasks (Moreira et al. 
2005), further supporting the  functional relevance of this regulatory interaction in 
the brain. Altogether this evidence supports that NMDAR can regulate mAChR G-
protein coupled actions.   
According to the above, since hTau can induce aberrant activation of NMDARs 
and associated neurotoxicity and NMDARs can result in the enhancement of 
mAChRs activity, a potential mechanism underlying the P-hTau-mediated 
potentiation of mAChRs function reported in the present study is the overactivation 
 




of NMDARs by P-hTau. This possibility remains to be determined but it could be 
relevant for AD pathological mechanisms, as overactivation of NMDARs is a 
feature of pathology (Molnár et al. 2004; Miguel-Hidalgo et al. 2002; Texidó et al. 
2011; Li et al. 2011). 
The fact that the enhancing effect of P-hTau on mAChR activation was not 
observed for group I mGluRs indicates that for some unidentified reason, mGluRs 
are more resistant to the presence of pathological tau. If assuming the hypothesis 
that NMDARs activation is a mechanism by which enhancement of mAChRs-
induced holding current change occurs, the lack of effect of P-hTau on mGluRs 
activation may rely on a specific feature of the modulatory effect of NMDARs on 
mGluRs.  
Interestingly, NMDAR-mediated enhancement of mGluRs involves the activation 
of a phosphatase. This is supported by studies showing that the potentiation of 
mGluR5-mediated phosphoinositide hydrolysis in rat cortex depends on the 
NMDARs-dependent activation of calcineurin (Alagarsamy et al. 1999; Alagarsamy 
et al. 2005). According to these studies, activation of calcineurin results in the 
dephosphorylation of mGluR5 at serine/threonine residues located at the C-
terminal domain, impeding its PKC-mediated desensitisation. Notably, the authors 
also provide evidence that the calcineurin mediated effect is due to the association 
of calcineurin with mGluR5 within a signalling complex in the PSD. The authors 
proposed that a possible intermediary between calcineurin and mGluR5 may be 
calmodulin, given that is both necessary for calcineurin activation (Rumi-Masante 
et al. 2012) and it can bind to the C-terminal domain of mGluR5 (Minakami et al. 
1997). Interestingly, calcineurin has been widely studied in the context of AD due 
to its ability to dephosphorylate tau (Reese & Taglialatela 2011). Indeed, in the 
presence of tau, calcineurin binds to the calmodulin-binding domain of tau to exert 
dephosphorylation effects in mouse brain extracts (Yu et al. 2008). According to 
this evidence, it is possible that in the experimental conditions of the present study, 
the intracellular expression of P-hTau sequesters calcineurin proteins present in 
the cytoplasmic space. In this case, calcineurin would no longer be available to 
mediate NMDARs-induced potentiation of mGluRs-mediated effects (Alagarsamy 
et al. 2005) triggered by P-hTau. Importantly, this would not necessary affect 
NMDAR-induced potentiation of mAChRs-mediated holding current change. 
Testing this hypothesis will require future work which would indeed help to 
 




understand the differential sensitivity of glutamatergic and cholinergic systems to 
acute effects of P-hTau. 
Reconcile the up-regulation of mAChR-mediated responses by P-hTau with the 
downregulation of receptor expression in neurodegenerative brains seen in 
Chapter 5 is challenging considering the intrinsic limitations of comparing an in 
vitro model with post-mortem human tissue preparations. However, leaving these 
limitations aside, one may consider that if P-hTau triggers an upregulation of 
mAChRs function this would lead to desensitisation of the receptor in the long-
term. It is important to note that in the present study, electrophysiology experiments 
may reflect effects of acute P-hTau expression, as they were performed 3-5 days 
after transfection of tau constructs. Although this may serve as an approximation 
to changes occurring at initial phases of AD, intracellular accumulation of P-hTau 
persists over time in the human diseased brain (Braak & Braak 1991). As a result, 
chronic enhancement of mAChRs function possibly leads to the activation of 
receptor downregulation mechanisms to counterbalance the initial exacerbated 
function (van Koppen & Kaiser 2003). Indeed, this is a common regulatory 
mechanism of GPCRs function (Grady et al. 1997; Kelly et al. 2008) that applies to 
agonist-activation of mAChRs (Lee & El-Fakahany 1987; Li et al. 2003). In addition, 
it has been shown that agonist-activation of mAChRs results in receptor loss due 
to increased degradation (Roskoski et al. 1985), explaining an overall loss of 
mAChRs expression. However, this would not explain why at later stages of AD 
pathology, the levels of mAChR in the brains of AD patients remain unchanged 
when compared to control subjects. Considering that the effects of pathology on 
mGluRs function were different from those on mAChRs, i.e. downregulation of 
mGluR5 expression was observed at late stages and that P-hTau did not affect 
mGluRs function; a possible mechanism that conciliates these findings may 
emerge from the interplay between mGluRs and mAChRs reported in this study.  
First, although the analysis of protein expression in AD brains is performed at a 
concrete time point, the outcome of this analysis is likely to reflect biochemical 
changes to which these brains have been subjected to for a long period of time. As 
outlined before in this thesis, one of these biochemical changes is probably the 
accumulation of glutamate. This is substantiated by in vitro findings showing that 
Aβ can induce reduced glutamate clearance (Li et al. 2009; Parpura-Gill et al. 
1997; Fernández-Tomé et al. 2004) and potentiate glutamate release (Kabogo et 
 




al. 2010; Arias et al. 1995; Abramov et al. 2009). In addition, a strong support 
emerges from studies of human AD brains showing reductions in glutamate 
transporters (Lauderback et al. 2001; Li et al. 1997; Jacob et al. 2007; Scott et al. 
2011; Kashani et al. 2008; Kirvell et al. 2006). Therefore, a prevalent hypothesis is 
that glutamate accumulates throughout AD progression and in doing so causes 
excitotoxic effects (Hynd et al. 2004a). Hence, these effects may be gradual as 
glutamate builds-up (Butterfield & Pocernich 2003). Importantly, the temporal 
occurrence of pathological changes to the glutamatergic system may be of crucial 
importance for therapeutic strategies aimed to restore disruptions of this system in 
AD. Supporting this concept, a two-stage model of neurodegeneration was 
proposed by Olney and colleagues (1997). In this model, they stated that 
accumulation of Aβ results in hyperactivity of NMDARs at the first stage, followed 
by a subsequent loss of receptors, which translates into the observed NMDAR 
hypofunction at a second, later stage of disease (Olney et al. 1997; Butterfield & 
Pocernich 2003). Although the absolute temporal definition of these “stages” is not 
well defined, this theory has laid the basis for the broad but nonetheless very 
important concept that pathological changes affect synaptic receptor function in a 
different manner as pathology progresses. Similar conclusion may be drawn for 
glutamate accumulation. An obvious implication of this model is that therapies 
directed to correct NMDARs dysregulation should aim to downregulate or 
upregulate NMDAR activity, depending on the point of AD progression that the 
therapeutic intervention is happening.  
Since the temporal pattern of changes to the glutamatergic system appears to be 
crucial to understand the molecular mechanisms underlying neurodegeneration, it 
may be worth considering that aberrant activation of mGluR5 may occur at a 
delayed phase compared to the enhancement of mAChRs. Indeed, the differential 
impact of P-hTau on these receptors indicates that this is a plausible idea. On the 
one hand, mAChRs may be first enhanced and subsequently downregulated, as 
previously discussed. On the other hand, and concomitantly to P-hTau 
accumulation, other pathological insults take place in the brain such as Aβ 
accumulation and glutamate excitotoxicity, which gradually spread throughout the 
brain and cause aberrant activation of mGluR5, among a myriad of other effects. 
Since glutamate accumulated at the synaptic cleft can spill-over to extrasynaptic 
sites (Oikonomou et al. 2012; Okubo et al. 2010; Rusakov & Kullmann 1998), 
where most mGluR5 is located (Conn & Pin 1997; Romano et al. 1995; Lujan et al. 
 




1996), it is expected that glutamate present at these sites causes mGluR5 
activation. In addition to glutamate, pathological activation of mGluR5 is thought to 
occur in the presence of Aβ (Wang 2004; Hu et al. 2014; Um et al. 2013; Hamilton 
et al. 2014; Renner et al. 2010). At this point when mGluR5 is overactive, it could 
exert enhanced inhibitory effects on mAChR. This could counterbalance the 
enhancement induced by P-hTau. Therefore, the overactivation of mGluR5 could 
potentially have two effects. First, to switch the initial upregulation of mAChR into 
a functional downregulation, which could result in the stoppage of compensatory 
changes at the level of protein expression. This, together with mechanisms of 
cholinergic sprouting activated in response to reduction in cholinergic activity 
discussed in Chapter 4, could explain the observed restoration of control levels of 
mAChRs at late stages of AD. Second, and similarly to the case of mAChRs, 
aberrant activation of mGluR5 could result in increased degradation or reduced 
synthesis of receptor as a plausible desensitisation mechanism occurring in AD 
(discussed in Chapter 4, section 4.3), which could account for reduced levels of 
mGluR5 at late stages of AD. 
Future work is required to evaluate whether these speculations are true and 
therefore whether this is a suitable model to explain AD-associated changes in 
synaptic GPCRs of the glutamatergic and cholinergic families.  
6.5 Relevance of tau isoforms 
Although tau refers to a heterogenous group of proteins (Cleveland et al. 1977), 
they are encoded by a single gene that is highly conserved across species 
(Himmler et al. 1989; Drubin et al. 1984). Alternative splicing of tau pre-mRNA 
originates several tau splice variants (Drubin et al. 1984; Himmler et al. 1989; 
Himmler 1989; Kosik et al. 1989; Lee et al. 1988; Andreadis et al. 1992) that are 
translated into different protein isoforms. In the adult human brain, there are six of 
these isoforms whereas the number is four to five in the rat brain (Cleveland et al. 
1977; Drubin et al. 1984; Francon et al. 1982; Goedert, Spillantini, Jakes, et al. 
1989). In the experiments of the present thesis, transfection of rTau-shRNA is 
expected to knock-down the expression of all four isoforms of tau without 
influencing human tau (Kimura et al. 2013; Regan et al. 2015). Furthermore, co-
transfecting hTau will result in the expression of one isoform, in this case full-length 
(2N4R) hTau, but not the others. Therefore, the finding that the phosphomimetic 
form of hTau 2N4R can enhance mAChRs-mediated holding current change does 
 




not imply that other isoforms will have the same functional effects.  Although this 
issue remains to be investigated, there are reasons to think that the variety of tau 
isoforms parallels differential functions in the neuronal environment.  
Tau isoforms differ in the number of repeat domains (isoforms with three repeats 
are denoted 3R and isoforms with four, 4R) in the microtubule-binding domain and 
in the number of N-terminal inserts (either none, one or two) (see Chapter 5, 
section 5.1). These aminoacidic sequences confer each isoform distinct structural 
properties that may underlie their different functions. For example, 3R tau binds 
microtubules with a lower affinity than 4R (Butner & Kirschner 1991; Gustke et al. 
1994; Goode et al. 2000; Goedert & Jakes 1990) which results in a cytoskeleton 
more prone to structural changes (Goode et al. 2000; Panda et al. 2003). In 
addition, support for separate functions of tau isoforms arises from their distinct 
developmental and regional/subcellular location profiles, which in turn may be 
isoform-dependent. Illustrating this, some isoforms are preferentially expressed in 
cell bodies, nucleus, dendrites or axons (Liu & Götz 2013; McMillan et al. 2008) 
and in specific brain regions during development (McMillan et al. 2008).  
This heterogeneity of isoforms expression and function also occurs in the so-called 
tauopathies and specific sets of tau isoforms seem to characterise each disease 
(Delacourte et al. 1996; Greenberg et al. 1992; Sergeant et al. 1997; Sergeant et 
al. 1999; Buée & Delacourte 1999). For instance, NFTs were strongly 
immunostained with an antibody against 3R isoforms but not with a 4N tau antibody 
in brain sections of patients with severe AD (Espinoza et al. 2008; de Silva et al. 
2003; Liu et al. 2001). These findings led to think that distinct tau isoforms may 
play different roles in neuropathological mechanisms. As an example, full-length 
tau and some N-terminal fragments can mediate NMDAR-induced cell death 
(Amadoro et al. 2006). In addition, different phosphorylated tau isoforms display 
different binding affinities to normal human tau, which impacts their capacity to 
sequester normal tau and inhibit microtubule assembly (A. D. Alonso et al. 2001). 
Complicating things further, it is not only the different isoform expression which 
may serve as a signature of disease but also the ratio between isoforms (Espinoza 
et al. 2008; de Silva et al. 2003; Glatz et al. 2006; Liu et al. 2001; Clark et al. 1998; 
Hutton et al. 1998; Spillantini et al. 1998; D’Souza et al. 1999) and their different 
cellular and regional expression in the diseased brain (Mori et al. 2003).  
 




Altogether this evidence provides a solid basis to think that tau proteins exert 
isoform specific functions and that these may be differentially involved in AD. 
Accordingly, the expression of full-length hTau in this study likely does not truly 
mimic the pathological situation. To overcome this limitation, future work aimed to 
investigate the specific effects of each isoform on synaptic GPCRs activity would 
be required. Undoubtedly, this would provide a more comprehensive 
understanding of the pathological effects of tau on neuronal function.  
6.6 Conclusions 
Contrary to the initial hypothesis, findings from this study have shown that 
activation of mGluR5 does not cause synaptic impairments under the experimental 
conditions here. Furthermore, and in agreement with the initial hypothesis, results 
from this thesis support a functional interplay between mAChRs and mGluRs in 
the hippocampus. This could have pathological implications for AD given the 
specific alterations of these receptors over AD progression, which are associated 
with specific targeting of these receptors by one of the main neurotoxic molecules 
in the AD brain, P-hTau. Although the molecular substrates for this interaction 
remain to be investigated, this knowledge will contribute to a better understanding 
of synaptic dysfunction in AD and hopefully to a better design of therapeutic 
interventions. 
The present chapter has aimed to cover the main relevant concepts and limitations 
of findings presented in this thesis. Currently, it is unclear whether mechanisms 
proposed here may account for the observations made. On a final note, it seems 
therefore appropriate to consider Alzheimer’s own conclusions (Alzheimer 1907): 
“These observations should compel us not to content ourselves with forcibly 
applying the knowledge we have to date to explain insufficiently understood 
mechanisms. Future study will enable us to gradually untangle specific 
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Supplementary Figure 1. Immunoblots quantified in Figures 4.2, 4.3 and 4.4. 
Immunoblots for (A) GluA2, (B) NR1, (C) mGluR1, (D) mGluR5, (E) mAChR1, (F) Homer 
1b/c, (G) PSD95 and (H) Synaptophysin (SYP). AD: Alzheimer’s disease patient, C: Non-








Supplementary Figure 2. Immunoblots quantified in Figures 4.9, 4.10 and 4.11. 
Immunoblots for (A) GluA2, (B) NR1, (C) mGluR1, (D) mGluR5, (E) mAChR1, (F) Homer 
1b/c, (G) PSD95 and (H) Synaptophysin (SYP). P-AD: Possible/probable Alzheimer’s 










Supplementary Figure 3. Example of full-length immunoblots for the antibodies used 
in this study. (A) GluA2, (B) NR1, (C) mGluR1 and (D) mGluR5. Expected molecular 
weight of the protein of interest is shown in red. Reference molecular weights of protein 
marker are shown in black. Red rectangles contain the band of interest and correspond to 
the cropped regions shown in the main text. For technical purposes, samples were loaded 









Supplementary Figure 4. Example of full-length immunoblots for the antibodies used 
in this study. (A) mAChR1, (B) Homer 1b/c, (C) PSD95, (D) SYP and (E) β-Actin. 
Expected molecular weight of the protein of interest is shown in red. Reference molecular 
weights of protein marker are shown in black. Red rectangles contain the band of interest 
and correspond to the cropped regions shown in the main text. For technical purposes, 
samples were loaded in numerical order to facilitate the work, but not due to scientific 
reasons. 
 
